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Summary 
 
Introduction:  
 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is an autosomal dominant inherited 
condition characterized by an increased susceptibility to colorectal (CRC) and other associated 
cancers and defined by the Amsterdam I and II clinical criteria. An important fraction of these 
families is known as Lynch Syndrome and is caused by germline inactivating mutations in the 
mismatch repair (MMR) genes. This results in tumors that lack the corresponding proteins and 
fail to repair DNA through this pathway, causing microsatellite instability (MSI) and leading to an 
accumulation of somatic mutations. However, it is estimated that almost half of the families that 
fulfill the Amsterdam criteria do not present any defects in the MMR genes. For this reason, the 
term Familial Colorectal Cancer Type X (FCCTX) emerged to designate such group of HNPCC 
families that lack the MMR deficiency and resulting MSI that define Lynch Syndrome. Thus, FCCTX 
patients have microsatellite stable tumors with normal expression of the MMR genes, and the 
genetic basis underlying their predisposition to CRC and other related cancers remains to be 
elucidated.  
 
Thanks to arrival of Next Generation Sequencing (NGS), some new CRC-predisposition 
genes have been recently identified; however, most FCCTX cases remain unexplained. FCCTX is 
thought to be a heterogeneous group of families, presumably including different yet-to-be-
discovered genetic syndromes involving germline mutations in novel cancer-predisposing genes, 
but that could also result from a combination of low-penetrance mutations in different genes. 
For this reason, identifying the genetic cause of the increased cancer susceptibility in FCCTX 
families is still a challenge. 
 
Objectives: 
 
The ultimate aim of this study is the identification of new genes that could explain the 
increased cancer susceptibility in FCCTX families. Within this aim are enclosed the following 
secondary objectives: 1) to obtain a list of potentially pathogenic candidate variants for each 
18 
family; 2) to classify and characterize the variants identified; 3) to perform functional and/or 
expression studies when possible and suitable. All this with the purpose of finding the cause of 
CRC heritability in the studied families. 
 
Methodology: 
 
The main method on which this work was based is whole-exome sequencing, one of the 
applications of NGS. The obtained data was strictly analyzed and those prioritized variants were 
validated by PCR followed by Sanger sequencing. In addition, the segregation and loss of 
heterozygosity (LOH) were studied. Finally, some of the candidate genes were characterized by 
different expression and functional essays, involving both recombinant proteins and cell cultures. 
 
Results: 
 
The thorough filtering and in silico analysis of the variants identified by whole-exome 
sequencing in the affected members of 13 FCCTX families allowed the prioritization of a list 
variants. After their validation, the segregation in other family members and LOH were studied 
when possible. A total of 44 candidate variants were selected, most of which affected genes 
involved in important cellular events such as DNA repair, tumor suppression or different cancer-
related signaling pathways. On the other hand, based on the relevance of the candidate genes 
and the nature of the alterations, three of the variants were selected for a more in-depth 
evaluation.  
 
One of the variants selected for further characterization was SETD6 c.791_792insA, 
p.(Met264IlefsTer3), carried by all the CRC-affected members of one of the families and absent 
in the healthy ones. SETD6 is a mono-methyltransferase known to regulate the NF-κB and Wnt 
signaling pathways, among other. The characterization of the truncated version of SETD6 proved 
that it lacked its enzymatic activity as a methyltransferase, while maintaining other properties 
such as its expression, localization and substrate-binding ability. In addition, the mutant allele 
was expressed in the tumor and the resulting mutant protein competes with the wild type for 
their substrates, pointing to a dominant negative nature. These findings suggest that this 
mutation impairs the normal function of SETD6, which may result in the deregulation of the 
19 
different pathways in which it is involved, contributing to the increased cancer susceptibility in 
this family.  
 
Another of the studied variants was PTPRT c.4099dup, p.(Asp1367GlyfsTer24), which 
showed a compatible segregation with the different types of cancer of the family (of the colon, 
breast and endometrium), without being present in two healthy elderly relatives. PTPRT is a 
tumor suppressor gene found to be frequently mutated at a somatic level in CRC and other 
cancers, having been proven that these mutations contribute to tumor development. The studied 
mutation resulted in the loss of a significant fraction of the second phosphatase domain of the 
protein, shown to be essential for its activity. In addition, the tumors of two of the carriers 
exhibited epigenetic inactivation of the wild-type allele and an altered expression of PTPRT’s 
downstream target genes, consistent with a causal role of this germline mutation in the cancer 
predisposition of the family. 
 
Last but not least, the third variant was PYGO1 c.1084T>C, p.(Ser362Pro). The protein 
encoded by this gene plays an important role in the Wnt pathway, which is essential in CRC. 
Despite being a missense mutation, this variant was located in one of the zinc fingers from the 
PHD domain of the protein. Even though the initial segregation study was favorable, a later 
analysis of the tumor of a third CRC-affected member showed that this patient did not carry the 
mutation. Interestingly, the study of mutant PHD proved that the mutation significantly 
decreased this domain’s affinity for two of Pygo1’s substrates, which would be expected to 
decrease the Wnt pathway contrary to what is usually seen in a CRC context.  Therefore, these 
results do not support a causal role of this variant in the increased cancer predisposition of this 
family, although its implication in tumor progression cannot be ruled out.  
 
Conclusions: 
 
Among all the selected candidate variants, this work proves the causality of two germline 
truncating mutations, in SETD6 and PTPRT, although more studies are necessary to determine 
the exact role that they play in cancer susceptibility. However, there is not enough evidence 
supporting a causal role for the variant identified in PYGO1. Additional studies will clarify the 
relevance of these and other candidate genes.
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Resumen 
 
Introducción: 
 
El Cáncer Colorrectal Hereditario No Polipósico (HNPCC) es una condición hereditaria 
autosómica dominante caracterizada por una aumentada susceptibilidad al cáncer colorrectal 
(CRC) y otros cánceres asociados, y definida por los criterios clínicos de Ámsterdam. Una parte 
de estas familias, conocida como Síndrome de Lynch, es causada por mutaciones germinales 
inactivantes en los genes MMR (del inglés “Mismatch Repair”), lo que resulta en tumores que no 
pueden reparar los errores en el apareamiento de bases del ADN, causando inestabilidad de 
microsatélites. Sin embargo, se estima que casi la mitad de las familias que cumplen los criterios 
de Ámsterdam no presenta defectos en los genes MMR. Por esta razón, el término Cáncer 
Colorrectal Familiar Tipo X (FCCTX) surgió para designar este grupo de familias HNPCC con genes 
MMR competentes y estabilidad de microsatélites. Desafortunadamente, la base genética de la 
aumentada susceptibilidad al CRC y otros tumores relacionados en familias FCCTX todavía se 
desconoce. 
 
Gracias a la llegada de la secuenciación masiva o “Next Generation Sequencing” (NGS), 
recientemente se han identificado algunos nuevos genes de predisposición al CRC; sin embargo, 
la mayoría de casos de FCCTX siguen todavía sin explicar. Se piensa que FCCTX es un grupo 
heterogéneo de familias, que engloba distintos síndromes genéticos causados por mutaciones 
en diversos genes de predisposición al cáncer aún sin identificar. No obstante, no se descarta que 
parte de estas familias resulten de una combinación de varias mutaciones de baja penetrancia 
en distintos genes, lo que hace aún más difícil la búsqueda de los mismos. 
 
Objetivos: 
 
El objetivo final de este estudio es la identificación de nuevos genes que expliquen el 
incremento en la susceptibilidad al cáncer en familias con FCCTX. Dentro de esta meta se 
encuentran los siguientes objetivos secundarios: 1) obtener una lista de variantes candidatas 
potencialmente patogénicas en cada familia; 2) clasificar y caracterizar las variantes encontradas; 
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3) hacer estudios funcionales y/o de expresión en aquellos casos en que sea recomendable y 
posible. Todo esto con el fin de encontrar la causa de la heredabilidad del CRC en las familias 
estudiadas. 
 
Metodología: 
 
El método principal en el que se ha basado este trabajo es la secuenciación de exoma 
completo, una de las aplicaciones de la NGS. Los datos obtenidos fueron analizados de forma 
rigurosa, y aquellas variantes priorizadas fueron validadas por PCR seguida de secuenciación 
Sanger. Además, se realizaron estudios de segregación y pérdida de heterocigosidad (LOH). Por 
último, para algunos de los genes candidatos se caracterizaron mediante distintos estudios de 
expresión y ensayos funcionales, tanto con proteínas recombinantes como en cultivos celulares. 
 
Resultados: 
 
El estricto filtrado y análisis in silico de las variantes encontradas por secuenciación del 
exoma en miembros afectos de 13 familias FCCTX permitió la priorización de una lista de 
variantes. Tras su validación, se estudió la segregación en otros familiares y la LOH en los casos 
posibles. Un total de 44 variantes candidatas fueron seleccionadas, la mayoría en genes 
involucrados en mecanismos celulares importantes, como la reparación del ADN, supresión 
tumoral o distintas vías de señalización esenciales. Por otro lado, en base a la relevancia de los 
genes candidatos y en la naturaleza de las alteraciones, tres de las variantes fueron seleccionadas 
para su estudio en mayor profundidad. 
 
Una de las variantes caracterizadas fue SETD6 c.791_792insA, p.(Met264IlefsTer3), 
presente en todos los individuos con CRC de una familia y ausente en los sanos. SETD6 es una 
mono-metiltransferasa conocida por regular, entre otras, las vías de señalización NF-κB y Wnt. 
La caracterización de la versión truncada de SETD6 demostró que ésta carecía de actividad 
enzimática como metiltransferasa, mientras que mantenía otras propiedades como la expresión, 
localización y habilidad de unión a sustratos. Además, mostramos que el alelo mutado está 
expresado en el tumor y que la proteína mutada compite con la nativa por sus sustratos, lo que 
apunta a un papel dominante negativo. Estos resultados sugieren que esta mutación altera la 
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función normal de SETD6, lo que resultaría en la desregulación de las diferentes vías en las que 
está involucrado, contribuyendo así a la aumentada susceptibilidad al cáncer de esta familia. 
 
Otra variante estudiada fue PTPRT c.4099dup, p.(Asp1367GlyfsTer24), que mostró una 
segregación compatible con los distintos tipos de cáncer de la familia (de colon, mama y 
endometrio), estando ausente en dos miembros sanos de edad avanzada. PTPRT es un gen 
supresor de tumores frecuentemente mutado a nivel somático en CRC y otros tipos de tumores, 
habiéndose demostrado que estas mutaciones contribuyen al desarrollo tumoral. La mutación 
estudiada truncaba gran parte del segundo dominio fosfatasa de la proteína, que es esencial para 
la actividad de la misma. Además, los tumores de dos portadores mostraron inactivación 
epigenética de PTPRT y alteración de la expresión de los genes diana de las vías en que está 
involucrado, lo que concuerda con un papel causal de esta mutación en la predisposición al 
cáncer de esta familia. 
 
Por último, la tercera variante fue PYGO1 c.1084T>C, p.(Ser362Pro). La proteína 
codificada por este gen tiene un importante papel en la vía Wnt, esencial en el CRC. A pesar de 
tratarse de una mutación puntual, esta variante estaba localizada en uno de los dedos de zinc del 
dominio PHD de la proteína. Aunque el estudio de segregación inicial fue favorable, un análisis 
posterior del tumor de un tercer familiar afecto reveló que este miembro no era portador. Por 
otra parte, el estudio del dominio PHD mutado demostró que la mutación disminuía la afinidad 
de unión a dos de sus sustratos significativamente, lo que conllevaría a una disminución de la vía 
Wnt que contradice lo esperado en un contexto de CRC. Con estos resultados no podemos 
concluir que esta variante sea la causa de la predisposición al cáncer en la familia, aunque no se 
puede descartar que esté jugando un papel en la progresión tumoral. 
 
Conclusiones:  
 
De entre todas las variantes candidatas seleccionadas, este trabajo demuestra la 
causalidad de dos mutaciones germinales truncantes en SETD6 y PTPRT, aunque más estudios 
son necesarios para determinar el papel exacto que juegan en la susceptibilidad al cáncer. Sin 
embargo, no hay evidencias suficientes que apoyen la causalidad de la variante encontrada en 
PYGO1. Estudios adicionales esclarecerán la relevancia de otros de los genes candidatos. 
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1.1 Colorectal cancer 
 
Cancer can be defined as a set of diseases in which cells have acquired the ability 
to divide and grow uncontrollably by disregarding the normal rules of cell division1,2. 
Specifically, colorectal cancer (CRC) refers to the development of an abnormal cell growth 
in the tissue of the colon or rectum with the potential to invade other parts of the body. 
Further information regarding its epidemiology, diagnosis, treatment, risk factors and 
pathways involved is detailed below. 
 
1.1.1 The colon and rectum 
 
The colon and rectum are sections of the large intestine, which is the terminal part 
of the lower gastrointestinal track and consists of the cecum, appendix, colon, rectum and 
anal canal3 (Figure 1.1 A and B). The colon extends upwards from the cecum and is divided 
into the ascending, transverse, descending and sigmoid colon3. The transverse colon is 
flanked by the right colic flexure, also known as the hepatic flexure for its proximity to the 
liver, and the left colic flexure or splenic flexure, located just below the spleen3. Finally, 
extending from the sigmoid colon is the rectum, which is in turn followed by the anal 
canal3. 
 
Unlike the small intestine, the colon does not play a major role in the absorption 
of food and nutrients4. Nonetheless, being at the end of the digestive system it has a series 
of essential functions, including the absorption of water and electrolytes from solid 
wastes, the production and absorption of vitamins5, the microbiota-aided fermentation 
of unabsorbed material4 and the formation of the feces, which are then propelled to the 
rectum for elimination5. The unique architecture of the colon facilitates these functions, 
its multiple folds resulting in an immense surface area that allows maximal absorption6. 
The intestinal wall is formed by multiple layers joined together by connective tissue and 
by the neural and vascular elements6 (Figure 1.1 C): the innermost layer is the mucosa 
(formed by the epithelium, a layer of connective tissue called lamina propia and a thin 
muscle layer called muscularis mucosa), underneath it is the submucosa, then the 
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muscularis propria or thick muscle layers, and finally the serosa, which is covered by the 
visceral peritoneum and forms a natural barrier from the spread of inflammatory and 
malignant processes6. 
 
 
 
 
1.1.2 Epidemiology of colorectal cancer 
 
CRC is the third most common cancer and the fourth leading cancer-related cause 
of death in the world, with 1,360,602 new cases and 693,933 fatalities registered in 20127 
(Figure 1.2 A). Regarding the gender, CRC is the third most commonly occurring cancer in 
men and the second in women, although in most parts of the world the incidence rate of 
CRC is higher in men than in women7,8.
Figure 1.1. Anatomy of the colon 
and rectum. A) Illustration of the 
lower gastrointestinal tract, modified 
from IMSS (www.imss.gob.mx). B) 
Representation of the different parts 
of a colon, modified from Bodytomy 
(bodytomy.com). C) Cross section of 
a healthy colon and amplified 
visualization of the layers of the 
colon wall, modified from the 
 Figure 1.2. World incidence and mortality of CRC. A) Number of new cases (blue) and deaths (red) x100 of the most frequent cancers in the 
world, in males (left) and females (right). CRC is situated in third position, although it is the fourth when it comes to mortality rates. B) 
Geographical variation in CRC incidence (blue) and mortality (red) in males (left) and females (right). Estimated age-standardized rates per 
100,000. CRC incidence is higher in countries with higher indices of development, but mortality rates are higher in developing countries. 
Obtained from Globocan 2012 (gco.iarc.fr). 
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Although the incidence rate of CRC varies greatly worldwide9, about two thirds of 
CRC cases occur in countries characterized by high indices of development and/or 
income10 (Figure 1.2 B). However, CRC incidence in developing countries has been steadily 
increasing11, which indicates a growth in the prevalence of CRC risk factors associated with 
Western lifestyle, such as unhealthy diet, obesity and smoking12. On the other hand, 
despite being more common in developed areas, mortality rates are higher in developing 
countries. Mortality rates have shown a descending trend in most economically-
developed countries, including Spain and most Western European countries13. The 
decrease in mortality could be due to improved diagnostic procedures and prevention, 
reduction of risk factors, and access to healthier diets13. However, CRC mortality rates are 
still high in some countries with limited resources, which could be due to the lack of 
predictive measures and/or the increase in the incidence of CRC8. Mortality rates are also 
30-40% higher in men than in women12.  
 
1.1.3 CRC risk factors 
 
No single risk factor accounts for most CRC cases. Instead, many lifestyle-related 
factors have been linked to CRC14. As a matter of fact, the links between diet, weight, and 
exercise and CRC risk are some of the strongest for any type of cancer10. In addition, there 
are other personal unmodifiable factors that are clearly involved in the lifetime risk of 
developing CRC, such medical history, age and genetic factors8,15. The main risk factors 
reported to be associated with CRC are summed up below. 
 
Nutritional and lifestyle factors:  
 
Diet plays a key role in the development of CRC16, and among the most extensively 
studied is probably the association between a high consumption of red and processed 
meat16–20, cholesterol-rich food and saturated fats8,21 with an increased risk for CRC. On 
the other hand, several epidemiological studies have shown that increased consumption 
of vitamin D, folate, fruits, vegetables16, a high-fiber diet22, calcium23 and dairy products 
reduce the risk for CRC8,10. Interestingly, recent studies have reported a dual role of the 
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gut microbiota in colorectal carcinogenesis24,25,  suggesting it may be an important 
effector in the relationship between diet and cancer16,26. 
 
The link between lifestyle and CRC is also well reported. Noteworthy, physical 
activity has a protector effect8,27, while obesity and increased body mass index can 
significantly increase the risk for CRC8,28. High alcohol consumption has been also reported 
to increase CRC incidence in a considerable amount of studies29–32, as well as tobacco 
consumption (specially cigarette smoking8), which is another common risk factor for 
CRC32–34. Conversely, although a correlation between caffeine consumption and increased 
risk for CRC has been suggested35, this relationship has not been definitively confirmed8. 
CRC rates have been also found to be higher in people with lower education or lower 
socioeconomic status, which could be due to higher incidence of moderating risk factors 
in those areas (such as immobility, unhealthy diet, smoking and obesity), as well as low 
screening rates8. On the other hand, several studies have shown that the use of aspirin 
and other nonsteroidal anti-inflammatory drugs (NSAIDs) can play a role in CRC 
prevention36–39. As a matter of fact, aspirin consumption is the only chemoprevention 
currently approved in patients with a higher genetic predisposition to CRC37, and can even 
reduce recurrence, metastasis and mortality38,39.  
 
Genetic factors: 
 
Inherited susceptibility contributes significantly to CRC predisposition, with an 
estimated 12-35% of risk attributed to genetic factors40,41. Certainly, people with a history 
of CRC in a first-degree relative (parent, sibling or child) are at a 2.25 increased risk of 
developing CRC42–45, and some studies suggest that the extended family history should be 
also considered46. This risk is even higher if the CRC was diagnosed before the age of 45 
or if more than one first-degree relative is affected, and can be due to inherited genes, 
shared environmental factors or the combination of both8,45. Having family members who 
have had adenomatous polyps is also linked to a higher risk for CRC47, given that 70-90% 
of CRCs arise from adenomatous polyps and that those larger than 2cm in diameter have 
a 50% chance of malignancy8,47. 
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This inherited susceptibility is caused by germline pathogenic variants in certain 
cancer risk genes, whose effect depends on the penetrance of the corresponding allele, 
which is defined as the percentage of individuals who present that variant that will 
develop the disease. The genetic factors that can predispose to CRC range between rare 
high-penetrance mutations that confer considerable elevations in the risk for hereditary 
syndromes and common low-penetrance variants or polymorphisms associated with 
weak effects on the risk for sporadic CRC41, including anything in between. In addition, 
common variants may also modify the risk in individuals with hereditary syndromes41. 
Figure 1.3 shows the main genes that have been associated with CRC predisposition, 
distributed by their conferred effect and risk allele frequency41. 
 
 
 
 
 
Figure 1.3. Genetic architecture of known CRC genetic susceptibility loci. Risk allele frequency 
shown for the ethnicity in which the locus was discovered. For variants with a recessive effect 
(MUTYH), the frequency of the homozygote rare allele is shown. Obtained from Peters et al. 
2016. 
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Personal medical history and other unmodifiable risk factors: 
 
Patients with long-term inflammatory bowel disease (such as ulcerative colitis and 
Crohn’s disease) have an increased risk for CRC48–50, which depends on the duration and 
extent of disease, the age of onset and the severity of inflammation8. Various studies have 
also shown that type 2 diabetes mellitus is associated with an increased risk for CRC51,52. 
Other CRC risk factors linked to the personal medical history include having undergone 
certain medical procedures such as cholecystectomy, ureterocolic anastomosis and pelvic 
radiotherapy8. Age is also a major risk factor for CRC, which is uncommon before the age 
of 409,11. The incidence begins to increase significantly between the ages of 40 and 50, 
with rates increasing in each succeeding decade8. On the other hand, the role of gender 
in CRC development has not been definitively confirmed, although in most studies it has 
been reported that CRC risk is higher in men than in women7,8. Interestingly, right-sided 
CRC has been observed more in women, while left-sided CRC is mostly observed in men53. 
 
1.1.4 Molecular mechanisms of colorectal carcinogenesis  
 
CRC is a heterogeneous group of diseases with distinctive genetic and epigenetic 
characteristics54. Colorectal carcinogenesis is driven by the sequential activation of proto-
oncogenes and inactivation of tumor suppressor genes55. Some of the genes that are 
particularly important in CRC are involved in pathways that are essential for cancer 
initiation and progression, such as the Wnt, MAPK, PI3K, TGF-β and p53 signaling 
pathways56. Alterations in these pathways can occur due to different molecular 
mechanisms of tumorigenesis. Most CRCs typically arise from one or a combination of 
three different mechanisms: chromosomal instability (CIN), microsatellite instability (MSI 
or MIN) and CpG island methylator phenotype (CIMP)57. Moreover, CIN, MSI, and CIMP 
often overlap, which has important implications for CRC prognosis, diagnosis and 
treatment57. The CIN pathway accounts for the majority of sporadic CRCs, whereas the 
MSI or mutator pathway accounts for the majority of hereditary cases and about 15% of 
sporadic CRCs58. On the other hand, the CIN pathway is thought to progress through the 
classic adenoma-carcinoma sequence55, while the CIMP pathway arises via the serrated 
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adenoma pathway (derived from sessile serrated adenomas)56, and MSI tumors have been 
reported to progress by both of these55,59.  
                                            
Chromosomal Instability:  
 
This is a hallmark of classical CRC that is associated with 70-85% of sporadic CRCs60, 
and typically begins with the acquirement of inactivating mutations in the APC gene, 
followed by the mutational activation of the  KRAS oncogene and the inactivation of tumor 
suppressor gene TP5357. This pathway is also associated with familial adenomatous 
polyposis, caused by germline mutations the APC gene61. APC is a tumor suppressor that 
negatively regulates the Wnt pathway. Its inactivation triggers the hyperactivation of the 
Wnt signaling pathway by increasing β-catenin levels and allowing its translocation to the 
nucleus, where it promotes the transcription of different oncogenes62. This inactivation 
may happen through somatic mutations (which occur in 72% of sporadic CRCs and 30%-
70% of sporadic adenomas) or by the hypermethylation of its promoter (which happens 
in 12% of primary carcinomas and adenomas)57. Mutations in other genes of this pathway, 
especially activating mutations in CTNNB1 (which encodes β-catenin), are also linked to 
CIN and are found in 48% of CRCs without APC mutations57. 
 
On the other hand, KRAS is the most commonly mutated member of the RAS family 
in CRC, and is an important component of the MAP kinase pathway, which regulates cell 
proliferation, differentiation, senescence and apoptosis62. Point mutations in exons 2 and 
3 of KRAS (mainly in codons 12, 13, and 61) activate this kinase, which further activates 
the Raf-MEK-ERK and PI3K/AKT/PKB pathways, promoting tumorigenesis57. KRAS 
mutations occur after APC mutations in 30%-60% of CRCs and play an important role in 
the adenoma-carcinoma sequence57,63. Last but not least, TP53 is a tumor suppressor 
gene that plays an essential role in the control of the cell cycle and apoptosis. The p53 
transcription factor induces G1 cell-cycle arrest and allows DNA repair prior to DNA 
replication, inducing cell death through apoptosis if DNA repair is unsuccessful62. TP53 
mutations are believed to occur at the time of transition from adenoma to cancer62, and 
are present in up to 75% of sporadic CRCs and approximately 30% of late adenomas58. In 
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addition, germline TP53 mutations cause Li-Fraumeni syndrome, which is an inherited 
condition that predisposes to a wide variety of neoplasms, including CRC64. 
 
Frequent genetic alterations observed in the CIN pathway include aneuploidy, 
which is an imbalance in the chromosome number57, chromosomal genomic 
amplifications on chromosomes 7, 8q, 13q, 20 and X, and a high frequency of loss of 
heterozygosity (LOH), which is the loss of one of the copies or alleles of a gene63. Broad 
deletions can occur at chromosomes 1, 4, 5, 8p, 14q, 15q, 17p, 18, 20p and 22q, with the 
highest LOH frequency affecting the long arm of chromosome 18 (18q)62, where many 
tumor suppressor genes are located, including SMAD4 and DCC58,63. Frequently affected 
by partial loss are also chromosome 5q ,where MCC and APC are located (20-50% of CRCs), 
8p (50% of CRCs) and 17p, where TP53 is located (75% of CRCs but not in adenomas)63. In 
addition, focal gains or losses are found in regions containing important cancer genes63, 
while mutations in other genes (such as TGFBR and PIK3CA) have been also recently 
described62. 
 
Microsatellite Instability:  
 
The MSI pathway is caused by the inactivation of the DNA mismatch repair (MMR) 
system, which is responsible for correcting the errors that occur during DNA replication 
as an additional system to preserve genomic integrity62, and whose most important 
components are ATPases MLH1, MLH3, MSH2, MSH3, MSH6, PMS1 and PMS257. Both 
alleles of a MMR gene must be inactivated for a deficient MMR system, which may be 
caused by somatic mutations in the MMR genes58 or by MMR promoter 
hypermethylation, mechanism that is often associated with the CIMP pathway57. 
Germline pathogenic mutations in the MMR genes (mainly MLH1, MSH2, MSH6 and 
PMS2) predispose to cancer causing Lynch Syndrome, a hereditary CRC syndrome that will 
be further explained in section 1.257. MSI is therefore a hallmark of Lynch Syndrome 
tumors, but is also found in 15-20% of sporadic CRCs62, usually caused by 
hypermethylation of the MLH1 gene promoter57. The MSI pathway is often associated 
with proximal colon tumors, mucinous histology, lymphocytic infiltration and poor 
differentiation but better prognosis57,62. 
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A defective MMR system results in genetic alterations in short tandem repeats 
(known as microsatellites), whose length variability in the tumor is termed microsatellite 
instability62. MSI can be detected by a five-marker panel which includes mono- or 
dinucleotide repeats in certain genes (such as BAT25, BAT26, D5S346, D2S123 and 
D17S250)57,63, while the immunohistochemical staining of MMR proteins is useful to 
identify which MMR protein is deficient62. Tumors with instability in ≥30% of these 
markers are called MSI-high (MSI-H), those with instability in <30% are called MSI-low 
(MSI-L), while those without MSI are called microsatellite stable (MSS)57. It is commonly 
accepted that the majority of MSS tumors follow the CIN pathway of tumorigenesis65. The 
consequence of MMR deficiency is the accumulation of somatic mutations, reason for 
which MSI tumors are hypermutated55 and this pathway is also known as the mutator 
pathway58. TGFβRII gene mutations are the most common in this pathway, but other 
genes targeted for mutations include BAX, CASP5, IGF2R, E2F4, TCF4, MSH3, MSH6, RIZ, 
PTEN, RAD50, BRAF and CDX258. LOH and mutations in APC, TP53 and KRAS are less 
frequently observed than in CIN, with APC mutations detected in only in 21% of MSI CRC 
cases58. BRAF mutations are common in sporadic but not hereditary MSI CRCs59. 
Interestingly, BRAF activating mutations activate the same RAS-RAF-MEK-ERK signaling 
pathway as KRAS, while TGFβRII mutations inactivate the TGF-β pathway, promoting 
growth and proliferation in the same way as SMAD4 loss, and BAX mutations can block 
p53-induced apoptosis as an alternative to TP53 mutations59. 
 
CpG Island Methylator Phenotype:  
 
Epigenetic regulation changes gene expression or function without affecting the 
DNA sequence, usually by DNA methylation or histone modifications63,65. DNA 
methylation commonly occurs at the cytosine within CG dinucleotides (called CpG islands) 
located around promoter regions near transcription start sites, leading to gene 
silencing59,63. Global DNA hypomethylation and localized promoter CpG island 
hypermethylation are common epigenetic events in cancer57, and environmental factors 
including smoking and advanced age have been shown to correlate with increased 
methylation63. Specifically, in CRC the CIMP pathway is characterized by widespread 
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promoter hypermethylation resulting in the transcriptional inactivation of multiple genes, 
including tumor suppressors or genes involved in the cell cycle57. This epigenetic gene 
silencing provides an alternative mechanism for loss of function of various tumor 
suppressor genes63, most importantly MGMT and MLH157, but also APC, MCC, CDKN2A, 
IGF2, RUNX3, SOCS1, MINTs and several others57,59,63. A classic example is the 
hypermethylation silencing of MLH1 in sporadic MSI-H CRC63.  
 
Although the CIMP phenotype can occur in either MSI-H or MSS tumors54, 
promoter hypermethylation usually overlaps with sporadic MSI CRCs66 and is associated 
with BRAF mutations and MSI57. Mutations in the BRAF proto-oncogene appear to be an 
early event in CIMP tumors57, specially the BRAF V600E mutation, which is strongly 
correlated with MLH1 hypermethylation and is observed in 18.7% of sporadic cases57. 
MLH1 hypermethylation has been confirmed in 80% of MSI-H sporadic CRCs, which 
present loss of MLH1 expression without germline MMR gene mutations57. Different 
marker gene panels (including MLH1, CDKN2A and other genes)57,59,63 have been 
developed to divide tumors as CIMP-high (CIMP-H), CIMP-low (CIMP-L) and CIMP-
negative65. Pathologically, CIMP-H tumors are often associated with older age, female 
gender, proximal tumor location, poor tumor differentiation, wild-type TP53, mucinous 
or signet ring cell morphology, marked peritumoral lymphocytic reaction and high levels 
of global DNA methylation56,63, features that are also associated with MSI-H tumors56. The 
precursor lesions are usually sessile serrated adenomas or serrated polyps, which account 
for 9% of colorectal polyps and have distinct features (flat or minimal elevation, strong 
predilection for the cecum and ascending colon, BRAF mutations and extensive DNA 
methylation)63. 
 
1.1.5 CRC classification 
 
Molecular CRC subtypes: 
 
Even though different combinations are possible, the analysis of the molecular 
mechanisms involved in tumor development has allowed the classification of CRC into 5 
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main molecular subtypes, each with a different molecular profile and clinico-pathological 
features59,63: 1) CIMP-H, MSI-H, MLH1 methylation, BRAF mutation, chromosomally 
stable, often originated in hyperplastic polyps, sessile-serrated lesions, and serrated 
adenomas, and known as sporadic MSI-H (12%). 2) CIMP-H, partial MLH1 methylation, 
BRAF mutation, chromosomally stable, MSS or MSI-L, originated in serrated polyps (8%). 
3) CIMP-L, KRAS mutation, MGMT methylation, CIN, MSS or MSI-L, with origin in 
conventional tubular or tubulovillous adenomas or serrated polyps (20%). 4) CIN, MSS, 
CIMP-negative, originated in traditional adenomas (57%). 5) Inherited MMR gene 
mutation, MSI-H, CIMP-negative, BRAF mutation negative, chromosomally stable, with 
origin in conventional adenomas or occasionally in serrated adenomas (3%)59,63. 
 
Sporadic, familial and hereditary CRC: 
 
According to the family history, CRC can be classified into 3 types67, as shown in 
Figure 1.4: 1) Sporadic CRC represents the vast majority of CRCs (60-80%) and appears in 
individuals with no family history of CRC and no cancer-predisposing germline 
mutations67. 2) Familial CRC refers to a group of cases with some familial aggregation of 
the disease but without a dominant inheritance pattern and for which no associated genes 
have been identified. These cases represent 20-40% of CRCs are thought to result from a 
combination of genetic predisposition due to low-risk alleles and environmental or 
lifestyle shared factors67. 3) Hereditary CRC comprises those cases that show a Mendelian 
inheritance of CRC and other associated cancers, and/or present pathogenic mutations in 
known CRC-predisposition genes. This group is further divided depending on the presence 
of polyps into polyposis and non-polyposis syndromes, and accounts for 5-10% of all 
CRCs67. 
 
CRC staging classification: 
 
 CRC stages were created for diagnostic purposes in order to help ascertain the 
extent to which a certain CRC had developed. Tumor staging is determined by histologic 
analysis of surgically resected lesions based on a series of parameters, and is important 
for the estimation of prognosis and the selection of the most suitable treatment for each 
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patient54. The most commonly used staging system for CRC is the American Joint 
Committee on Cancer (AJCC) TNM system68, which assigns a number based on 3 
categories: the size of the tumor and degree of invasion of the colon wall (T), the degree 
of spreading to nearby lymph nodes (N) and the degree of spreading to other organs or 
metastasis (M). Carcinoma in situ (stage 0) is the earliest stage, after which stages range 
from I to IV, with higher numbers meaning a higher spreading (Figure 1.5). Stages II, III and 
IV are in addition divided into further subgroups (A, B and C) for a more accurate 
classification.  
 
Other staging systems that have been used over the years include the Dukes 
classification69,70, ranging from dukes A to D, and the Ashton-Coller classification71, which 
is an adaptation from the former that further divides stages B and C. However, currently 
both of these have been largely replaced by the TNM system68. 
 
 
 
 
 
 
Figure 1.4. CRC classification based on family history. Even though the majority of CRCs are 
sporadic, it is estimated that about a 20-30% of CRCs have a familial component, with a 5-10% 
showing a dominant pattern of inheritance or presenting mutations in CRC predisposition 
genes. That fraction is called hereditary CRC, and is comprised of a few different polyposis 
syndromes and a majority of Hereditary Non-Polyposis Colorectal Cancer (HNPCC) cases. 
HNPCC is defined by the fulfillment of the Amsterdam I/II criteria and is further divided into 
Lynch Syndrome, Lynch-like Syndrome and Familial Colorectal Cancer Type X (FCCTX), which is 
the group in which this thesis is focused. 
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Figure 1.5. CRC staging classification. Simplified representation of the different stages in the 
development of a colorectal tumor, from a carcinoma in situ (stage 0) until the invasion of 
lymph nodes (stage III) and distant organs (stage IV). Images have been modified from the 
National Cancer Institute (www.cancer.gov). 
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1.2 Hereditary CRC syndromes 
 
Even though the majority of CRCs are sporadic, genetic susceptibility to CRC is 
more common than previously thought72. Several recent studies have identified 
pathogenic germline variants in a broad spectrum of high and moderate penetrance 
cancer susceptibility genes in >10% of individuals with CRC72. Genetic susceptibility 
appears to be even more prevalent among young CRC patients, with several studies 
documenting prevalence of germline mutations of 16-33% among those diagnosed under 
the age of 5073,74. The hereditary CRC syndromes, characterized by dramatic increases in 
risk for colorectal neoplasia, are phenotypically divided into polyposis and nonpolyposis 
syndromes, based largely on the number and histology of colorectal polyps75.   
 
1.2.1. Polyposis syndromes 
 
Polyposis syndromes represent around 1% of all CRC cases and can be divided, 
based on their histology and genetic basis, into the broad categories detailed below75,76. 
 
Adenomatous polyposis: 
 
 Familial adenomatous polyposis (FAP) is an autosomal dominant genetic disease 
characterized by the development of multiple colorectal adenomas (usually from 
dozens to hundreds), and caused by pathogenic germline variants in the APC gene75,77. 
Despite its inheritance pattern, approximately 25-30% of the cases have no family 
history and are explained by de novo mutations or somatic mosaicisms77–80. The clinical 
presentation varies significantly, from a classic phenotype (100s-1000s polyps) that 
usually requires surgical colectomy, to more subtle presentations (10-100 polyps), 
known as attenuated polyposis (AFAP) 77,78. If untreated, individuals with FAP and 
AFAP have a lifetime risk of developing CRC of 100% and 69%, respectively77. In 
addition, they can also develop upper gastrointestinal tract lesions (including gastric 
fundic gland polyps and duodenal adenomas) and extraintestinal manifestations such 
as increased risk for papillary thyroid cancers and desmoid tumors75.  
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 MUTYH-associated polyposis (MAP) is an autosomal recessive syndrome associated 
with biallelic germline variants in the base-excision repair gene MUTYH. Individuals 
with MAP can present a wide range of phenotypes including classic and attenuated 
polyposis, with an increased risk for CRC77,81. Although adenomatous polyps 
predominate in MAP, hyperplastic polyps are also common77. It is still unclear whether 
monoallelic MUTYH variants could be associated with a moderate CRC risk increase75,82. 
 
 Polymerase Proofreading-Associated Polyposis (PPAP) is associated with germline 
pathogenic variants in the exonuclease proofreading domains of the POLE and POLD1 
polymerases83,84. PPAP patients may present autosomal dominant classic or 
attenuated polyposis, and show ultramutated tumors with MMR-proficient 
phenotypes75. 
 
 Other adenomatous polyposis syndromes include two recently identified rare 
autosomal recessive forms caused by biallelic mutations in NTHL1, a DNA glycosylase 
involved in base excision repair, and in MSH3, a MMR gene not associated with Lynch 
syndrome75,85. The latter has been reported to confer susceptibility to classical or 
attenuated adenomatous polyposis and possibly extracolonic tumors, including breast 
cancer86,87. 
 
Hamartomatous polyposis syndromes:      
 
Although rare, hamartomatous polyposis syndromes are characterized by the 
presence of gastrointestinal hamartomatous polyps and exhibit autosomal dominant 
patterns of inheritance75. This type of polyposis includes the following syndromes: 
 
 Peutz-Jeghers syndrome (PJS) is characterized by multiple hamartomatous polyps 
throughout the gastrointestinal tract and increased risk for various cancers including 
gastric, colorectal, pancreatic, breast, lung, and sex cord tumors. Individuals with PJS 
may have prominent mucocutaneous pigmentation and bowel obstructions due to 
polyp intussusceptions. Germline pathogenic variants in STK11 are identified in 50-70% 
of individuals75,88. 
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 Juvenile polyposis syndrome (JPS) is characterized by multiple gastric and/or colonic 
hamartomas and increased risk for gastric cancer and CRC. Germline pathogenic 
variants in BMPR1A and SMAD4 are identified in 50-70% of affected individuals, and 
those with SMAD4 mutations are also at risk for hereditary hemorrhagic 
telangiectasia75,89. 
 
 PTEN-hamartoma tumor syndrome (PHTS) is associated with increased risk for breast, 
thyroid, endometrial, renal and gastrointestinal cancers and is caused by germline 
pathogenic variants in PTEN75. The gastrointestinal phenotype of PHTS can include 
gastric and colorectal hamartomas, adenomas, serrated polyps, hyperplastic polyps, 
lipomas and ganglioneuromas90. PTEN pathogenic variants confer variable clinical 
phenotypes, which include different conditions such as Cowden, Bannayan-Riley-
Ruvalcaba and Proteus-like syndromes75,91–93. 
 
Serrated polyposis:  
 
Previously known as hyperplastic polyposis, serrated polyposis is defined by: 1) 
more than 5 serrated polyps proximal to the sigmoid colon with at least two bigger than 
1cm; 2) any number of serrated polyps proximal to the sigmoid colon in an individual with 
a first-degree relative who has serrated polyposis; or 3) more than 20 serrated polyps of 
any size throughout the colon54. Germline mutations in the tumor suppressor gene RNF43 
have been identified in rare cases of serrated polyposis, but the mutation frequency 
among affected individuals is low94,95. Although germline mutations in GREM1 and MUTYH 
have been reported, genetic testing is usually uninformative75,96,97. 
 
Mixed polyposis: 
 
Mixed polyposis is characterized by the presence of multiple colorectal polyps of 
mixed histological type (including serrated lesions, hamartomas and conventional 
adenomas), and is associated with an increased risk for CRC. While the genetic cause is 
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still unknown in most cases, germline variants in and upstream of GREM1 have been 
identified in some affected individuals75,98. 
 
1.2.2. Hereditary non-polyposis CRC 
 
Even though the CRC syndromes associated with polyposis phenotypes are the 
most easily recognized, the vast majority of individuals affected by genetic predisposition 
to CRC do not exhibit multiple polyps75. Syndromic non-polyposis CRC is called Hereditary 
Non-Polyposis Colorectal Cancer (HNPCC) and accounts for about 5-10% of all the cases 
of CRC. HNPCC is defined by the fulfillment of one of two sets of selection criteria, known 
as the Amsterdam Criteria I and II (AC-I/II), which are shown in Table 1.199. Although 
HNPCC shows a clear dominant inheritance pattern of CRC and other associated cancers, 
the genetic basis underlying the increased cancer risk of these families is only known in 
50-60% of them. These explained cases are known as Lynch Syndrome, and present 
tumors with defects in the mismatch repair pathway of DNA repair (known as MMR) and 
a MSI phenotype. For this reason, HNPCC has been subdivided on the basis of the 
molecular tumor phenotype as MMR-deficient/MSI (Lynch Syndrome) or MMR-
proficient/MSS (Familial Colorectal Cancer Type X)75. The pipeline for the diagnosis of the 
different HNPCC syndromes is shown in Figure 1.6. 
 
Lynch Syndrome: 
 
Lynch Syndrome (LS) is the most common of the hereditary CRC syndromes, 
accounting for 50-60% of the families that fulfill the AC-I/II clinical criteria and 3-5% of all 
CRC cases. In these patients, the cancer predisposition is caused by germline pathogenic 
mutations in one of the MMR genes, mainly MLH1, MSH2, MSH6 and PMS299, although 
deletions of the 3’ end of EPCAM (which leads to methylation of the promoter region of 
MSH2) have also been described as a cause behind LS75. Germline pathogenic mutations 
in these genes lead to the lack of expression of the corresponding protein in the tumors, 
what results in a deficient MMR pathway that fails to repair the errors produced during 
DNA replication100. Stretches of DNA with repetitive sequences of nucleotides known as 
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microsatellites are particularly susceptible to DNA errors when the MMR genes are 
damaged99, leading to microsatellite instability (MSI). For this reason, LS-associated 
tumors have distinctive molecular phenotypes of MMR-deficiency, high MSI and loss of 
expression of the corresponding DNA mismatch repair protein as observed by 
immunohistochemistry (IHC)75. Although CRC and endometrial cancer are the most 
common cancers in families affected by germline mutations in these genes, the 
International Collaborative Group on HNPCC claims that risk for other cancers is also 
increased among mutation carriers, including cancers of the stomach, ovary, urinary tract, 
brain (glioma), hepatobiliary tract and skin (sebaceous tumors)75. Lynch-associated 
colorectal neoplasms tend to develop at younger ages and progress more rapidly 
compared with sporadic CRCs, requiring specialized surveillance75. However, only four 
HNPCC-associated cancers (cancer of the endometrium, small bowel, ureter or renal 
pelvis) are included in the AC-II. 
 
Even though the terms HNPCC and LS have been often used as synonyms, it is now 
suggested that LS is defined as a cancer syndrome caused by a defect in one or more of 
the MMR genes, while HNPCC is defined based on the fulfillment of the AC99. Families who 
fulfill the AC or the more lenient revised Bethesda Guidelines (which are only used for 
clinical purposes in order to increase diagnose sensitivity) comprise a risk group and 
should be tested for MMR deficiency. Sequencing the MMR genes in germline DNA is 
necessary in order to identify the exact disease-causing germline mutations (point 
mutations, small insertions, splice site alterations and deletions), but sequencing cannot 
identify mutations in which the entire gene or whole exons are deleted. These deletions 
can be identified by multiplex ligation-dependent probe amplification (MLPA). In addition, 
NGS targeted sequencing platforms have been developed for use in clinical settings. Other 
strategies applied prior to sequencing include testing for MSI or absence of the MMR 
proteins by IHC in the tumors. MSI-status is assessed using a panel of microsatellite 
markers, classifying tumors as MSI-high, MSI-low or MSS. MSI-H or absence of MMR 
proteins are indicators of LS, but the diagnosis cannot be made just on this basis, because 
10-15% of sporadic CRC's also exhibit MSI or absence of MLH1 due to promoter 
hypermethylation99.  
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Regarding the histopathological features, CRCs linked to LS have a predominant 
right-sided location and are characterized by poorly differentiated tumors, mucinous 
differentiation, an expanding growth pattern, abundant peritumoral and tumor-
infiltrating lymphocytes, Crohn-like reactions and lack of dirty necrosis101,102. The gene 
expression signature of LS is characterized by upregulation of genes related to antigen 
processing and presentation, apoptosis, natural killer cell-mediated cytotoxicity and T-cell 
activation103. 
 
 
Table 1.1. Selection criteria for Hereditary Non-Polyposis Colorectal Cancer. The Amsterdam 
I or II criteria (AC-I/II) must be fulfilled by the family for their classification as HNPCC. The only 
difference between AC-I and II is that AC-II also takes into account extracolonic tumors in 
certain locations. The more lenient Bethesda criteria is only used to determine those high-risk 
families that should be tested for Lynch syndrome in the clinical practice in order to increase 
the sensitivity. 
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Lynch-like Syndrome: 
 
There is a subgroup of HNPCC that presents MMR deficiency and the 
corresponding MSI in the tumors, but where MMR germline mutations have not been 
identified. This group of families has been classified as Lynch-like Syndrome, although 
some of these cases may be explained by false negative results caused by technical errors 
of the screening method. The arrival of Next Generation Sequencing has reduced the 
Figure 1.6. Pipeline for the diagnosis of the different HNPCC syndromes. This diagram is a 
simplification of the steps that follow a CRC diagnosis for its classification as one of the 3 HNPCC 
entities described to date. Note that other cases such as polyposis syndromes, familial CRC and 
sporadic CRC have not been included. 
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amount families incorrectly classified, due to a higher efficiency than the previous 
methods. However, there is still a fraction of HNPCC families that remain under this 
category. These cases may be caused by promoter hypermethylation of the MMR genes 
(such as MLH1) or by any alteration that is not detectable by the commonly used 
mutational screening techniques, like variants affecting non-coding regions of the MMR 
genes. Certainly, many authors believe that patients with Lynch-like Syndrome have 
actually LS with germline mutations in MMR genes undetectable by current testing, 
although there are other mechanisms that could inactivate MMR genes resulting in 
tumors that resemble LS104. 
 
Familial Colorectal Cancer Type X: 
 
The genetic basis underlying the cancer inheritance is unknown for the remaining 
40-50% of HNPCC families, which have MMR-proficient tumors. This group, referred to as 
Familial Colorectal Cancer Type X (FCCTX), is characterized by being microsatellite stable 
(MSS) and by the absence of germline mutations in the MMR genes99. This group of 
families is the subject of study of this thesis and is therefore further explained in section 
1.3. 
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1.3 Familial Colorectal Cancer Type X 
 
1.3.1. Definition and terminology 
 
Among patients with clinical characteristics of HNPCC, there is a group known as 
Familial Colorectal Cancer Type X or FCCTX that is defined based on the fulfilment of the 
Amsterdam I or II clinical criteria but presenting MMR-proficient, MSS tumors. FCCTX 
cases lack the MMR germline mutations that define LS, and therefore progress through 
different mechanisms of carcinogenesis105. The name FCCTX is adequate for an entity with 
an unclear carcinogenesis pathway and unknown genetic basis. Even though the first 
study that used the term FCCTX only included AC-I families106, most groups currently 
include both AC-I and AC-II in their definition of FCCTX. Noteworthy, this group of MMR-
proficient, MSS, HNPCC families had already been identified before this name emerged. 
For that reason, there is a remarkable diversity of abbreviations that have been used to 
designate these families over the years, including FCCTX, FCC-X, HNPCC-MSS, fCRC-X and 
MMR-p HNPCC, which hinders the literature search for this condition. However, the term 
FCCTX is currently the most widespread. 
 
In addition to the MSS phenotype, various clinical, morphological and molecular 
features differ between FCCTX and LS. Unfortunately, despite the recent progress in 
clinical detection of FCCTX, its genetic etiology still remains unknown105. Current evidence 
suggests that FCCTX is a highly heterogeneous disease, presumably caused by germline 
mutations in novel high or moderate-risk cancer predisposition genes. However, it could 
also result from a combination of low-penetrance alleles in different genes increasing the 
cancer susceptibility in some families107, or even from the aggregation of sporadic cases 
due to shared lifestyle factors11,106. This makes the identification of the genetic basis 
underlying FCCTX tumorigenesis a challenge that many groups are currently facing using 
different approaches. In addition, there is also heterogeneity regarding the clinical and 
histopathologic features, epigenetic, genomic profiles and gene expression profiles, and 
altered pathways101. 
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The detection of the genes associated with FCCTX will facilitate the molecular 
diagnosis of the disease105, and allow optimal counselling, screening and treatment, as 
well and prevention programs for other family members. Therefore, investigation of the 
genetic background of FCCTX is of great importance99. 
 
1.3.2. Clinical, morphological and molecular features 
 
Clinical and histopathologic features:  
 
FCCTX family members have been reported to show a lower risk for CRC compared 
to LS106,108. In addition, the age of onset in FCCTX patients shows considerable variability 
between families, and even between individuals within the same family101. However, it is 
well established that CRC is diagnosed at a higher mean age in FCCTX patients than in LS 
(60.7 years vs 48.7 years, respectively, as described by Lindor et al)101. Although this 
increase in the age at diagnosis is supported by all studies published to date, the specific 
mean onset age varies according to the study, ranging from 51 to 63 years for FCCTX and 
from 38 to 54 for LS108–111,102,112–117. In the same way, the mean age difference reported 
between the two syndromes ranges from as low as 3 years to up to 15 years depending 
on the study99, but is generally believed to be closer to 10 years. Consistent with this, 
HNPCC families with higher diagnosis ages show a high proportion of MSS families118.  
 
On the other hand, many studies claim that FCCTX’s tumor spectrum is 
predominated by CRC117 and that there is a lower incidence of extracolonic tumors than 
in LS108–110, some of them even suggesting that FCCTX families do not show any increased 
risk for other HNPCC-associated cancers101,106. This may be due to the fact that some 
studies have defined FCCTX as families fulfilling the Amsterdam I criteria with MMR-
proficient tumors, while others also included Amsterdam II families101. Apart from the 
lower cumulative incidence of extracolonic cancers, their frequency, number of organs 
and mean age at diagnosis has also been reported to be lower in FCCTX than in LS119. 
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However, unlike other clinical features, the lower risk for extracolonic tumors is not 
supported by all the groups120. 
 
Regarding the histopathological features, a number of studies have shown that 
CRCs from FCCTX and LS show different morphological features105. In the first place, CRCs 
linked to FCCTX are characterized by a predominant distal location108–
111,102,112,113,115,116,121, with 65-75% of the cases developing in the left colon or rectum, 
which differs from the right-sided preference of LS CRCs117. In addition, FCCTX tumors 
show a higher adenoma/carcinoma ratio109,121, a lower frequency of multiple CRCs 
(synchronous or metachronous)109,121 and more frequent polyp detection (including 
synchronous or metachronous adenomas)101,116, which may indicate a slower adenoma-
carcinoma progression rate in FCCTX101,105. Moreover, FCCTX is associated with a more 
sporadic-like phenotype, with a higher tumor differentiation111,102,112,113,121, glandular and 
infiltrative growth patterns (as opposed to expanding)101,102, and a higher degree of dirty 
necrosis (glands filled with necrotic debris) and tumor budding compared to LS102. Other 
features observed in FCCTX tumors include a lower rate of lymphocytic reactions 
(including peritumorous and tumor-infiltrating lymphocytes102,111,112,121 and Crohn-like 
reactions102,112), a more heterogeneous and frequently tubular architecture102 and a lower 
frequency of mucin production110,111,102,121. Unfortunately, despite these generally 
observed morphological trends, FCCTX tumors lack distinct histopathologic features. This 
makes the pathological identification of FCCTX-associated CRCs challenging, implying that 
these cases cannot be recognized based only on histopathological features and that family 
history needs to be taken into account102. Lastly, despite the lower CRC cumulative risk 
described for FCCTX family members, it has been suggested that this subgroup has a 
worse prognosis than LS101, with a lower overall and disease-free survival122. Another 
study has reported that FCCTX’s overall survival is similar to LS for stage II tumors, while 
between LS and sporadic CRC for stage III tumors (LS > FCCTX > sporadic CRC)116. 
 
Epigenetic profile: 
 
As already described, the CIMP pathway is characterized by CpG island hypermethylation, 
and is often associated to the MSI phenotype. Conversely, global DNA hypomethylation is 
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observed in 30-40% of CRCs and has been associated with poor prognosis, shorter survival, 
younger age of onset and familial CRC risk.101. As a matter of fact, a series of studies has 
demonstrated that FCCTX tumors are highly hypomethylated compared with other CRCs, 
including LS and sporadic MSS CRC123,124. While each of the studied groups showed lower 
methylation in the tumor than in healthy tissue, the lowest methylation was observed for 
FCCTX in both tissues124. For this reason, Chen et al even suggested a 5-gene marker panel 
targeted at certain loci as useful biomarkers to distinguish LS from FCCTX123. Actually, it 
has been reported that although most FCCTX tumors present some degree of CpG 
methylation, none of them showed a high methylation index125. Among the 
hypomethylated loci, LINE-1 can be pointed out. LINE-1  hypomethylation has been linked 
to familial CRC and specifically to FCCTX, with a decreasing trend for LINE-1 methylation 
from sporadic CRC to LS to FCCTX124. Global hypomethylation can result in LINE-1 
activation, what is thought to interfere with chromosomal segregation leading to CIN113. 
The predisposition to LINE-1 hypomethylation in FCCTX tumors provides evidence for a 
link between distinct molecular signatures and phenotypes associated with specific 
epigenotypes101.  
 
Genomic profiles:  
 
The genomic profiles of FCCTX tumors also show some similarities to sporadic MSS 
CRCs, typically presenting from 6 to 8 copy number variations (CNVs)101. FCCTX tumors 
have been reported to show increased and distinct CNVs compared to MSI126. Some CNVs 
associated to FCCTX tumors include recurrent gains of chromosomes 5p, 7p, 7q, 8q, 13q, 
17, 19, 20p and 20q, and losses of 8p, 15, 17p, 18p and 18q101,126–128. Probably the most 
extended of all these chromosomal alterations is the gain of the 20q region, which has 
been specifically linked to FCCTX tumors and is observed in 65-70% of these cases127,128. 
Several candidate target genes are located in this region, including GNAS, AURKA, SRC, 
TOP1, NELFCD, ADRM1, ASIP, CDH26 and HNF1A101. Loss of chromosome 18 is another 
common alteration in FCCTX tumors, which is also observed in sporadic CRCs. Some 
candidate genes downregulated by this alteration include SMAD2, SMAD4, DCC, SERPINB5 
and BCL2, among other101. Gain of 20q and loss of chromosome 18 particularly 
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discriminated between FCCTX and LS tumors, suggesting different preferred tumorigenic 
pathways128. 
 
Another frequently observed alteration is high levels of genome-wide copy neutral 
loss of heterozygosity, detected in 32-40% of FCCTX tumors101,127. In addition, low 
frequency of chromosomal losses (14%) have been demonstrated in FCCTX tumors, which 
could indicate the involvement of DNA repair mechanisms still unidentified101. Mutations 
in several cancer-related genes such as TP53, KRAS, BRAF, APC and CTNNB1 divide FCCTX 
tumors into two major groups: one-third of the tumors are characterized by stable 
genotypes with few genetic changes, retained membranous β-catenin expression and 
infrequent TP53 mutations, and two-thirds of the tumors show frequent loss of tumor 
suppressor gene loci such as APC, TP53, SMAD4 and DCC, somatic methylation of APC, 
KRAS, and MGMT and nuclear translocation of β-catenin101. These genetic subsets have 
been suggested to differ in clinical presentation: the first group predominantly develops 
tumors in the proximal colon at a lower age (mean 54 years), whereas the second group 
more often develop tumors in the distal colon and are diagnosed at a higher age (mean 
59 years)101.  
 
Gene expression profiles and altered pathways: 
  
Although studies aiming to clarify the molecular characteristics of FCCTX tumors have 
increased in the past few years, most gene expression studies in CRC have focused on the 
differences between sporadic – but not hereditary – MSI and MSS tumors. These show 
distinct profiles with significant deregulation of 65-2070 genes, including those involved 
in growth factor receptor pathways, transcription, cell cycle, DNA repair, chromatin 
structure, drug metabolism and chemoresistance101. Gene expression data from FCCTX 
tumors reportedly show some similarities to sporadic MSS CRCs, with upregulation of 
genes involved in cellular functions such as amino acid modification, enzyme-linked 
receptor signaling, growth regulation, DNA repair, vascular smooth muscle contraction 
and G protein-coupled receptor signaling101. A total of 2188 genes have been shown to 
have distinct expression in FCCTX when compared to LS, including NDUFA9, AXIN2, MYC, 
DNA2 and H2AFZ113. This suggests that these two entities have deregulation of different 
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canonical pathways. For instance, genes regulating the G-protein coupled signaling are 
reportedly upregulated in FCCTX, while genes relating to the cell cycle, mitosis and 
oxidative phosphorylation are upregulated in LS113.   
 
The current understanding of the influence that gene expression profiles have in 
the development of FCCTX tumors suggests increased proliferation, reduced apoptotic 
activity, and enhanced migration and invasion, which could contribute to the poor 
prognosis suggested in this subgroup101. Candidate genes involved in proliferation and 
migration that have been described in FCCTX include in chromosome 20q genes CDH26, 
SRC and ASIP. On the other hand, upregulation of the SRC-dependent pathway (through 
COX-2/PGE-2 signaling, PTGER1 and ANGPTL4) may drive FCCTX tumor development 
during anaerobic conditions, what would explain the frequent dirty necrosis and the 
downregulation of aerobic oxidative phosphorylation metabolism genes (such as ATP5L, 
ATP5A1, ATP5B and ATP5D)101. In addition, copy number gains and EGFR-mediated 
activation of SRC have been correlated to migration and invasion101. A growth advantage 
may be also achieved in FCCTX tumors by biallelic loss of certain genes, such as SMAD2 
and SMAD4 (which inhibit TGFβR-mediated growth), BCL2 (which induces apoptosis) and 
SERPINB5 (tumor suppressor activated by TP53 that induces apoptosis and inhibits 
migration and invasion)101.  
 
The majority of FCCTX tumors (61-63%) showed membranous location of β-
catenin, indicating normal regulation of the Wnt signaling pathway unike most LS tumors, 
which showed deregulation of this pathway (81%). In addition, 56-57% of FCCTX tumors 
with aberrant β-catenin presented APC mutations, while none harbored CTNNB1 
mutations120,129. Membranous localization of β-catenin was associated with chromosomal 
stability (CIN-), younger age of onset, right-sided tumors and infrequent TP53 mutations, 
while aberrant β-catenin was associated with older age of onset, left-sided tumors and 
CIN+ phenotype129. Mutations in genes related to the Wnt pathway, such as GNAS, might 
only explain a fraction of FCCTX tumors105. 
 
1.3.3. Surveillance recommendations and management 
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Given the higher age at diagnosis and the lower CRC cumulative risk reported for 
FCCTX families, most professionals recommend in this group of families a less intense 
surveillance than for LS101,130. This means less frequent and more individualized 
surveillance131.  Although the benefits of colonic surveillance are clear, since screening 
colonoscopies in asymptomatic FCCTX family members significantly decrease CRC risk132, 
the interval between colonoscopies is debated for different hereditary CRC subgroups131. 
Surveillance programs in FCCTX are mainly targeted at CRC, with colonoscopies generally 
recommended with 3-5-year intervals, starting 5-10 years before the earliest age of onset 
in the family101. It has been suggested that FCCTX families should be managed similarly to 
families with CRC aggregation but diagnosed above 50, since they both have high CRC 
prevalence and develop high-risk adenomas133. Given that the genetic basis responsible 
for the increased susceptibility is not known, all members from a certain FCCTX family 
should undergo the same surveillance101.  
 
On the other hand, therapeutic strategies and surgical management differs in LS, 
FCCTX and sporadic CRC cases134. Patients with a higher risk should ideally be identified in 
advance in order to perform the best surgical management. However, when the molecular 
basis of family CRC aggregation are unknown, as is the case of FCCTX, surgical indications 
and techniques should remain as in standard cases, although an individualization of 
subjects and their families is mandatory considering age at diagnosis, family cancer 
history, and characteristic phenotypes134. 
 
1.3.4. Approaches to identify CRC risk genes/loci 
 
Linkage analysis: 
 
Genome-wide linkage analyses are used for relatively frequent high-risk alleles and 
have previously helped identify causal genes in monogenic diseases with classical 
Mendelian inheritance patterns99. The method is based on the observation that genes 
localized close to each other on a chromosome are inherited together and are thus in 
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linkage disequilibrium99. DNA polymorphisms can be used as markers to identify the locus 
of a disease-causing gene by determining the haplotype and recombination frequency in 
family members99. The logarithm to odds (LOD) score is used to statistically estimate how 
likely two loci are linked, with LOD>3 meaning a significant link and LOD<-2 an unlikely 
link99. However, this approach has some limitations, such as the loss of power in the 
presence of heterogeneity given that it is not possible to calculate correct LOD scores in 
heterogenic diseases, the requirement of multigenerational pedigrees of affected 
individuals and the potential misleading results misdiagnoses and phenocopies can give99.  
 
Genome wide association studies: 
 
Genome wide association studies (GWAS) have increased over the last few years 
and are used for the identification of common low-risk alleles. These are a non-hypothesis 
driven method with a case-control design based on the ‘common-disease, common-
variant’ model, where the cause of the disease is attributed to various risk-alleles with a 
relatively high frequency99. For this purpose, the prevalence of genetic markers covering 
both coding and non-coding regions is compared in affected and unaffected (control) 
individuals99. However, a sample size with sufficient statistical power is critical for the 
success of genetic association studies to detect causal genes in complex diseases, and 
GWAS require much larger sample sizes  to achieve an adequate statistical power135, 
which is this method’s main limitation.  In addition, GWAS is underpowered to detect 
associations in rare variants, given their small sample size99.  
 
Next generation sequencing: 
 
Next generation sequencing (NGS) is used for the identification of rare variants in 
high or moderate-risk alleles, and has replaced previous “classical” approaches, such as 
Sanger sequencing. In NGS, DNA sequences of interest are captured and sequenced in 
millions of parallel reactions that are afterwards analyzed, which requires comprehensive 
bioinformatics work for the identification of causative mutations99. However, causal 
mutations may be discarded in the filtering process, for instance, by focusing on nonsense 
variations, if the causative mutation is a low/moderate penetrance missense variation, 
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which might be important in diseases with reduced penetrance such as FCCTX99. Since 
NGS is the method that was used in this thesis for the identification of putative causal 
mutations in FCCTX, the different NGS technologies and applications are further detailed 
in section 1.4.  
 
1.3.5. Genetic susceptibility 
 
Despite the high expectations created by NGS and other aforementioned 
approaches, identifying new CRC genes in FCCTX has remained a challenge136. This may 
be due to the lack of major high-penetrance genes, the heterogeneity of FCCTX families 
and the difficulty of demonstrating the causality of candidate genes. After high efforts to 
identify new genes that could potentially explain the dominant inheritance of FCCTX, only 
a few putative familial CRC genes have been proposed. However, most are extremely 
uncommon, while others may only moderately increase the risk for CRC, which 
complicates the assessment of their contribution to CRC predisposition75,136–139. So far, 
most novel candidate genes lack corroborative data136, and information from additional 
mutation carriers is required to estimate risks and recommend surveillance 
measures140,141.  
 
Some of the genes that have been associated with FCCTX predisposition in recent studies 
include RPS20140, BRCA2142, FAN1143, GALNT12144, BMPR1A145, SEMA4146, NTS147, 
RASSF9147, TGFBR1148 and OGG1149. However, it has been suggested that the only 
candidate gene that has shown consistent association with HNPCC is RPS20, which 
encodes a ribosomal protein75,140. Although scarce, available data suggest high 
penetrance for RSP20 mutations and absence of extracolonic manifestations75,140. Other 
studies consider that given that BRCA2 has the highest mutation rate and is one of the 
most crucial DNA repair genes, it will be soon considered a big role player in this type of 
cancer in comparison with other genes105. This well-known gene for its essential role in 
the predisposition to hereditary breast and ovarian cancer has more recently been linked 
to CRC risk142, and is also associated with the fanconi anemia pathway. Interestingly, 
different studies have suggested an association between other genes from this pathway 
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(such as FAN1, BRIP1/FANCJ, FANCC, FANCE, REV3L/POLZ and FANCM) and CRC 
susceptibility in a considerable number of families143,150,151. 
 
Some of the other pathways in which reported FCCTX-associated genes are involved 
include the TGF-β pathway (TGFBR1 and BMPR1A)145,148 and base excision repair (NUDT1 
and OGG1)149. In addition, SEMA4A mutations were proved to increase MAPK/Erk and 
PI3K/Akt pathways and cell cycle progression146. Nonetheless, certain studies suggest that 
some of these genes associated with FCCTX are not major contributors of CRC 
susceptibility in FCCTX families145,152. That is the case of BMPR1A and GALNT12, even 
though mutations in the latter have been consistently associated with CRC144. In fact, that 
is probably the case of most of these genes and other genes that are still to be found, 
which implies that candidate susceptibility genes may explain individually a quite reduced 
number of FCCTX families. 
 
On the other hand, a number of GWAS have addressed low-risk susceptibility loci 
in hereditary CRC, although not specifically linked to FCCTX. Several loci associated to CRC 
identified by GWAS include genes implicated in CRC development, such as BMP2, BMP4, 
CDH1 and RHPN299. BMP2 and BMP4 are part of the TGF-β family that signal intestinal 
stem cells through suppression of the Wnt/β-catenin signaling pathway, CDH1 is also 
involved in the Wnt/β-catenin signaling pathway, while RHPN2 is involved in the actin 
cytoskeleton and cell motility, which can promote cancer invasiveness through adherence 
junction formation99. Other candidate genetic variants have been reported in CENPE, 
CDH18, GALNT12, ZNF367, HABP4 and GABBR2 on chromosome 9, GREM1 and KIF24 on 
chromosome 15, and BCR at 22q11101. Current understanding suggests that the risk alleles 
identified are insufficient to independently account for FCCTX cases, but a combination of 
moderate and low-risk alleles could contribute to the familial aggregation101. 
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1.4 Next Generation Sequencing 
 
The main method on which this study was based is Next-Generation Sequencing – 
NGS – or massive parallel sequencing, a state-of-the-art sequencing technology that has 
revolutionized genomic research, increasing our understanding of the genetic basis of 
Mendelian diseases exponentially153. Certainly, the arrival of NGS has been a major 
breakthrough in the search for new predisposition genes that explain the inheritance of 
different cancer syndromes, including FCCTX105,154. However, NGS does not denote a 
single technique, but a diverse collection of post-Sanger high-throughput sequencing 
technologies extended in the last decade. These technologies include sequencing-by-
synthesis, sequencing-by-ligation, ion semiconductor sequencing, and others155. 
Regarding its applications, NGS can be used for include de novo sequencing, who-genome 
or targeted resequencing, transcriptome and epigenome analysis, etc156. However, the 
three most common approaches for the search of genetic variants are: 1) whole-genome 
sequencing (WGS), which sequences the complete genome of an organism; 2) whole-
exome sequencing (WES), which is targeted at the coding regions of the genome or exons; 
and 3) multigene panels, which targeted sequencing of a previously designed set of 
genes99. The benefits and drawbacks of each of these technologies and applications are 
discussed below 
 
1.4.1. NGS technologies 
 
Pyrosequencing: Roche 454 
 
Roche 454 was he first commercially successful NGS system and is based on 
pyrosequencing technology, which relies on the detection of the pyrophosphate released 
during nucleotide incorporation. The DNA library is prepared with specific adaptors and 
then denatured into a single strand and captured by amplification beads, followed by 
emulsion PCR156. Then on a picotiter plate, one dNTP will complement the bases of the 
template strand and release pyrophosphate equaling the amount of incorporated 
nucleotide156. The ATP transformed from pyrophosphate drives the luciferin into 
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oxyluciferin and generates visible light, while the unmatched bases are degraded. Then 
another dNTP is added into the reaction system and the pyrosequencing reaction is 
repeated156. The biggest advantages of the Roche system are its speed, its high read length 
and its possible automatization. However, the high cost of reagents remains a challenge, 
and it has a relatively high error rate with polybases longer than 6 bp156.  
 
Sequencing-by-ligation: SOLiD 
 
The Applied Biosystems’ SOLiD (Sequencing by Oligo Ligation Detection) sequencer 
adopts a technology based on ligation sequencing. Here, the libraries are sequenced on a 
flowcell using an 8-base ligation probe, which contains a ligation site (1st base), a cleavage 
site (5th base) and 4 different fluorescent dyes (linked to the last base)156. The fluorescent 
signal is recorded during the probes’ complementary ligation to the template strand and 
vanished by the cleavage of the probes’ last 3 bases. After 5 rounds of sequencing, the 
sequence of the fragment can be deduced using ladder primer sets156. The main 
advantage of this method is its high accuracy, while its principal drawbacks are the short 
read length and its incapability of sequencing de novo156. A complete run can be finished 
within 7 days, and automation can be used in library preparations. Its applications include 
WGS, targeted resequencing, transcriptome research and epigenome156.  
 
Sequencing by synthesis: Illumina  
 
Illumina systems adopt the technology of sequencing by synthesis. The most 
extended sequencer of this company is called HiSeq, which is comparable to the 
aforementioned systems. It addition, there are other platforms with different scales, 
including NextSeq and MiSeq, a compact sequencer that is small in size with fast turnover 
rates but limited data throughput. All of Illumina’s instruments are based on the same 
principles, and given that the NGS platform used in this thesis was the HiSeq 2000, this 
technology is shown in Figure 1.7 and will be explained more in depth.  
 
In the first place, the DNA library (which involves generating a collection of DNA 
fragments for sequencing) is typically prepared by fragmenting a genomic DNA sample 
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and ligating specialized adapters to both fragment ends. An alternative is called 
tagmentation, which combines the fragmentation and ligation reactions into a single step. 
Adapter-ligated fragments are then PCR amplified and gel purified. The library 
preparation will depend on the NGS application157. The DNA library prepared with fixed 
adaptors is then denatured to single strands and grafted to the flowcell, followed by 
bridge amplification to form clusters that contain clonal DNA fragments156. Before 
sequencing, the library splices into single strands with the help of a linearization enzyme, 
and then four kinds of nucleotides containing different cleavable fluorescent dyes and a 
removable blocking group complement the template one base at a time. Finally, the 
emitted signals are captured by a charge-coupled device156. Compared with Roche 454 
and SOLiD, HiSeq 2000 has the lowest reagent cost and features the biggest output, while 
the SOLiD system has the highest accuracy, and the Roche 454 system has the longest 
read length156. 
 
Regarding the data analysis, HiSeq control system and real-time analyzer calculate 
the number and position of clusters based on their first 20 bases, based on which the 
output and quality of each sequencing is decided156. HiSeq 2000 uses two lasers and four 
filters to detect the four types of nucleotide, whose emission spectra have cross-talk 
resulting in images that are not independent and the quality of sequencing affected by 
the distribution of bases156. The standard sequencing output files of the HiSeq 2000 
consist of *bcl files, which contain the base calls and quality scores in each cycle. These 
files are then converted into *_qseq.txt files by the BCL Converter156.  
 
Ion semiconductor sequencing: Ion Torrent 
 
Ion Torrent has two platforms of different capacity based on semiconductor 
sequencing technology: the compact Ion Personal Genome Machine (PGM), and the larger 
Ion Proton. In these sequencers, when a nucleotide is incorporated into the DNA 
molecules by the polymerase, a proton is released. The instrument recognizes whether 
the nucleotide is added or not by detecting the change in pH156. The chip is flooded with 
one nucleotide after another, detecting no voltage if it is not the correct nucleotide. On 
the other hand, if 2 nucleotides are added, the voltage detected would be double156. PGM 
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was the first commercial sequencing machine that did not require fluorescence and 
camera scanning, resulting in higher speed, lower cost, and smaller instrument size156. Ion 
Torrent has a stable quality along sequencing reads and a good performance on mismatch 
accuracies, but rather a bias in detection of indels156. 
 
 
 
 
Figure 1.7. Sequencing-by-synthesis NGS technology used by the Illumina platforms. In the 
first place, the DNA library is prepared by fragmentation and ligation of specific adapters (1). 
Then, the DNA fragments are attached to the flowcell through those adapters (2) and the 
clusters are generated after several consecutive bridge amplifications (3 and 4). Finally, single 
strands are sequenced by synthesis of the complementary strand using fluorescent dNTPs (5). 
The fluorescence is detected after each round to obtain the sequence of each cluster (6), which 
is later aligned against a reference genome (7). Adapted from seqanswers.com.  
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Third generation sequencers: 
 
Third-generation sequencing has two main characteristics. First, PCR is not needed 
before sequencing, which shortens DNA preparation time156. Second, the signal is 
captured in real time, which means that the signal – no matter whether it is fluorescent 
(Pacbio) or electric current (Nanopore) – is monitored during the enzymatic reaction of 
adding nucleotides to the complementary strand156. 
 
1.4.2. NGS applications for the search of genetic variants 
 
WGS and WES:  
 
WGS and WES are the two main NGS approaches for the search of new genes 
involved in Mendelian diseases. Although the latter is without doubt more extensively 
used, they each have their own advantages and disadvantages that should be borne in 
mind. The main drawback of WES is that it only covers coding regions of the genome, so 
any defects affecting regulatory regions such as promoters and enhancers would be 
missed.  Conversely, WGS allows the identification of SNVs, insertions, deletions, 
structural variants and CNVs both in coding and non-coding regions of the genome. In 
addition, WGS has a more reliable and uniform sequence coverage than WES, given that 
differences in the hybridization efficiency of WES capture probes can result in regions of 
the genome with little or no coverage, what means that some information is completely 
lost. This disparity in coverage among the different areas of the exome obtained by WES 
also makes WGS a best option for the analysis of CNVs. Finally, WES may enrich 
preferentially one of the alleles at heterozygous sites, producing false negative SNV calls. 
 
 Nonetheless, despite these disadvantages, WES still has one huge advantage that 
explains its wider use: the fact that WES is targeted to protein coding regions involves that 
reads represent less than 2% of the genome. This not only reduces the cost of high-depth 
sequencing, but it also decreases storage and analysis costs. These reduced costs make it 
feasible to increase the number of samples to be sequenced, enabling large population 
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based comparisons. Moreover, with our current understanding of the human genome, at 
the moment the vast majority of data that would be obtained by WGS cannot be 
interpreted. For these reasons, so far WES has been undoubtedly the most widely used 
out of the two, although the rapidly decreasing prices suggest that WGS will be the way 
to go in the future. 
 
Multigene panels: 
 
As mentioned earlier, multigene panels are the third NGS option to search for 
causal mutations that could potentially explain the inheritance of Mendelian diseases. 
This targeted sequencing option is best suited for clinical practice, has a lower potential 
for the identification of new susceptibility genes, limited to those included in the panel. 
In spite of this, it is still a very effective method to attempt to clarify a part of the large 
amount of unexplained FCCTX families. And one of its main advantages is that it is even 
cheaper than WES, which allows the analysis of a higher number of samples.  
 
Another undeniable advantage of multigene panels compared to WES is that you 
find less uncertain results, given that all the genes that are sequenced have already been 
linked to cancer predisposition. This eliminates the challenge of dealing with genes with 
still unknown functions or whose association with cancer is questionable. Therefore, this 
application extremely simplifies the filtering and prioritization steps, saving a lot of time 
in data analysis. It also allows a faster translation to the clinic of the results found. For that 
reason, multigene panels are useful for the screening of candidate genes previously 
identified by other approaches. 
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1.5 Genes of interest: SETD6 
 
1.5.1. Lysine methylation 
 
 Covalent post-translational modifications (PTMs) of proteins serve as a major 
mechanism for the regulation of biological processes. Among these modifications, lysine 
methylation involves the transfer of up to three methyl groups to the ε-amine of a lysine 
residue, with the potential to modulate the function of the methylated substrate158. This 
modification has been found to regulate protein activity, protein-protein interactions and 
interplay with other PTMs, playing a vital role in the regulation of many cellular signaling 
pathways158. Interest in this PTM increased by the discovery that histone lysine 
methylation is involved in heterochromatin formation and that the methylation of 
histones can either suppress or activate gene transcription depending on which lysine is 
methylated, which can lead to dramatic effects on gene expression158. However, lysine 
methylation also occurs on various non-histone proteins both nuclear and cytoplasmic158, 
but especially transcription- and chromatin-regulating proteins159. Some non-histone 
proteins known to undergo lysine methylation are p53, RB1 and STAT3, which have 
important roles in human tumorigenesis160.  
 
Lysine methylation is catalyzed by protein lysine methyltransferases (PKMTs) that 
transfer a methyl group from a donor S-adenosyl-L-methionine (SAM), which can be in 
turn removed by the less known demethylases161. The SET-domain PKMT superfamily 
includes all but one of the proteins known to methylate histones on lysine162. Even though 
there are over 70 PKMTs present in the human proteome, little is known about their 
enzymatic activity beyond histones159. The dysregulation of lysine methylation on both 
histones and non-histone proteins, mediated by dysregulation of methyltransferases and 
demethylases, is involved in the development and progression of various diseases, 
including cancer160.   
 
1.5.2. SETD6 
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 SET domain-containing protein 6 (SETD6) is a member of the PKMT family that is 
known to monomethylate both histone and non-histone proteins and that has been 
recently found to regulate many essential biological processes. Figure 1.8 shows some of 
the main pathways in which this PKMT is involved. SETD6 was initially discovered to 
monomethylate the NF-κB transcription factor subunit RelA on lysine 310 (RelAK310me1), 
effectively inactivating it at the chromatin (Figure 1.8 B). Upon recognition of this methyl 
mark, histone methyltransferase GLP methylates histone H3 on lysine 9, promoting a 
repressed chromatin state and silencing the transcription of NF-κB target genes163. Given 
that deregulation of NF-κB is linked to pathologic inflammatory processes and cancer164, 
SETD6-mediated inhibition of NF-κB signaling may influence tumor suppression and anti-
inflammatory responses165. In contrast, it was recently reported that SETD6 promotes 
RelA's transcriptional activity in bladder cancer166.  
 
 Noteworthy, SETD6 has also been reported to participate in the canonical Wnt 
signaling pathway by forming a complex with PAK4 and β-catenin at the chromatin (Figure 
1.8 C)167. SETD6 methylates PAK4, which was recently shown to regulate β-catenin 
signaling167. In the presence of SETD6, the physical interaction between PAK4 and β-
catenin is dramatically increased, leading to a significant increase in the transcription of 
Wnt target genes167. In this way, SETD6 acts as a key mediator of this pathway by the 
activation of β-catenin target gene transcription167. Interestingly, depletion of SETD6 was 
reported to significantly hinder the activation of Wnt/β-catenin target genes167. 
 
 Another study demonstrated that SETD6 negatively regulates Nrf2-mediated 
oxidative stress response through a physical and catalytically-independent interaction 
with the oxidative stress sensor DJ1 at the chromatin (Figure 1.8 D)168. Under basal 
conditions, DJ1 is directly associated to SETD6 at the chromatin, which inhibits DJ1’s 
activity and leads to the repression of Nrf2-dependent transcription168. In response to 
oxidative stress, Nrf2 expression is raised, SETD6 protein levels are reduced, the 
interaction between SETD6 and DJ1 at the chromatin weakens, and the transcription of 
Nrf2 antioxidant genes increases 168. Depletion of SETD6 from cells results in elevated Nrf2 
levels and a significant increase in Nrf2 antioxidant target gene expression168. 
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Additionally, it has been suggested that SETD6 may play a role in embryonic stem 
cell differentiation through monomethylation of histone H2A variant H2AZ at lysine 7 
(H2AZK7me1)169. H2AZ is an essential chromatin signaling factor significantly increased 
upon cellular differentiation, and is also a key component of nuclear receptor-dependent 
transcription. SETD6 was also reported to associate with the estrogen receptor α (ERα), 
histone deacetylase HDAC1, metastasis protein MTA2, and the transcriptional co-
activator TRRAP, acting as a repressor of the estrogen-responsive-dependent 
transcription. HDAC1 and MTA2  are subunits of the NuRD complex, a group of associated 
proteins with chromatin remodeling and histone deacetylase activities170. However, 
SETD6 also acts as a co-activator of several estrogen-responsive genes, such as PGR and 
TFF1, in the nuclear hormone receptor signaling pathway170. The same study showed that 
SETD6 is an essential factor for nuclear receptor signaling and cellular proliferation, and 
that its silencing induces cellular proliferation defects, enhances expression of the cell 
cycle inhibitor CDKN1A and induces apoptosis170.  
 
Last but not least, SETD6 has been recently identified to methylate PLK1, a key 
regulator of mitosis that is highly expressed in tumor cells, providing evidence that SETD6 
is involved in cell cycle regulation171. During mitosis, SETD6 binds and methylates PLK1 on 
two lysine residues (K209 and K413). Lack of methylation of these two residues results in 
increased PLK1 kinase activity, leading to accelerated mitosis and faster cellular 
proliferation171. 
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Figure 1.8. Different pathways in which SETD6 is involved. A) Schematic summary of the most 
relevant pathways regulated by SETD6, together with the effect it has on them: inactivation (-
) or activation (+). B) SETD6 in the NF-kB pathway (obtained from lifewp.bgu.ac.il). C) SETD6 in 
the Wnt pathway (obtained from Vershinin et al. 2016). D) SETD6 in the oxidative stress or 
Nrf2-antioxidant response element pathway (obtained from Chen et al. 2016). 
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1.6 Genes of interest: PTPRT 
 
1.6.1. Tyrosine phosphorylation 
 
As previously mentioned, PTMs are involved in a wide variety of cellular activities 
and phosphorylation is one of the most extensively studied PTM172. Since it was 
discovered, tyrosine phosphorylation has been proven to be an essential mechanism of 
signal transduction and regulation in all eukaryotic cells, regulating many processes such 
as cell proliferation, cell cycle progression, metabolic homeostasis, transcriptional 
activation, neural transmission, differentiation, development and aging173. In addition, 
perturbations in tyrosine phosphorylation are involved in many human diseases, including 
cancer173. 
 
Tyrosine phosphorylation is coordinately regulated by protein tyrosine kinases 
(PTKs), which add a phosphate group to tyrosine residues of their substrates, and protein 
tyrosine phosphatases (PTPs), which remove such phosphate. The phosphate status of 
tyrosines is important in many signaling pathways underlying tumorigenesis, such as cell 
growth, proliferation, differentiation, cell cycle, apoptosis and invasion174. Therefore, 
genetic and epigenetic alterations in genes encoding PTKs and PTPs can result in changes 
to the equilibrium of kinase-phosphatase activity that might have a deleterious effect, 
producing abnormal cell proliferation, which could ultimately lead to cancer174. The 
human genome encodes 107 members of the protein tyrosine phosphatase superfamily, 
which are divided into four classes based on the amino acid sequence of their consensus 
catalytic domain signatures174,175. Class I PTPs comprises by far the biggest group, with 99 
members that are divided into two subfamilies, consisting on 38 tyrosine-specific or 
“classical” PTPs and 61 dual-specificity phosphatases174,175. Classical PTPs strictly 
recognize phospho-tyrosine residues as substrates and can be further divided into two 
groups: 21 receptor PTPs (PTPRs) and 17 non-receptor PTPs (PTPNs)174,175. 
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1.6.2. PTPs in human cancers 
 
Cancer is a genetic disease that is driven by mutations in oncogenes and tumor 
suppressor genes. Many PTKs have been long known to act as oncogenes in cancer 
initiation and progression, while most PTPs have been proven to act as tumor suppressors, 
reversing the negative effects of PTKs174. However, some PTPs also have oncogenic 
properties174. Wang et al were the first to discover that PTPs are frequently mutated in 
CRCs when they identified 6 genes that contained recurrent somatic mutations, including 
3 receptor PTPs (PTPRF, PTPRG and PTPRT) and 3 non-receptor PTPs (PTPN3, PTPN13 and 
PTPN4)176. Mutations in these 6 genes affected 26% of the CRCs analyzed in the study, 
none of which were synonymous. It was later discovered that PTPs are somatically 
mutated in many other cancers, but play particularly important roles in colon and 
endometrium cancers175. 
 
 Among all PTP genes, PTPRT is the most frequently mutated in human cancers, 
with somatic mutations identified in 11% of colon, 11% of esophagus, 10% of lung, 9% of 
stomach, 8% of endometrium, 6% of bladder and 6% of head and neck cancers175. 
Moreover, PTPRT is also mutated in a smaller fraction of leukemia, breast, ovary, liver, 
pancreas and prostate cancers175. Promoter DNA methylation had been proposed to be 
another possible mechanism leading to loss of PTPRT function175, but it was not until 
recently that PTPRT’s promoter was found to be frequently hypermethylated in CRC177 as 
well as in head and neck cancer178. 
 
1.6.3. PTPRT 
 
Protein Tyrosine Phosphatase Receptor Type T or Rho (PTPRT PTPρ), belongs to 
type IIB subfamily of classical receptor PTPs (class I), which includes PTPRK, PTPRM and 
PTPRU. This subfamily of PTPs share similar structures that consist of an extracellular 
region, a transmembrane domain and a specific intracellular structure (Figure 1.9). The 
extracellular portion of the type IIB PTPRs consists of a MAM domain, an immunoglobulin 
(Ig) domain and four fibronectin type III (FNIII) repeats. It has been shown that the FNIII 
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repeats of PTPRK, PTPRM and PTPRT mediate homophilic cell-cell adhesion, while the 
extracellular region of PTPRU lacks such activity179. Consistent with this, Besco et al 
showed that PTPRT interacts with adherence junction components, such as cadherins and 
catenins through this extracellular region180. Interestingly, most tumor-derived mutations 
located in the extracellular domain of PTPRT impair cell-cell adhesion180.  
 
On the other hand, the cytoplasmatic segment of this subfamily consists of a 
cadherin-like juxtamembrane domain and two phosphatase domains: D1 and D2 (Figure 
1.9). It is generally believed that the membrane-proximal PTP domain (D1) is responsible 
for the tyrosine phosphatase activity per se, whereas the second is a pseudophosphatase 
domain (named D2) that has no phosphatase activity181. However, many tumor-derived 
mutations are located in the second catalytic domain176, suggesting that this domain has 
an important structural function or harbors a still unknown enzymatic activity. As a matter 
of fact, both catalytic domains have been proven to be essential for the correct function 
of the protein182. While the D1 domain is responsible for the phosphatase activity of 
receptor PTPs, D2 is important for the regulation of such activity. 
 
 Regarding PTPRT’s substrates, two main proteins have been reported to be 
modified by this enzyme: STAT3 and paxillin182,183. These two substrates are well-known 
oncogenes that are inactivated upon dephosphorylation by PTPRT, proving once more its 
role as a tumor suppressor gene (Figure 1.9). PTPRT dephosphorylates STAT3’s well-
characterized residue Y705182, whose phosphorylation is key to STAT3’s activation184. It 
has been shown that pY705 STAT3 is up-regulated in a variety of human cancers and that 
this phosphorylation plays an oncogenic role in tumor development184. The relevance of 
STAT3 Y705 phosphorylation in CRC was demonstrated by Zhang et al, who showed that 
STAT3 Y705F mutant CRC cells showed reduced tumorigenicity185. Furthermore, PTPRT-
regulated STAT3 signaling appears to be critical for head and neck tumorigenesis in a 
recent study that showed that phospho-STAT3 is up-regulated in HNSCC tissues with 
PTPRT mutations186.  
 
  In contrast to STAT3, the target site of PTPRT on paxillin was the previously 
uncharacterized residue Y88183. Evidence suggesting that the PTPRT-regulated paxillin Y88 
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phosphorylation may be crucial for colorectal tumorigenesis include the failure of paxillin 
Y88F knock-in CRC cells to form xenograft tumors in nude mice and the up-regulation of 
pY88 paxillin in a majority of colorectal tumor tissue183. In addition to STAT3 and paxillin, 
other substrates of PTPRT, including BRC and Syntaxin-binding protein 1187,188, were 
identified in brain tissue where PTPRT is abundantly expressed. However, the relevance 
of these substrates in the context of cancer remains to be determined. 
 
 
 
 
 
   
 
 
 
  
Figure 1.9. PTPRT target genes and pathways. PTPRT dephosphorylates and inactivates two 
well-known oncogenes, STAT3 and paxillin, resulting in the inhibition of the different 
downstream pathways in which they are involved. In this way, PTPRT acts as a tumor 
suppressor by inhibiting the expression of STAT3’s target genes (such as Bcl-XL and SOCS3) and 
inhibiting the phosphorylation of paxillin’s target proteins (such as p130CAS, SHP2 and Akt). 
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1.7 Genes of interest: PYGO1 
 
1.7.1. The canonical Wnt signaling pathway 
 
The Wnt pathway is a highly conserved signaling pathway that regulates many 
essential cellular processes, including cell fate determination, cell motility and polarity, 
primary axis formation, organogenesis and stem cell renewal189. However, the Wnt family 
of ligands can stimulate several intracellular cascades189, based on which this pathway can 
be classified into a canonical or Wnt/β-catenin dependent pathway and a non-canonical 
or β-catenin independent pathway, which is in turn divided into a planar cell polarity and 
a Wnt/Ca2+ pathways189. 
 
 When Wnt signals are transduced through the Frizzled (Fzd) family of receptors 
and LRP5/LRP6 coreceptors, the β-catenin signaling cascade is activated, which regulates 
cell fate determination190. This canonical pathway has a number of positive regulators, 
such as PAR-1, CKIε, and FRAT, as well as negative regulators, such as APC, AXIN1, AXIN2, 
CKIα, NKD1, NKD2, βTRCP1, βTRCP2, ANKRD6, NLK, and PPARɣ190. The hallmark of 
canonical Wnt pathway is the accumulation and translocation of β-catenin into the 
nucleus189. Conversely, in the absence of Wnt signals, cytoplasmic β-catenin forms a 
destruction complex with Axin, APC, PP2A, GSK3 and CK1α189,190. This allows its 
phosphorylation by CK1α and GSK3, which targets it for ubiquitination and subsequent 
proteolytic degradation by the proteosomal machinery189 (Figure 1.10 A, left). On the 
other hand, binding of Wnt ligands triggers series of events that disrupt the 
APC/Axin/GSK3 complex and lead to the prevention of β-catenin degradation and its 
consequent stabilization and accumulation in the cytoplasm, followed by its translocation 
into the nucleus where it acts as a transcriptional co-activator189 (Figure 1.10 A, right).  
 
Many β-catenin binding partners have been described in the nucleus, including 
LEF/TCF, Legless/BCL9 and Pygopus (Pygo1 and 2), which influence the nuclear retention 
and transactivating ability of β-catenin for transcriptional regulation of its target genes. 
This complex binds to the promoter of the different Wnt target genes and activates their 
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transcription 189,190. The canonical Wnt signaling plays a pivotal role in cell fate 
determination during early embryogenesis190, and has been shown to play important roles 
in stem cell renewal and oncogenesis189. 
 
 
 
Fig. 1.10.  Role of the Pygo proteins in the canonical Wnt pathway. A+B) Canonical Wnt 
signaling pathway in the presence (A) or absence (B) of Wnt ligands. When the Wnt pathway 
is inactive, β-catenin forms a complex with APC, Axin and other proteins and is degraded by 
the proteasomal machinery upon its phosphorylation and ubiquitination. When active, β-
catenin expression is stabilized and accumulated in the cytoplasm before translocating to the 
nucleous, where it promotes the transcription of downstream target genes forming a complex 
with a number of nuclear proteins, including pygopus, BCL9 and TCF. Image obtained from Yu 
et al 2014. C) Schematic representation of the Pygo-BCL9 complex and its interaction with β-
catenin N-terminus and methylated histone H3 tail (H3K4me2). Recruitment of β-catenin to 
Wnt target genes requires its binding to TCF factors (bound to specific enhancers through their 
HMG domain) but also its binding to Pygo-BCL9. Image modified from Miller at all 2014. 
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1.7.2. Wnt signaling in cancer 
 
 Epigenetic silencing and loss-of-function mutations of negative regulators of the 
canonical Wnt pathway occur in a variety of human cancers190, and deregulation of Wnt 
pathway component is associated with a causal or progressive role in cancer191. 
Specifically, the vast majority of CRCs show a hyperactivated Wnt signaling, mainly due to 
the inactivation of the APC gene. Germline variants in this gene also predispose to CRC 
and are the cause of the most extended polyposis syndrome. In addition, it has been 
reported that common germline variants in the Wnt/beta-catenin pathway may be 
involved in CRC development. These variants may be informative in CRC risk assessment 
to identify individuals at increased risk who would be candidates for screening192. 
 
 The Wnt signaling pathway, together with many other pathways, is implicated in 
the maintenance of tissue homeostasis by regulating self-renewal of normal stem cells, 
proliferation and differentiation of progenitor cells. Thus, misregulation of this signaling 
network leads to carcinogenesis190. For that reason, NSAIDs and PPARg agonists with the 
potential to inhibit the canonical Wnt signaling pathway are candidate agents for 
chemoprevention, and have been proven to decrease the risk for CRC8. In fact, anti-Wnt1 
and anti-Wnt2 monoclonal antibodies have shown in vitro effects in cancer treatment, 
suggesting that, after their optimization, small-molecule derivatives and human 
monoclonal antibodies targeted to the Wnt signaling pathway could be used in cancer 
medicine190. 
 
1.7.3. PYGO1 
 
Pygo1 is one of the two pygopus homologs present in mammals191, and is a nuclear 
protein involved in signal transduction through the Wnt pathway. Pygo1 forms a complex 
with β-catenin, LEF/TCF, BCL9 and other components at the chromatin, allowing the 
transcription of Wnt target genes when the Wnt pathway is activated193. In this way, 
Pygo1 – together with Pygo2, BCL9 and B9L – contributes to efficient β-catenin-mediated 
transcription in Wnt stimulated mammalian cells and in CRCs with elevated Wnt pathway 
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activity. Wnt signaling outputs depend on histone decoding by the Pygo-BCL9/Legless 
complex, suggesting that this complex facilitates an early step in the transition from gene 
silence to Wnt-induced transcription194. However, it has been reported that, in mammals, 
the Pygo1/Pygo2 genes are not absolutely required for canonical Wnt signaling in most 
developing systems, but rather function as significant modulators of Wnt signal 
intensity195. 
 
Noteworthy, Pygo’s interaction with β-catenin is not direct but mediated by 
BCL9193. Pygopus proteins are characterized by a Zn-coordinated PHD finger domain that 
is critical for the β-catenin-dependent transcriptional switch in normal and malignant 
tissues196. This PHD domain associates with its analogous HD1 domain from BCL9 in order 
to bind specifically to the histone H3 tail methylated at lysine 4 (H3K4me), preferentially 
when di-methylated (H3K4me2)194 (Figure 1.10 B). Although histone-binding residues are 
identical between the two human Pygo paralogs, Pygo2 complexes exhibit slightly higher 
binding affinities for methylated histone H3 tail peptides than Pygo1 complexes196. BCL9 
co-factors binding to Pygo PHD fingers impact indirectly on their histone binding affinity 
through an allosteric communication, and a highly conserved tryptophan is the signature 
residue defining the PHD subclass of Zn fingers197. Efficient histone binding requires this 
PHD-HD1 association 194. 
 
As previously mentioned, a vast majority of CRCs bear mutations in APC or β-
catenin, resulting in an abnormally high Wnt signaling activity. Knockdown of the pygopus 
genes in CRC cells containing a mutant APC reduces Wnt reporter gene expression, 
suggesting that endogenous pygopus proteins modulate signaling output in these cancer 
cells191. Interestingly, experimental evidence has suggested that the pygopus proteins 
may be involved in neoplastic transformation of multiple cells types191. The Pygo-BCL9 
complex is a chromatin reader, facilitating β-catenin-mediated oncogenesis, and is thus 
emerging as a potential therapeutic target for cancer, with small molecules that block 
protein−protein PHD finger interacƟons, such as a set of benzothiazoles that bind to the 
PHD-HD1 interface 197. 
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2.1 Hypothesis 
 
The hypothesis on which the work presented in this thesis is based is that an 
important number of FCCTX cases comprise yet-to-be-discovered genetic syndromes 
caused by mutations in high or moderate-penetrance CRC-predisposition genes. Due to 
the heterogeneity of this group of families, we believe that the best strategy is to address 
each family individually. 
 
2.2 Objectives 
 
2.2.1. Main objective 
 
The ultimate aim of this study is the identification of new potential CRC-risk genes 
that can explain the increased cancer susceptibility in FCCTX families. This is meant to be 
accomplished by whole-exome sequencing of different members from each of the 13 
studied families. 
 
2.2.2. Secondary goals 
 
Encompassed within this first objective are the following secondary goals, all this 
with the purpose of finding the potential cause of CRC heritability in at least a fraction of 
the studied families: 
1) To obtain a list of potentially pathogenic candidate variants that may potentially 
explain the increased cancer susceptibility of each family subject to study.  
2) To classify and characterize the candidate variants identified. 
3) To perform functional and/or expression studies for a few selected cases in which 
it is possible and suitable, in order to further demonstrate the pathogenicity of the 
corresponding variants. 
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3.1 Subjects and sample collection 
 
3.1.1. Study population 
 
The present study included 13 FCCTX families selected from a larger cohort of 37 
HNPCC-MSS families that had been recruited over the years at the Genetic Counseling 
Unit of Hospital Clínico San Carlos (Madrid). The 13 families were selected based on the 
availability of germline and tumor DNA from more than one patient per family, and are 
detailed in the Appendix (A1). All of the families fulfilled the Amsterdam I/II clinical criteria 
for HNPCC (Table 1.1) or a borderline AC-I/II criteria in which we allowed the earliest age 
at CRC diagnosis to be up to 52 years old. In addition, they all presented MSS tumors with 
normal expression of the MMR proteins, and did not carry any germline mutation in the 
MMR genes (Appendix, A2). Between two and three members of each family were 
selected for whole-exome sequencing, being at least two affected of cancer. 
 
Other family members, whether healthy or affected, were also recruited when 
possible for segregation studies. In addition, the formalin-fixed paraffin-embedded (FFPE) 
tumor blocks from the probands and/or their relatives were obtained when available from 
the Anatomical Pathology Service of the corresponding hospital. Personal and family 
histories were obtained, and cancer diagnoses were confirmed by medical and pathology 
reports. The study was approved by the Institutional Review Board of Hospital Clínico San 
Carlos, and a written informed consent was signed by each participant.  
 
3.1.2. Control population 
 
Healthy individuals with no cancer family history were recruited from the Blood 
Bank of Hospital Clínico San Carlos (Madrid) and used as healthy controls. The FFPE tumor 
blocks of sporadic CRC patients were also selected for their use as CRC controls in some 
experiments. Moreover, FFPE blocks containing non-tumor colon tissue were used as 
healthy colon controls. A total of 100 germline controls, 10 sporadic CRC controls and 10 
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healthy colon controls were used. All of these subjects had previously signed a broad 
informed consent allowing the donation of their biological samples to the hospital's 
biobank and their use for research. 
 
3.1.3. DNA and RNA extraction 
 
At the time of their initial visit, 10ml of blood were collected from all the 
participants in BD Vacutainer® K2E (EDTA) Plus Blood Collection Tubes. Germline DNA and 
RNA were extracted from peripheral blood using the MagNA Pure Compact extractor 
system (Roche Diagnostics), according to the manufacturer's recommendations. The 
PAXgene® Blood RNA Kit and Tubes (PreAnalytiX) were used to extract germline RNA 
when the patient could not come to our hospital.  
 
Tumor DNA and RNA were extracted from 7µm-thick FFPE tissue sections. A 
hematoxylin and eosin-stained (H&E) section of each block allowed the assessment of 
tumor cell area and content by two experienced pathologists. Tumor DNA was extracted 
using the QIAamp® DNA FFPE Tissue Kit from Qiagen, while tumor RNA was isolated 
employing the RNeasy® FFPE Kit (Qiagen), according to their corresponding protocols.  
 
3.1.4. Quantification and quality assessment of nucleic 
acids 
 
The NanoDrop® ND-1000 Spectrophotometer was used to assess the DNA and RNA 
quantity and quality (recommended A260/A280 ratio value >1.8 and A260/A230 ratio 
>1.9). However, for Next Generation Sequencing purposes, the quality of DNA samples 
was also tested by agarose gel electrophoresis (0.8% agarose in TAE buffer), and the 
concentration of the samples was measured in a Qubit® 3.0 Fluorometer (Life 
Technologies) using the QubitTM dsDNA HS Asay Kit (Invitrogen). 
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3.1.6. Reverse transcription PCR 
 
Reverse transcription polymerase chain reaction (RT-PCR) was performed to 
convert RNA into complementary DNA (cDNA) using the PrimeScriptTM RT Reagent Kit 
(Perfect Real Time, Takara, Clontech), following the kit's instructions. For this purpose, 
RNA was previously normalized to 100ng/μl, except for the breast tissue samples, for 
which it could only be normalized to 50ng/μl. The RT-PCR reactions took place in a 2720 
Thermal Cycler (Applied Biosystems), with a final volume of 10μl and 650ng of RNA (325ng 
of RNA for the breast samples).  
 
In order to confirm the absence of genomic DNA (gDNA) in our cDNA samples prior 
to their use, a PCR targeting exons 2-3 of PALB2 was performed using 1μl of RT-PCR 
product, and subsequently run on an agarose gel (2% agarose in TAE buffer). This allowed 
the discrimination between gDNA and cDNA, with a PCR product of 152bp in the absence 
of intron 2 (cDNA) and a 269bp product when intron 2 was present (gDNA). The PCR was 
performed with an annealing temperature of 60ºC and 30 cycles of reaction (40 cycles 
when paraffin-embedded tumor samples were being tested). The primers used for this 
test and detailed PCR conditions are shown in the Appendix (A3). 
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3.2 Whole-exome sequencing strategy 
for the study of FCCTX 
 
3.2.1. Whole-exome sequencing 
 
Whole-exome sequencing (WES) was outsourced to two different companies: 
NIMGenetics (first 8 families) and Sistemas Genómicos® (last 5 families). The switch of 
company was made in order to remain with the Illumina sequencing system after the first 
company replaced their sequencers by another brand. In both places, the exome capture 
was performed using SureSelectXT Human All Exon V3 (51Mb, Agilent Technologies). The 
final library size and concentration were determined on an Agilent 2100 Bioanalyzer and 
a Qubit Fluorometer (Thermo Fisher Scientific), respectively. Finally, the library was 
sequenced on an Illumina HiSeq 2000 platform with paired-end reads of 101bp and a 50x 
average coverage depth, following the manufacturer's protocol. Images produced by the 
HiSeq 2000 were processed using the manufacturer's software to generate FASTQ 
sequence files. Reads were trimmed and subsequently aligned against the human 
reference genome version GRCh37/hg19 using the BWA software, creating the BAM files. 
Low quality reads, PCR duplicates and other sequences that could introduce major biases 
were removed using Picard-tools and SAMtools198,199. Variant calling was performed using 
a combination of two different algorithms (VarScan200,201 and GATK202) and the identified 
variants were annotated and described according to the recommendations of the Human 
Genome Variation Society (HGVD)203 and Ensembl204 databases. 
 
3.2.2. Variant filtering 
 
WES data was then thoroughly filtered at our laboratory for each of the different 
families. The overall filtering strategy used for this study is summarized in Figure 3.1 and 
comprised the following steps for selection of those variants that were: 1) shared by all 
the affected members sequenced (allele frequency ≥0.25); 2) carried in heterozygosis 
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(allele frequency between 0.25 and 0.75); 3) coding (frameshift, inframe, nonsense, 
splicing or missense) and affecting autosomes; 4) rare (MAF≤0.01 in the general 
population and not present in 3 or more families); 5) damaging (deleterious effect 
predicted by at least 4 out of 5 in silico tools for missense variants, by 2 out of 2 for inframe 
variants and predicted to alter splicing for splice region variants by one tool); and 6) 
absent in healthy elderly relative sequenced (when applicable). On the other hand, an 
extensive literature search was performed in order to select genes previously associated 
with CRC predisposition, as well as CRC-susceptibility loci identified by GWAS studies. 
Coding variants in these genes detected in heterozygosis in all the affected members from 
each family were then subjected to a more lenient filtering strategy, with a MAF≤0.05, 
and a damaging effect on the protein predicted by at least 3 out 5 in silico tools for 
missense variants or 1 out of 2 for inframe variants. 
 
3.2.3. In silico studies 
 
In the first place, the minor allele frequency (MAF) of each variant was checked in 
three different databases: 1000 Genomes Project205, Exome Variant Server (EVS)206 and 
GnomAD207. On the other hand, for every missense variant five online tools were used to 
predict the impact of each amino acid substitution on the protein: SIFT208, PolyPhen209, 
MutationTaster210, PROVEAN211 and finally Condel212, which is in turn an optimized 
combination of two other tools, MutationAssessor213 and FATHMM214. Variants were 
considered damaging when at least four out of these five tools predicted a deleterious 
effect. All of this was done with the help of the Ensembl Variant Effect Predictor (VEP)215, 
and only the canonical transcripts were selected for convenience. When one or more of 
the predictors failed to give a result, only those variants described as damaging by at least 
two tools ─ and neutral by no more than one ─ were selected. The damage effect of 
inframe variants could only be predicted by two of the tools mentioned above 
(PROVEAN211 and MutationTaster210). In this case, any variant with a deleterious 
prediction by both tools was further considered. Splicing variants were also analyzed in 
silico by the Human Splicing Finder (HSF)216 in order to predict splicing alterations. These 
included splice donor/acceptor variants and splice region variants (near the splice site but 
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without affecting the donor or acceptor sites). Variants with no significant splicing 
alteration detected by any of the two algorithms used by the HSF tool (HSF and 
MaxEnt217,218) were discarded. 
 
3.2.4. Variant prioritization 
 
The variants that remained after the filtering step were then prioritized based on 
the gene or locus affected by each variant. For this purpose, all the genes affected by 
filtered variants were examined in the UniProt219 and OMIM220 databases in order to learn 
about the function of each protein and their relevance in the context of cancer. The 
Reactome221 and PathCards222 tools were then used in order to check them against a list 
of genes involved in relevant biological functions (e.g. DNA repair, cell cycle, DNA 
replication, proliferation, apoptosis and important signaling pathways such as the Wnt, 
MAPK, TGF-β, GPCR, Hedgehog, Notch, mTOR, BMP, PIP3-Akt  and NF-κB pathways). This 
data was used in a first prioritization step to discard those missense, inframe of splice 
region variants without further evidence pointing to a potential role in cancer 
development. 
 
For all the remaining genes, references were extensively reviewed using the 
Pubmed search engine223. The STRING database224 was then consulted so as to check 
protein-protein interactions, while SMART225,226 and cBioPortal’s MutationMapper227,228 
were used to find out if any described domains were affected by each selected variant. 
Finally, when possible, the 3D structure of the genes affected by these variants was 
simulated by SWISS-MODEL229 or downloaded from the Protein Data Bank230 and then 
viewed by the Jmol 3D molecule visualization tool231. This was done in order to visualize 
the effects of a truncating mutation on the structure or to determine the location of a 
missense variant within the tertiary structure of the protein. After this thorough search, a 
number of candidate variants were selected based on the relevance of the gene and the 
location of the variant in the protein structure. This prioritization was especially important 
for missense variants, and included DNA repair genes, tumor suppressor genes, CRC 
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susceptibility loci, genes from pathways involved in cancer progression or genes 
previously associated with cancer. 
 
3.2.5. Validation, segregation and loss of heterozygosity 
studies 
 
All the candidate variants selected were validated by PCR followed by Sanger 
sequencing of the corresponding region of each gene using germline DNA. Specific 
primers for each variant were designed using the online tool Primer3232 and synthesized 
by Isogen Life Science (HLPC purification)233. The PCRs were carried out in a 2720 Thermal 
Cycler (Applied Biosystems) using the FastStartTM Taq DNA Polymerase (Roche), with a 
final volume of 25μl and 30 cycles of reaction. All the primers used, together with the PCR 
conditions, are summarized in the Appendix (A3). PCR products were analyzed by agarose 
gel electrophoresis (2% agarose in 0.5x TAE buffer) and subsequently sequenced. Sanger 
sequencing involved three different steps: thermal cycling, purification and capillary 
electrophoresis. In the first place, the sequencing reactions were performed in a 2720 
Thermal Cycler and a final volume of 10μl, using the fluorescent BigDye® Terminator v1.1 
Cycle Sequencing Kit (Applied Biosystems), together with either a forward or reverse 
primer (Appendix, A3) and 1-3μl of PCR product depending on the intensity of the agarose 
gel band. Then, the extension fragments were purified for 30min with the BigDye® 
Xterminator Purification Kit (Applied Biosystems) and diluted 1:2 in sterile water. Lastly, 
capillary electrophoresis took place in an ABI 3130 Genetic Analyzer (Applied Biosystems).  
 
The segregation and LOH studies were also assessed by PCR and subsequent 
Sanger sequencing. The segregation study was carried out in germline DNA from the 
available members of each family for all the candidate variants. Tumor DNA was only used 
in the case of deceased members. For the LOH analyses, tumor DNA was extracted from 
the FFPE tumor blocks available as described earlier and 40 cycles of reaction were used 
in the PCR step. Then, the electropherograms of the germline and tumor sequences were 
compared in order to detect possible variations in the peak height of any of the alleles. 
 Figure 3.1. Filtering strategy used 
for the selection of candidate 
variants. The different colors of 
each step correspond to the colors 
of the filtered variants in Table 4.2. 
MAF: minor allele frequency, MS: 
missense, IF: inframe. 
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3.3 Other approaches to handle FCCTX 
families 
 
3.3.1. Tumor whole-exome sequencing 
 
The whole exome was also sequenced from tumor DNA of two members from two 
different families. This time, WES was outsourced to the CNAG (Centro Nacional de 
Análisis Genómico). The quality of the DNA was previously analyzed by agarose gel 
electrophoresis (1%) and the A260/A280 and A260/A230 ratios were obtained using 
Nanodrop. Then, the concentration was measured in a Qubit Fluorometer and 6μg of DNA 
were used for the library preparation. The exome capture was performed using Agilent's 
SureSelect XT V5, and the DNA library was subsequently sequenced in a HiSeq 2000 
(Illumina) with 100bp paired-end reads and a 140x average coverage depth. After the 
generation of the FASTQ and BAM files, two different somatic variant callers were used, 
namely Mutect2234 and Strelka235. 
 
For the data analysis, the results from the tumor WES were compared to the 
corresponding germline WES data. This was done with the aim of looking for germline 
variants that presented either loss of heterozygosity or a second hit in the same gene in 
the tumor. Therefore, the filtering strategy used for this study sought either the transition 
of heterozygous to homozygous variants (event 0/1 > 1/1) or the co-occurrence of a 
heterozygous somatic variant and a heterozygous germline variant in the same gene (0/0 
> 0/1 + 0/1 > 0/1), with the allelic frequency of the germline variants in the general 
population being lower than 0.03 (ExAc207). The percentage of altered allele used for the 
filtering was calculated taking into account the tumor cell content of each tissue sample 
as determined by an experienced pathologist (70% for patient 275 and 40% for patient 
2310). 
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3.3.2. Copy number variations 
 
The BAM files obtained from germline WES were analyzed in order to look for DNA 
CNVs. This was achieved with the help of Dr. Juanjo Lozano, head of the Bioinformatics 
platform of CIBEREHD, who evaluated the number of reads of each area after correcting 
for biases using the R software236. In order to confirm all suspected structural variations, 
array-based comparative genomic hybridization (CGH) was used in some selected 
samples, allowing genome-wide CNV profiling. This was done in 7 samples (448, 772, 948, 
2695, 6134, 6139 and 6230) in collaboration with IDIBAPS (Institut d'Investigacions 
Biomèdiques August Pi i Sunyer). The quality of every DNA sample was previously tested 
by agarose gel electrophoresis and by measuring the A260/A280 and A260/A230 ratios 
on Nanodrop. The latest version of Agilent Technologies' Human Genome CGH Microarray 
was then used to analyze 3μg of germline DNA, according to the instructions of the 
different kits employed. In the first place, the sample preparation was done using the 
SurePrint G3 Human CGH Microarray Kit. Then, the samples were labeled with different 
fluorescent dyes for the patient and reference DNAs with the help of the SureTag 
Complete DNA Labeling Kit. Finally, the Hybridization Gasket Slide Kit was used for the 
hybridization step, where the two DNAs competed to bind the microarray. The fluorescent 
signals were then measured in Agilent's SureScan Microarray Scanner System and the data 
was analyzed by Agilent CytoGenomics Software to generate a plot. For the analysis of the 
results, copy number ratio cutoffs of 1.25 and 0.75 were used for the identification of 
regions of gain and loss, respectively, and general population frequencies were also taken 
into account (MAF≤0.05). 
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3.4 Characterization studies 
 
3.4.1. Digital PCR 
 
For the allele-specific expression assays, a TaqMan digital PCR (dPCR) was carried 
out taking advantage of the QuantStudioTM 3D Digital PCR System (Applied Biosystems) 
and according to the manufacturer's recommendations. To this end, 15μL of a mix 
containing cDNA, QuantStudio® 3D Digital PCR Master Mix v2 (2x) and specific TaqMan 
probes (20x) were loaded into a dPCR chip (QuantStudioTM 3D Digital PCR Chip Kit) with 
the help of the QuantStudio 3D Digital PCR Chip Loader, according to the kit's instructions. 
The amount of sample used for the reaction was calculated and set up in order to ideally 
have one molecule of cDNA per well. After the chips had been thoroughly sealed, the 
dPCRs took place in a GeneAmp® PCR System 9700 (Applied Biosystems), with an 
annealing temperature of 60ºC and 40 cycles of reaction. Lastly, the fluorescence of each 
well was measured, allowing the absolute quantification of the samples. 
 
The primers and TaqMan probes used for the dPCR were designed with the Custom 
TaqMan® Assay Design Tool (Thermo Fisher Scientific) and produced by the same 
company. The FAM probes specifically identified the mutant transcripts, while the VIC 
probes only recognized the wild type ones. The dPCR was used to analyze the cDNA from 
the paraffin-embedded tumors for two variants in SETD6 and PTPRT. Tumor cDNA from 
sporadic CRC patients served as non-carrier control, and cDNA from healthy colon tissue 
was also used as a control. 
 
3.4.2. Quantitative real-time PCR 
 
For the quantification of the overall gene expression of two PTPRT downstream 
target genes (BCL-XL and SOCS3), a quantitative real-time PCR (qPCR) was performed in a 
7500 Fast Real-Time PCR System (Applied Biosystems). For this purpose, cDNA was 
analyzed in a 96-well plate with the TaqMan® Gene Expression Master Mix (Applied 
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Biosystems) and specific TaqMan probes designed by Thermo Fisher Scientific (BCL-XL 
assay Hs00236329_m1, SOCS3 Hs02330328_s1). PSMB4 was used as a housekeeping gene 
whose levels served as a reference (assay Hs00160598_m1), and a pool of 5 healthy colon 
cDNAs was used as a control. All samples were analyzed in triplicates, and the qPCR 
reaction took place with an annealing temperature of 60ºC and 40 cycles. 
 
The qPCR results were expressed as a Ct value for each sample-probe combination. 
The Ct (cycle threshold) is defined as the number of cycles required for the fluorescent 
signal to exceed the background level. Those measurements differing in more than 1 unit 
with their corresponding replicates were discarded. The quantification of the relative 
target gene expression was calculated as 2-ΔΔCt, where ΔΔCt was the difference between 
ΔCt of the studied sample and ΔCt of the control pool, and ΔCt was the Ct value of the 
target gene minus the Ct of the housekeeping gene (PSMB4). The standard deviation was 
calculated for each sample.  
 
3.4.3. Promoter methylation assay 
 
Tumor DNA from two PTPRT mutation carriers was used for the promoter 
methylation assay. DNA obtained from healthy colon or breast was used as a control, as 
well as tumor DNA from sporadic CRC patients. The first step of this study was the bisulfite 
conversion of 1μg of DNA, which was done using the EpiTect® Bisulfite Kit (Qiagen) 
according to its protocol. A methylation specific PCR (MSP) was then performed with the 
EpiTect® MSP Kit (Qiagen) and using two different sets of specific primers targeting the 
promoter region of PTPRT. Each set was composed of 2 pairs of primers, which specifically 
detected methylated (M and M2) or unmethylated DNA (U and U2). These primers had 
been previously described by Laczmanska et al.177 (in CRC, set 1) and by Peyser at al.178 (in 
head and neck carcinoma, set 2) (Appendix, A3). The MSP was carried out following the 
manufacturer's instructions in a final volume of 25μl, with an annealing temperature of 
55ºC and 40 cycles of reaction. Finally, the PCR products were analyzed by electrophoresis 
in a 2.5% agarose gel, and the fractional methylation was quantified by densitometry 
using the ImageJ software. 
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3.4.4. Pyrosequencing 
 
Pyrosequencing was used for the measurement of PTPRT’s promoter methylation. 
For this purpose, pyrosequencing primers were designed using the PyroMark Assay Design 
2.0 software, consisting in 2 PCR primers targeting a fraction of PTPRT’s promoter (with a 
biotinylated reverse primer) and a biosynthesis primer targeted between them. All the 
primers were HPLC purified and are shown in the Appendix, A3. DNA from CRC, healthy 
colon, breast cancer and healthy breast from PTPRT mutation carriers was obtained, 
followed by the bisulfite conversion of 1μg of DNA using the EpiTect® Bisulfite Kit (Qiagen) 
according to its protocol. A PCR was then performed using 1μL of converted product and 
a Taq polymerase (Thermo Fisher Scientific), with an annealing temperature of 48ºC and 
45 cycles of reaction. Commercial high-methylated and non-methylated DNAs were used 
as controls (CpGenome Human Methylated/Non-Methylated DNA Standard, Millipore). 
 
The sample preparation was performed using 10μL of each PCR product and 
PyroMark Annealing Buffer, streptavidin-coated Sepharose beads, Binding Buffer, Wash 
Buffer and Denaturation Solution (Qiagen), following the manufacturer’s instructions and 
with the help of a vacuum prep work station. Finally, the pyrosequencing took place in a 
PyroMark Q96 MD sequencer (Biotage, Qiagen) with the help of the Pyro-Q-CpG Software 
and using PyroMark Gold Q96 reagent Kit (containing the PyroMark Enzyme Mixture, 
Substrate Mixture and dNTPs for the pyrosequencing reaction) and PyroMark Q96 HS 
Capillary Tips. The PCRs and subsequent pyrosequencing were performed in triplicates, 
and the relative methylation (%) and standard deviation were represented. 
 
3.4.5. Histone binding affinity assay 
 
The histone binding affinity of mutant Pygo1 was tested by isothermal titration 
calorimetry (ITC) at Mariann Bienz's laboratory (Cambridge University, United Kingdom) 
as described by Miller et al196. The ITC was carried out at 25°C with an iTC 200 
Microcalorimeter (GE Healthcare) following dialysis of purified wild type and mutant His-
tagged PHDPygo1-HD1BCL9 and PHDPygo1-HD1B9L complexes in 25mM Tris (pH 8.0) and 
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100mM NaCl. Titrations consisted of 19 consecutive 2-μl injections of peptide solution 
(following a pre-injection of 0.5μl) into the protein at time intervals of 120s or 150s. The 
15-mer H3K4me2 histone tail peptide was used as previously described194, and its 
concentration was determined by amino acid analysis. 
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3.5 Characterization of a frameshift 
variant in SETD6 
 
The functional characterization of a frameshift variant identified in SETD6 was 
performed at Dan Levy's laboratory, in Ben Gurion University and The National Institute 
for Biotechnology in the Negev (Beer Sheva, Israel). This was done during a research stay 
that was possible thanks to a fellowship awarded by the Federation of European 
Biochemical Societies (FEBS). 
 
3.5.1. Cloning and plasmids 
 
Two mutant versions of SETD6 were cloned into pcDNA3.1 plasmids (Appendix, 
A4), one mimicking the mutation identified in one of the families (SETD6-N) and another 
one resulting in the C-terminal half of the protein (SETD6-C). For this purpose, the two 
versions were amplified by high-fidelity PCR using the KAPA HiFi HotStart PCR Kit (Kapa 
Biosystems) according to its instructions, with an annealing temperature of 59ºC and a 1-
minute elongation. A wild-type SETD6 pcDNA3.1 plasmid provided by Dan Levy163 was 
used as a template (Appendix, A4). Primers were designed with the help of SnapGene® 
and synthesized by Isogen Life Science (Appendix, A3). The forward primer included an 
AscI restriction site tail, while the reverse primer had a PacI restriction site tail attached. 
PCR products were run on a 1% agarose gel and the bands were extracted from the gel 
using the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel), according to the 
manufacturer’s recommendations. Then, the extracted products and the vector were 
simultaneously digested with two restriction enzymes (AscI and PacI, New England 
BioLabs) for 2h at 37ºC, in a final volume of 20μL with 10μL of sample and 1.5μL from each 
enzyme. For the digestion of the vector, calf-intestinal alkaline phosphatase (CIP, New 
England BioLabs) was added after the first hour for an additional hour, so as to prevent 
self-ligation. The digestion products were run in a 1% agarose gel and the bands were 
extracted once again.  
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For the ligation step, 1μL of each product was run on a gel in order to evaluate the 
amount of vector/insert needed to achieve a 1:1 molecular ratio. The ligation reaction 
was carried out using the T4 DNA Ligase (Sigma-Aldrich) for 1h at room temperature, in a 
final volume of 10μL and following the manufacturer's recommendations. A self-ligation 
control containing no insert was also added. The ligation products were immediately 
transformed into 100μL of DH5α Competent Bacteria (Thermo Fisher Scientific) by the 
heat shock method (30min on ice, 45sec at 42ºC, 2min on ice), after which 0.90mL of 
warm LB media was added and the mix was incubated for 1h at 37ºC. The tubes were then 
centrifuged at maximum speed and 0.9mL of media were removed before the pellet was 
resuspended, plated on LB plates containing 100ng/μL of ampicillin and incubated 
overnight at 37ºC. Finally, plasmid DNA extracted from a few colonies using NucleoSpin 
Plasmid EasyPure (Macherey-Nagel) was validated by digestion with AscI/PacI followed by 
visualization on an agarose gel. Positive clones were then sequenced using a primer that 
targeted the T7 promoter of the plasmids for additional validation. 
 
The pcDNA3.1 plasmids in which the two forms of SETD6 (N and C) were subcloned 
for the different experiments included pcDNA3.1-FLAG, pcDNA3.1-HA and pcDNA3.1-GFP. 
Apart from these pcDNA3.1 plasmids, used for transfection and overexpression assays in 
human cells, the two versions were also subcloned into a pET-Duet plasmid (Appendix, 
A4) for their expression in E.coli and protein purification. Wild-type SETD6 had already 
been cloned into all these plasmids with the same purposes. In the same way, RelA and 
PAK4 had been also cloned into pcDNA3.1-FLAG for the overexpression experiments, and 
pMAL-c2x or pET-Duet plasmids (respectively) for the expression and purification of 
recombinant proteins (Appendix, A4)163,167. 
 
3.5.2. Cell lines and transfection 
 
Two different cell lines were used for the characterization of mutant SETD6: 
human embryonic kidney cells (HEK293T) and human colon carcinoma cells (HCT116). 
Both were maintained in Dulbecco's modified Eagle's medium (Sigma-Aldrich) with 10% 
fetal bovine serum (Gibco), 2mg/mL L-glutamine (Sigma-Aldrich), 1% penicillin-
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streptomycin (Sigma-Aldrich) and 1% MEM non-essential amino acids (Sigma-Aldrich), 
and they were cultured at 37ºC in a humidified incubator with 5% CO2. For transient 
transfection, Mirus transfection reagents (TransIT®-LT1 for HEK293T cells and TransIT®-
X2 for HCT116 cells) were used according to the manufacturer's instructions, together 
with Opti-MEM serum-free medium (Gibco). 
 
3.5.3. Western blot 
 
For western blot analyses, cells were homogenized and lysed in RIPA buffer buffer 
[50mM Tris-HCl, pH 8, 150mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% 
SDS, 1mM DTT, and 1:100 protease inhibitor mixture (Sigma-Aldrich)] (Appendix, A5), 
except for the biochemical fractionation and chromatin immunoprecipitation 
experiments, in which the cells were lysed as described below. Samples were heated at 
95ºC for 5min in Laemmli sample buffer (Sigma-Aldrich), run on an 8-12% SDS-PAGE 
electrophoresis gel, and then transferred to a polyvinylidene difluoride (PVDF) 
membrane. Membranes were blocked with either 10% skim milk in PBST or 5% BSA in 
TBST for 1h on a shaking platform, and subsequently incubated with primary antibody for 
another hour with agitation. After three washes with the corresponding buffer (PBST or 
TBST), a 30-minute incubation with HRP-conjugated secondary antibody and three 
additional washes, a 2-minute reaction with a chemiluminiscent substrate (EZ-ECL, 
Biological Industries) allowed the visualization of the proteins. 
 
The mouse monoclonal antibodies used were: anti-FLAG M2 (Sigma-Aldrich, 
F1804), anti-HA (Millipore, 05-904), anti-GAPDH (Abcam, ab8245), anti-histone H3 
(Abcam, ab10799) and anti-tubulin (Abcam, ab44928). The rabbit polyclonal antibodies 
used were: an HRP-conjugated pan methyl lysine antibody (ImmuneChem, ICP0502) and 
a specific antibody against monomethylated RelA-Lys310 developed by Levy et al.163. HRP-
conjugated secondary antibodies (goat anti-rabbit and goat anti-mouse) were purchased 
from Jackson ImmunoResearch (111-035-144 and 115-035-062, respectively). Antibodies 
were diluted and prepared in PBST with 10% skim milk or in TBST with 5% BSA, according 
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to the manufacturer's recommendations. All the details regarding the antibodies used are 
summarized in the Appendix (A5). 
 
3.5.4. Biochemical fractionation 
 
Biochemical fractionation was performed as previously described by Mendez et 
al.237, with the addition of a final resuspension of the chromatin pellet for 30min on ice in 
RIPA buffer with 1mM MgCl2 and benzonase nuclease enzyme (Sigma-Aldrich). The 
chromatin fraction was obtained by the collection of the supernatant after low-speed 
centrifugation (5min, 1700g, 4ºC). 
 
3.5.5. Recombinant protein expression and purification 
 
The Escherichia coli BL21-derivative Rosetta host strain was transformed with pET-
Duet plasmids containing the gene of interest (SETD6 wt, SETD6-N, PAK4 or RelA) and 
grown overnight in 3mL LB medium +100μg/mL ampicillin (37ºC, 220rpm). The culture 
was then expanded to 100mL LB medium and incubated at 37ºC until the absorbance (OD) 
reached values of 0.6-0.8, when it was induced with 1:10000 IPTG and left overnight at 
18ºC and 220rpm. After IPTG induction, the bacteria were harvested by centrifugation 
(10min, 12000rpm, 4ºC), resuspended in cold lysis buffer (10mM imidazole, 1% PMSF, 
protease inhibitor cocktail, 0.1% triton and PBS) and then lysed by sonication on ice (25% 
amplitude, 1min 30s, 10s on/5s off). Finally, the lysate was centrifuged (20min, 4ºC, 18000 
rpm) and filtered, and the His-tagged proteins were purified using an ÄKTATM column. 
 
3.5.6. ELISA 
 
A high-binding 96-well polystyrene microplate (Greiner Bio-One MICROLON®) was 
coated with 2mg of the recombinant proteins of interest (His-PAK4, MBP-RelA or BSA) 
diluted in PBS. The plate was blocked with 3% BSA in PBST and subsequently covered with 
0.5mg of the recombinant tested proteins (His-SETD6 wt, His-SETD6-N or His-SUMO as a 
control) diluted in 1% BSA in PBST. A rabbit polyclonal anti-SETD6 primary antibody163 was 
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then added, followed by incubation with an HRP-conjugated secondary antibody (goat 
anti-rabbit, 1:2000; Jackson ImmunoResearch, 111-035-144). All the incubation steps 
were performed at room temperature with vigorous agitation for 1h, and followed by 
three washes with PBST. After the final washes, 100μL of TMB reagent were added to 
each well, succeeded after a few minutes by the same amount of 1N H2SO4, in order to 
stop the reaction. The absorbance at 450nm was then detected using an Infinite® M200 
plate reader (Tecan). All samples were analyzed in duplicates.  
 
3.5.7. Cell-free in vitro methylation assay 
 
Cell-free in vitro methylation reactions with recombinant proteins took place in a 
final volume of 25μL, containing 4μg of substrate (His-PAK4 or MBP-RelA), 4μg (or 
increasing amounts for the competition assay) of His-SETD6 (either wt or N), 2mCi of 3H-
labeled S-adenosyl-methionine (SAM) (AdoMet, Perkin-Elmer) and PKMT buffer (20mM 
Tris-HCl, pH 8, 10% glycerol, 20mM KCl, 5mM MgCl2). The reaction tubes were incubated 
overnight at 30ºC and then resolved by SDS-PAGE electrophoresis and subsequent 
autoradiogram. For the immunoprecipitation followed by cell-free in vitro methylation, 
human cells were transfected with empty, FLAG-SETD6 wt, FLAG-SETD6-N, FLAG-RelA or 
FLAG-PAK4 pcDNA3.1 plasmids, and 24h post-transfection they were lysed with RIPA 
buffer and pulled down overnight with anti-FLAG M2 Affinity gel beads (Sigma-Aldrich, 
A2220) on a rotor at 4ºC. After two washes in RIPA buffer and another two in PKMT buffer, 
samples were subjected to an on-beads cell-free in vitro methylation assay as described 
above. 
 
3.5.8. Protein-protein chromatin immunoprecipitation 
 
Protein-protein chromatin immunoprecipitation was modified from a published 
protocol238. After cross-linking, cells were harvested and washed twice with PBS and then 
lysed in 1mL of lysis buffer (20mM Tris-HCl, pH 8, 85mM KCl, 0.5% Nonidet P-40, and 1:100 
protease inhibitor mixture) for 10min on ice. Nuclear pellets were resuspended in 200μl 
of nuclei lysis buffer (50mM Tris-HCl pH 8, 10mM EDTA, 1% SDS, 1:100 protease inhibitor 
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mixture) for 10min on ice, and sonicated (Bioruptor, Diagenode) with high power settings 
for three cycles of 6min each (30s on/off). Samples were then centrifuged (20min, 
13000rpm, 4ºC), and the soluble chromatin fraction was collected. The FLAG-labeled 
substrates present in the soluble chromatin were then immunoprecipitated overnight on 
a rotor at 4ºC, using 20μl per tube of anti-FLAG M2 Affinity gel beads (Sigma-Aldrich). The 
beads were then washed according to the published protocol, heated for 30min in 
Laemmli sample buffer at 95ºC, and resolved on 10-12% SDS-PAGE gels followed by 
western blot analyses. 
 
3.5.9. RNA extraction, reverse transcription and qPCR 
 
RNA was extracted from cells using the NucleoSpin RNA Kit (Macherey-Nagel), 
normalized to 100ng/μL and reverse-transcribed to cDNA using the iScript cDNA Synthesis 
Kit (Bio-Rad), according to the manufacturer's instructions. For the NF-κB target genes, 
cells were previously induced with 20ng/mL TNF for 1h. Real-time quantitative 
polymerase chain reaction (qPCR) was carried out in a LightCycler® 480, using the UPL 
probe library system (Roche). All samples were amplified in triplicates in a 384-well plate, 
using 0.2μL of cDNA, 0.45μL of each primer, 0.1μL of the corresponding UPL probe and 
LightCycler480 Probes Master Mix for a final volume of 12μL. The housekeeping gene 
GAPDH was used for the relative analysis of gene expression levels, and qPCR results were 
analyzed as previously described. 
 
3.5.10. Viability assay 
 
A viability assay of HCT116 cells after 24, 48 and 72h post-transfection with either 
SETD6 wt or SETD6-N plasmids was performed using the PrestoBlue® Cell Viability Reagent 
(Thermo Fisher Scientific), with a 30-minute incubation and according to the 
manufacturer's recommendations. The absorbance at 570nm was detected using an 
Infinite® M200 plate reader (Tecan), normalized to the 600nm values and plotted in a 
graph. All samples were analyzed in triplicates. 
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4.1 Whole-exome sequencing strategy 
for the study of FCCTX 
 
4.1.1. FCCTX study cohort 
 
With the aim of identifying new genes involved in their increased cancer 
predisposition, a total of 33 members from 13 FCCTX families were selected for their 
subsequent study (Table 4.1). The pedigrees of the 13 families and additional information 
about the probands and other family members can be found in the Appendix (A1 and A2). 
The selected families fulfilled either the Amsterdam I or II criteria for HNPCC239,240 (46.2% 
and 53.8%, respectively), except for 4 high-risk families selected as “borderline AC-I/II”, in 
which the lowest age at diagnosis was 50 (cc81 and cc525), 51 (cc440) or 52 years old 
(cc763). These families were included based on a strong cancer inheritance. 
 
In our cohort of 33 participants, 36.4% were male and 63.6% were female. In 
addition, 3 were healthy and 30 were affected of a colorectal or HNPCC-associated 
carcinoma, or a colorectal adenoma. Out of the 30 affected probands, 24 had developed 
CRC, 1 had an endometrial cancer, 1 had been diagnosed of a renal cancer and 4 had 
developed colorectal adenomas (without fulfilling the clinical criteria for polyposis). In 
addition, three of the CRC-affected patients also had other cancers: cc565-III:4 had an 
endometrial cancer besides the CRC, cc108-III:1 had two CRCs and two breast cancers, 
and cc7-III:1 had an additional breast cancer. The mean age at diagnosis was 54.3 years 
old when considering the earliest CRC or HNPCC-associated tumor (without taking into 
account the adenomas). Among the 4 patients that did not have a diagnosed cancer 
(cc108-III:2, cc406-III:1, cc406-III:4 and cc525-IV:1), 3 fulfilled the criteria for advanced 
adenoma (>10mm or villous component or high-grade dysplasia), and the fourth (cc525-
IV:1) was selected based on the very early age at diagnosis. The patient with renal cancer 
(cc7-III:2) had also developed at least 4 colorectal adenomas at ≤50 years old. 
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  Exome 1 Exome 2 Exome 3   
Fam Crit WES ID Tumor Dx Sex ID Tumor Dx Sex ID Tumor Dx Sex Relationship 
cc7 AC-II 2a III:1 CRC 42 F III:2 ADE/RC 42/47 M         Sibling 
cc28 AC-I 2b II:1 CRC 67 F III:1 CRC 48 M         Child 
cc81 AC-I* 3a,b II:5 CRC 66 F II:6 CRC 69 F II:7 CRC 50 F Siblings 
cc89 AC-I 2a III:1 CRC 52 F III:2 CRC 46 M         Sibling 
cc108 AC-II 2a III:1 CRC 38/44 F III:2 ADE 32 M       Sibling 
cc122 AC-I 2a III:1 CRC 52 F IV:1 CRC 28 F         Child 
cc406 AC-I 3a II:1 CRC 73 F III:1 ADE 49 F III:4 ADE 52 F Child & niece 
cc440 AC-II* 3a III:1 CRC 51 M III:2 CRC 60 M III:3 NO   M Siblings 
cc525 AC-II* 3b II:2 CRC 67 M III:1 CRC 50 F IV:1 ADE 30 M Niece & grandnephew 
cc565 AC-II 2a III:1 CRC 49 F III:4 EC/CRC 51/68 F         Cousin 
cc598 AC-I 3b II:1 CRC 64 M II:1 CRC 56 M II:3 NO  F Siblings 
cc763 AC-I* 3b II:1 CRC 81 F III:3 CRC 52 F III:4 CRC 56 M Daughter & nephew 
cc765 AC-II 3b II:6 CRC 70 F II:7 EC 28 F II:5 NO   F Siblings 
 
 Table 4.1. Family members selected for exome sequencing. The different fields are specified below. Fam: family identification number; Crit: clinical 
criteria by which the family was classified (AC-I: Amsterdam I, AC-II: Amsterdam II, *borderline: earliest age of onset allowed up to 52 years old); WES: 
number of exomes sequenced in that family and company where they were outsourced (a: NINGenetics and b: Sistemas Genómicos); ID: identification 
number of each member referred to the pedigree (Appendix, A1); Tumor: tumor type (CRC: colorectal cancer, EC: endometrial cancer, RC: renal cancer, 
ADE: colorectal adenoma); Dx: age at diagnosis; Sex: gender of the patient (F: female, M: male); Relationship: relationship of the second and third 
members (Exomes 2 and 3) referred to the first one (Exome 1). Only HNPCC-associated carcinomas and colorectal adenomas are displayed in this table. 
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Regarding the location of the colorectal carcinomas and adenomas, 16.7% were 
located in the right colon, 16.7% in the left colon, 33.3% in the sigma and 33.3% in the 
rectum, which means that 83.3% had been developed in the distal colon or rectum. This 
percentage of distal location goes up to 87% when taking into account CRCs from other 
family members. On the other hand, there was a wide range of CRC stages among the 
probands, going from carcinoma in situ to stage IIIC, but none of the patients had 
metastasis at the time of diagnosis. 
 
4.1.2. NGS data analysis and filtering 
 
The whole exome was sequenced in at least 2 members from each of the 13 FCCTX 
families, and the data obtained was subsequently filtered. The filtering strategy used is 
summarized in the diagram of Figure 3.1. The number of variants that remained after each 
filtering step for the different families is shown in Table 4.2. There were a total of 1646 
rare variants (MAF≤0.01), ranging from 34 to 207 per family. After the in silico predictions, 
532 variants were left, which were reduced to 460 when the healthy relatives sequenced 
in 3 of the families were taken into account (filtering out those variants that were present 
in the healthy individuals). This final selection ranged from 11 to 72 per family and 
comprised a total of 29 frameshift, 24 nonsense, 357 missense, 10 inframe, 13 splice 
donor/acceptor and 37 splice region variants. Note that 10 missense variants were splice 
region variants at the same time and are counted in both categories, although just 
counted once in the total number.
   
 
 
 Table 4.2. Number of variants remaining after each filtering step. The colors correspond to the ones used in the diagram of Figure 3.1. The first four 
columns (yellow) refer to the main initial stages of the variant filtering (Shared: shared variants between affected members of each family; Hete: variants 
present in heterozygosis in all the carriers; Coding: frameshift, nonsense, inframe or missense or splicing variants, affecting coding transcripts and located 
in autosomes; Rare: MAF≤0.01 in the general population and not present in more than 3 families). In the next 7 columns (blue), rare variants are separated 
by their effect (FS: frameshift, NS: nonsense, MS: missense, IF: inframe, SP a/d: splice donor/acceptor, SP r: splice region). The same separation is shown 
for damaging variants (red columns), which include variants predicted to be deleterious by at least 4 out of 5 (for missense) or 2 out of 2 (for inframe) in 
silico prediction tools and splice region variants predicted to affect the splicing by HSF. Finally, the green columns show the number of rare damaging 
variants not present in the healthy relative sequenced for the three families in which it was applicable (cc440, cc598 and cc765) a: Including one start-
lost variant that produces a shift in the reading frame; b: Including one start-lost variant that does not produce a shift in the reading frame; c: Including 
one stop-lost variant. 
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4.1.3. Variant prioritization, validation, segregation and 
loss of heterozygosity 
 
After this filtering, the variants were further prioritized according to the function 
and/or previous literature on the genes, the predicted alteration or domains affected by 
each variant and the frequency in the general population, in order to select the candidate 
variants that would be further studied. This step was particularly relevant for missense, 
inframe and splice region variants, while more lenient for frameshift, nonsense and splice 
donor/acceptor variants. Among the 460 filtered genes, a total of 207 passed a first 
prioritization step for having any previously reported association with cancer or for being 
involved in relevant pathways (see Materials and Methods). A more thorough analysis of 
the variants and the corresponding genes allowed the final prioritization of 44 variants 
that were successfully validated by Sanger sequencing, after which the segregation and 
LOH was studied when possible. Table 4.3 shows the results from these studies. 
 
The segregation was used to discard those variants that did not segregate with the 
disease within the family (not carried by affected members with early onset ages as 
observed in germline DNA) or to further prioritize variants with a positive or compatible 
segregation. Only those prioritized variants that showed a positive, compatible or non-
informative segregation were further considered as candidate variants, eliminating the 
ones that clearly did not segregate. Unfortunately, the segregation study was not very 
informative for most of the families and did not discard many variants. On the other hand, 
the LOH allowed the detection of significant reductions of either the wild-type or mutant 
allele in the available tumors of the carriers, but was only used as additional information 
to further prioritize the variants, not for selection purposes. Most of the tumors did not 
present a significant loss of any of the alleles, with the exception of those shown in the 
table as either LOH wt (loss of the wild type allele) or LOH mut (loss of the mutant allele). 
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4.1.4. Variants detected in CRC susceptibility genes 
 
In order not to miss any potential causal mutation, all the genes that had been 
previously associated with CRC predisposition, as well as CRC loci identified by GWAS 
studies, were carefully screened separately from the rest with a more lenient filtering 
(Figure 3.1). The filtered variants in CRC susceptibility genes are shown in Table 4.4. This 
analysis allowed the identification of 2 missense variants in POLE: c.2083T>A and 
c.6494G>A. The former was carried by two families (cc28 and cc598) and affected POLE’s 
polymerase domain (POLBc), but it was only predicted to be damaging by 3 out of the 5 
in silico programs and, in addition, it was classified as benign in ClinVar with 9 submissions 
(2*). The latter, detected in family cc440, was predicted to be deleterious by all the in 
silico tools used, but did not affect any protein domain and was reported to be either 
benign or likely benign in ClinVar by 7 submitters (2*). In addition, three missense variants 
were detected in breast cancer genes previously associated with CRC75,142: BRCA2 
c.502C>A, BRCA2 c.4258G>T and PALB2 c.2993G>A. However, the two BRCA2 variants 
were classified as benign in ClinVar by an expert panel (3*), while the PALB2 variant was 
reported to be benign or likely benign by 15 submitters (2*). For these reasons, none of 
these SNPs were further considered as candidate variants. 
 
Apart from these, only 2 other variants were identified in genes that had been 
previously reported to be potentially associated with CRC, but with much weaker 
evidence136. WIF1 c.850A>G involved the substitution of two very similar amino acids241 
(Asn284Asp) not located in any specific secondary structure, while LAMB4 c.368T>C was 
predicted to be damaging by just 3 out of the 5 in silico programs. Although both 
mutations affected protein domains and were rare in the general population, the 
involvement in CRC predisposition had not been supported for neither of them by their 
corresponding studies136. This, together with the weak predicted effect of these variants, 
prevented us from including them as candidate variants.  
 
On the other hand, 7 variants affected genes previously associated with CRC 
through GWAS (Table 4.5). Out of these, 6 were missense and there was only one splice 
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donor variant. No other truncating mutations were found in CRC predisposition loci. 
Taking into account the frequency of the variants in the general population, the secondary 
structure and domains affected, and the relevance of the genes, none of the missense 
variants were further considered as candidate high-risk variants either. Another gene 
reported to have its expression altered in FCCTX (NDUFA9) also presented a missense 
variant that was not prioritized based on all of the above. Therefore, among all the 
variants detected in CRC genes/loci, only ABCC2 c.1209+2T>G was further considered as 
a candidate variant.  
 
 
 
Table 4.3. Candidate variants. 
 
 
 
 
 
 
Table 4.3. Candidate variants (cont.). Final selection of candidate variants per family. The different columns indicate the family, official gene name, type of mutation 
(NS: nonsense, FS: frameshift, MS: missense, IF: inframe, SP d: splicing donor, SP r: splicing region), transcript  used for the nomenclature of the variant, variant name at 
cDNA and protein level, reference rs number of previously described variants, minor allele frequency  (MAF) according to GnomAD, in silico prediction (number of tools 
with a deleterious prediction, out of 5 for missense and out of 2 for inframe and splicing variants, result  from the segregation study (number of members carrying the 
mutation vs total) and LOH (LOH mut: loss of mutant allele; LOH wt: loss of the wt allele). a: 3rd is tumor DNA, b: 3rd was in tumor DNA and there is no left, c: 3rd was 
diagnose very late (85y), NP: not possible. 
 
 
 
 
Table 4.4. Variants identified in previously described CRC predisposition genes. 
Family Gene V. type Variant (c.) Variant (p.) Transcript dbSNP MAF ClinVar Pred Domain Notes
cc7 WIF1 MS c.850A>G p.Asn284Asp ENST00000286574 rs768033163 0,000004 N/A 5/5 EGF Association not clear
cc28, cc598 POLE MS c.2083T>A p.Phe695Ile ENST00000320574 rs5744799 0,011230 Benign (2*) 3/5 POLBc CRC susceptibility gene
cc81 BRCA2 MS c.502C>A p.Pro168Thr ENST00000380152 rs80358726 0,000037 Benign (3*) 3/5 NO Breast cancer susceptibility gene
cc108 BRCA2 MS c.4258G>T p.Asp1420Tyr ENST00000544455 rs28897727 0,006602 Benign (3*) 3/5 NO Breast cancer susceptibility gene
cc108 PALB2 MS c.2993G>A p.Gly998Glu ENST00000261584 rs45551636 0,016430
Likely 
benign (2*)
5/5 WD40 Breast cancer susceptibility gene
cc440 POLE MS c.6494G>A p.Arg2165His ENST00000320574 rs5745068 0,005857
Likely 
benign (2*)
5/5 NO CRC susceptibility gene
cc440 LAMB4 MS c.368T>C p.Leu123Ser ENST00000388781 - - N/A 3/5 LamNT Association not clear
Family Gene V. type Variant (c.) Variant (p.) Transcript dbSNP MAF ClinVar Pred Domain Notes
cc7 TPD52L3 MS c.401G>A p.Gly134Glu ENST00000344545 rs117022582 0,004959 N/A 5/5 TDP52
Reported to be testis-specific and 
involved in spermatogenesis.
cc28 TDGF1 MS c.307G>A p.Gly103Arg ENST00000296145 rs554684465 0,000004 N/A 5/5 EGF
Higher expression associated with 
CRC and poor prognosis.
cc81 NDUFA9 MS c.881C>T p.Pro294Leu ENST00000266544 rs34076756 0,016300
Likely 
benign (1*)
3/5 NO
Decreased expression in ecreased 
expression in FCCTX.
cc89 FSTL5 MS c.578G>A p.Gly193Glu ENST00000306100 rs72689202 0,014950 N/A 4/4 EF hand
Down-regulated promotes cell 
proliferation through Wnt signaling.
cc108, cc440 ABCC2 MS c.2546T>G p.Leu849Arg ENST00000370449 rs17222617 0,015570
Likely 
benign (1*)
3/5 NO
Involved in early stages of 
carcinogenesis.
cc122 CUBN MS c.8902G>C p.Glu2968Gln ENST00000377833 rs45569534 0,015070 VUS/Benign 3/5 CUB
Involved in vitamin absoption and  
renal and intestinal biology.
cc406 ABCC2 SP don c.1209+2T>G N/A ENST00000370449 - - N/A 2/2
ABC 
transmb
Involved in early stages of 
carcinogenesis.
cc440 LAMB1 MS c.2383C>G p.Arg795Gly ENST00000222399 rs80095409 0,011420 Benign (1*) 5/5
Laminin 
EGF
Higher expression in serum of CRC 
patients.
Table 4.5. Variants identified in genes associated with CRC in GWAS studies or genes relevant to FCCTX biology. 
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4.2 Other approaches to handle FCCTX 
families 
 
4.2.1. Tumor whole-exome sequencing 
 
In addition to the germline WES analysis, the whole exome was also obtained from 
tumor DNA for two of the families (cc7 and cc440). The corresponding tumor and germline 
exome pairs were then compared in order to detect germline variants that showed a 
second hit in the tumor (with either loss of heterozygosity or a second mutation in the 
same gene). However, this study did not detect any second hits or LOH at the genes 
affected by rare germline variants in these two families. Unfortunately, no more tumor 
samples could be studied due to the availability, quality and/or quantity of the paraffin-
embedded tumor blocks. 
 
4.2.2. Copy number variations 
 
The raw data obtained by germline NGS also allowed a broad evaluation of the 
CNVs in the studied individuals. This analysis showed a possible CNV in chromosome 6, 
where some anomalies could be noted in various samples. However, it was likely that this 
occurrence was a false positive caused by a systematic error of the methodology, since 
the area was poorly covered and there were some similarities in samples outsourced to 
the same sequencing company. For this reason, a few representative DNAs with possible 
CNVs based on the NGS results (from families cc28, cc89, cc525 and cc763) were selected 
in order to verify if there was a real structural variation by CGH. Regrettably, no CNVs were 
detected in the studied samples, so the potential CNVs observed in the WES data could 
be ruled out by this study. However, we cannot discard the possibility of the existence of 
germline CNVs in other members of our cohort not analyzed by CGH, since they could 
have been missed by the WES analysis. 
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4.3 Candidate variants 
 
As mentioned before, a total of 44 variants were finally selected as candidate 
variants for the 13 FCCTX families after the prioritization, validation and segregation 
studies. These variants are shown in Table 4.3 and further described below. 
 
4.3.1. Predicted consequences of the candidate variants 
 
Among the 44 candidate variants, there were a total of 10 frameshift, 7 nonsense, 
2 inframe, 22 missense, 2 splice donor and 1 splice region variants. All the frameshift and 
nonsense variants produced a truncated protein and were therefore predicted to have a 
relevant effect on the protein structure and/or function. However, the extent of the 
damage caused by these truncating variants depends on the location of the mutation 
within the protein. Actually, among the truncating mutations prioritized, 2 were located 
at the end of the corresponding proteins and did not affect any protein domains. In the 
same way, although there were 3 splicing variants, only 2 directly affected donor sites. 
The remaining variant was located in the splice region and predicted by both HSF216 and 
MaxEnt217,218 algorithms to affect the splicing by altering a splicing donor. 
 
Regarding the missense variants selected, although all the filtered mutations were 
predicted to be deleterious by in silico tools, only 14 out of 22 affected known protein 
domains according to the sources checked, while 1 additional variant affected the 
proximity of a domain (Table 4.3).  However, it is worth noting that in some cases the 
structure of the corresponding protein was not completely understood yet. In addition, 
changes in the tertiary structure caused by truncating mutations, as well as the location 
of missense variants within the protein, were visualized when possible in order to see the 
overall effect or to check whether the affected amino acids were involved in any 
secondary structure. 
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4.3.2. Candidate genes 
 
Regarding the genes affected by the candidate variants, there are some that are 
worth mentioning. As seen in Table 4.4, among all the candidate variants, a total of 12 
were located in genes reportedly involved in DNA damage repair by different sources219–
223. However, only 4 of them were deleterious: POLQ c.4262_4268del in family cc89, 
NME7 c.1109_1110insACTT in family cc108, MUS81 c.1586_1587insGAGGT in family 
cc122 and PHACTR2 c.620dup in family cc440. The NME7 variant only meant the loss of 
the last 6 amino acids of the protein, though. The vast majority of the remaining variants 
were either missense (6) or inframe (2), and only 4 of these were situated in previously-
described protein domains, although 1 more affected the close vicinity of a domain. In 
addition, there were 3 other variants reported to be involved in the oxidative stress-
dependent Nrf2 pathway: two frameshift (TXNRD3 c.614dup and SETD6 c.863_864insA) 
and one splice donor variant (ABCC2 c.1209+2T>G).  
 
On the other hand, there were a total of 10 candidate variants in tumor suppressor 
genes (TSGs) or candidate TSGs. These included not only well established tumor 
suppressors, but also putative TSGs published in the literature. Out of these, 1 was 
frameshift (PTPRT c.4099dup), 1 nonsense (IQGAP2 c.1282C>T) and the remaining 8 were 
missense. Among the missense variants, only 3 were located within a protein domain, 
although 1 more affected the proximity of a domain.  
 
Other candidate variants selected affected genes that were involved in different 
relevant signaling pathways. For instance, a total of 9 variants were situated in genes 
reported to be involved in the Wnt pathway (2 frameshift , 1 nonsense, 5 missense and 1 
splice region with broken donor). In addition, 1 missense variant was involved in the BMP 
pathway, and 5 variants were involved in the TGF-β pathway, including 1 frameshift and 
4 missense variants. It is worth noting that in some cases one single gene was involved in 
more than one of these pathways; that is the case of SETD6, which is further addressed in 
section 4.4. 
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Table 4.6. Candidate genes.  
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4.3.3. Further characterization of candidate variants 
 
Although a few candidate variants were addressed with some preliminary essays, 
only three of them were assessed with a more in-depth characterization. These include a 
frameshift variant in SETD6, which is involved in a high number of essential pathways, a 
frameshift variant in PTPRT, which is a tumor suppressor gene, and a missense variant in 
PYGO1, which is involved in the Wnt pathway. The characterization of these variant is 
further discussed in sections 4.3, 4.4 and 4.5.
Table 4.6. Candidate genes (cont.). Final selection of candidate variants per family. The 
different columns indicate the family, official gene name, locus, type of variant (NS: nonsense, 
FS: frameshift, MS: missense, IF: inframe, SP d: splicing donor, SP r: splicing region), variant 
name at protein level, position of the alteration relative to the length of the protein, protein 
domains affected and finally function or pathways in which the gene is involved (TSG: tumor 
suppressor gene). 
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4.4 Functional characterization of a 
frameshift variant in SETD6 
 
4.4.1. SETD6 c.791_792insA (M264Ifs*3) identified in 
family cc598 
 
The whole-exome sequencing from one healthy and two affected members of 
FCCTX family cc598 (II:1, II:2 and II:3, Figure 4.1 A) allowed the identification of a 
frameshift variant in the SETD6 gene. The corresponding family fulfilled the Amsterdam I 
criteria, with four CRCs affecting two successive generations and the earliest age at 
diagnosis being 34 years old. Appendix A2 shows in detail the clinical data available from 
the different members of this family. The variant detected was SETD6 c.791_792insA, 
p.(Met264IlefsTer3) (rs768456822, ENST00000310682), simplified as M264Ifs*3. It is 
worth noting that this nomenclature was given based on SETD6’s main functional 
transcript, while the list of candidate variants shows variant names based on the longest 
transcripts, which in this case would be c.863_864insA, p.(Met288IlefsTer3), 
(ENST00000219315). Despite this discrepancy, this variant will be hereon referred to as 
M264Ifs*3. 
 
SETD6 M264Ifs*3 is truncating mutation that was therefore predicted to have a 
damaging effect on the protein. And in spite of not being a novel variant, it is quite rare in 
the general population, with a minor allele frequency of 0.0012 according to GnomAD. 
Moreover, it is not found in the 1000 Genomes Project nor observed in homozygous state 
in neither of these databases. In addition, this frameshift mutation affects the three main 
protein-coding transcripts of this gene (ENST00000310682, ENST00000219315 and 
ENST00000394266). 
 
121 
 
 
 
 
4.4.2. Other candidate variants 
 
Other candidate variants selected for this family included CCDC60 c.1558C>T 
(p.Arg20*) and ST18 c.1708A>C p.(Thr570Pro). Like the selected SETD6 mutation, both of 
these variants were present in the two affected members (II:1 and II:2) and absent in the 
Figure 4.1. SETD6 M264Ifs*3 cosegregates with colorectal cancer in FCCTX family cc598. A) 
Pedigree of Amsterdam I family cc598 carrying the SETD6 deleterious mutation c.791_792insA 
(p.Met264IlefsTer3). Whole-exome sequencing was performed in family members II:1, II:2 and 
II:3 (green box), and segregation was studied in members II:4, III:1 and III:2. All affected 
participants were carriers (+), while the healthy were non-carriers (WT). Colorectal cancer (CRC)-
affected members are marked in red. The age at diagnosis or current age of healthy members is 
included beneath each individual (in years). B) Electropherogram of the reverse wild-type and 
mutant sequence of the SETD6 gene. The arrows show the point where the adenine is inserted.
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healthy sibling (II:3). However, among them, the SETD6 mutation resulted in the most 
relevant changes for the protein. Given the relevance of the different pathways in which 
SETD6 is involved163,167–169,171 and their implication in cancer development242,243, SETD6 
c.791_792insA (p.Met264IlefsTer3) was selected among all the candidate variants of this 
family for additional characterization.  
 
4.4.3. SETD6 M264Ifs*3 results in the loss of the C-
terminal half of the protein 
 
The identified SETD6 mutation involves the insertion of an adenine between 
positions 791 and 792 of the cDNA (ENST00000310682), producing a shift in the reading 
frame of the codons (Figure 4.1 B). This results in the introduction of two new amino acids 
at positions 264 and 265 — Ile264 and Gly265, instead of the original Met and Ala — 
followed by a premature stop codon (Figure 4.2 A). The resulting truncated SETD6 has an 
intact SET domain (responsible for the activity of the protein) but lacks the C-terminal half 
of the protein, which includes a linker sequence and the whole Rubisco domain, 
presumably responsible of mediating protein-protein interactions244 (Figure 4.2 B).  Figure 
4.2 C shows the broad effect that this mutation has on the tridimensional structure of the 
protein. 
 
4.4.4. SETD6 M264Ifs*3 cosegregates with CRC but shows 
no LOH in the tumor  
 
SETD6 M264Ifs*3 was carried by the two affected members sequenced (II:1 and 
II:2, with CRC diagnosed at ages 64 and 56, respectively), while not present in the healthy 
sibling (II:3, 76 years old) (Figure 4.1 A). Although there was only germline DNA of two 
young healthy relatives to study the segregation, the FFPE tumor block of a deceased CRC-
affected member allowed the extension of this analysis. The segregation study confirmed 
that the mutation was also present in II:4 (CRC diagnosed at 34), while absent in the other 
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two healthy relatives (III:1 and III:2, 51 and 49 years old, respectively) (Figure 4.1 A and 
Appendix, Figure A2). 
 
 
 
Figure 4.2. SETD6 M264Ifs*3 causes the loss of the C-terminal half of the protein. A) Amino 
acid sequence of SETD6 wt and SETD6-N with the changes marked in red. B) Representation of 
the different domains within the SETD6 protein showing the loss produced by the truncation. C) 
Effect that the mutation is predicted to have on the 3D structure of SETD6 by SWISS-MODEL.  
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On the other hand, the LOH analysis revealed that there was no loss of any of the 
alleles in the tumor of II:2 (Figure 4.3). Although an apparent partial loss of the mutant 
allele was observed in the tumor of II:4, there was no germline DNA from the same patient 
to strengthen this observation. Nevertheless, it is noteworthy that member II:4 had a 
more advanced form of the disease than II:2 (stage IIIB versus I, Appendix, A2). 
 
 
 
 
 
4.4.5. Mutant SETD6 is stable and can be overexpressed in 
human cells 
 
With the aim of checking whether mutant SETD6 was stable and normally 
expressed, a truncated version of the protein mimicking the frameshift mutation — 
hereon referred to as SETD6-N — was cloned and overexpressed in two different human 
cell lines. SETD6-N was found to be expressed to the same extent as wild-type SETD6 both 
in HEK293T and HCT116 cells (Figure 4.4 A and B, respectively). It is worth noting that an 
attempt to overexpress the C-terminal half of SETD6 that contained everything which 
SETD6-N is missing (known as SETD6-C) was unsuccessful. 
Figure 4.3. LOH study of SETD6 M264Ifs*3. 
Electropherograms of the reverse sequences 
of SETD6's exon 7 (ENST00000310682) from 
either germline or tumor DNA of two different 
members of family cc598, obtained by Sanger 
sequencing. The LOH was analyzed in tumor 
DNA from members II:2 and II:4, however, 
only II:2 had germline DNA for the correct 
comparison of the mutant and wild-type 
alleles. A negative wild-type control has been 
added as a reference. 
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4.4.6. SETD6-N shows the same localization pattern as 
wild-type SETD6 
 
In order to test if the SETD6 mutation affects its subcellular localization, HEK293T 
and HCT116 cells were transfected with GFP-tagged SETD6 (either SETD6 wt or SETD6-N). 
Fluorescence microscopy of the transfected cells revealed that SETD6-N presented the 
same distribution within the cell as the wild type, both of which were mainly concentrated 
to the nucleus (Figure 4.5 A and B). We could detect, however, the presence of speckles 
inside the nucleus of the cells expressing mutant SETD6, which suggested that the 
association with the chromatin might be altered. To better understand the localization 
pattern, both proteins were transfected into cells followed by a biochemical fractionation 
of the cytosolic and chromatin fractions237. This experiment confirmed a similar 
subcellular localization between the mutant and the wild-type, with no significant 
differences in the cytosolic fraction (Figure 4.5 C and D). Some differences between the 
wild-type and SETD6-N were only observed at the chromatin level. To further verify these 
observations, we used an additional method to extract the chromatin (see the Materials 
and Methods section for more details). This experiment confirmed comparable amounts 
Figure 4.4. Mutant SETD6 is successfully overexpressed. Overexpression of FLAG-SETD6 (wt, N 
or C) in HEK293T (A) or HCT116 (B) cells. SETD6-N is the truncated version of the protein that 
mimics the mutation found in our family; SETD6-C is a truncated SETD6 that lacks the N-terminal 
part of the protein and the SET domain. The different versions of SETD6 were detected by 
western blot using an anti-FLAG antibody. GAPDH was used as a loading control. 
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of SETD6 wt and SETD6-N at this fraction (Figure 4.5 E and F), suggesting that SETD6-N 
shows the same chromatin localization pattern as the wild-type enzyme. 
 
4.4.7. Recombinant SETD6-N binds its substrates to the 
same extent as wild-type SETD6  
 
An ELISA was next performed to test whether the studied mutation would affect 
the binding ability of SETD6 in a cell-free in vitro system. To this end, we compared the 
direct binding of the wild type and mutant SETD6 to two well-known substrates, RelA and 
PAK4163,167. Recombinant RelA and PAK4 were used to coat an ELISA plate, together with 
BSA, which was used as a negative control. Recombinant SETD6 wt, SETD6-N and SUMO 
were used as tested proteins, being the latter another negative control. As shown in 
Figure 4.6, SETD6-N bound at equal levels to both substrates as did wild-type SETD6, 
which suggests that the mutation does not impair the interaction between SETD6 and its 
substrates in vitro. 
 
4.4.8. Recombinant SETD6-N fails to methylate its 
substrates 
 
To compare the enzymatic activity of wild-type SETD6 and SETD6-N, both 
proteins were subjected to a cell-free in vitro methylation assay with RelA and PAK4 as 
substrates (Figure 4.7 A and B, respectively). As expected, both substrates were 
specifically methylated by wild-type SETD6. However, no methylation was observed when 
SETD6-N was present in the reaction instead. It is worth noting that SETD6's 
automethylation activity was also lost in the truncated mutant. Consistent with these 
results, we found that while the recombinant wild-type SETD6 methylated 
immunoprecipitated RelA and PAK4 from HEK293T cells, SETD6-N failed to do so (Figure 
4.7 C and D, respectively). In a reciprocal experiment, we observed that recombinant RelA 
and PAK4 were specifically methylated by wild-type SETD6 isolated from human cells and 
not by SETD6-N (Figure 4.7 E and F, respectively). These complementary assays further 
127 
demonstrate that the SETD6 truncating mutation identified in this FCCTX family abrogates 
SETD6’s enzymatic activity. 
 
 
Figure 4.5. SETD6-N shows similar subcellular localization as wild-type SETD6. A+B) HEK293T 
(A) and HCT116 (B) cells were transfected with GFP-tagged empty, SETD6 wt or SETD6-N 
plasmids. The distribution of GFP within the cells was observed by fluorescence microscopy. 
C+D) HEK293T (C) or HCT116 (D) cells were transfected with FLAG-SETD6 (wt or N) and 
biochemically separated into cytoplasmic (Cyt) and chromatin (Chr) fractions. SETD6 was 
detected by western blot with an anti-FLAG antibody. Histone H3 and tubulin were used as 
chromatin and cytoplasmic controls, respectively.  E+F) The chromatin fraction of HEK293T (E) 
or HCT116 (D) cells transfected with FLAG-SETD6 (wt or N) was isolated and SETD6 was 
detected by western blot using the indicated antibodies. Histone H3 was used as a chromatin 
control. 
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4.4.9. SETD6-N binds its substrates but loses its activity in 
colon cancer cells 
 
Since the SETD6 mutation was identified in hereditary colon cancer patients, we 
next aimed to confirm our findings in the colon cancer cell line HCT116. For this purpose, 
either wild-type SETD6 or SETD6-N were overexpressed in the presence or absence of 
FLAG-RelA (Figure 4.8 A). As expected, SETD6 wt and SETD6-N physically interacted with 
RelA at the chromatin to the same extent. Consistent with our cell-free in vitro 
experiments, we also observed that while SETD6 wt methylated RelA, SETD6-N did not. 
The methylation of RelA at the chromatin was identified using a RelAK310me1 antibody 
that could specifically recognize monomethylation of RelA at position K310163. The same 
results were obtained when PAK4 was used as the substrate (Figure 4.8 B). These findings 
support the dominant negative nature of SETD6 c.791_792insA (p.M264Ifs*3) in a colon 
cancer cellular model. 
Figure 4.6. Recombinant SETD6-N shows similar binding to its substrates RelA and PAK4 as 
wild-type SETD6. A) Interaction between recombinant SETD6 (wt or N) and PAK4/RelA 
determined by an ELISA. The plate was coated with 2μg of His-PAK4, MBP-RelA or BSA 
(negative control), and then covered with 0.5μg of His-SETD6 wt, His-SETD6-N or His-SUMO 
(negative control). Bound proteins were detected using a rabbit anti-SETD6 antibody. Data 
and error bars are from two technical replicates and represent two independent biological 
experiments. B+D) Coomassie staining for the coating (B) and tested (C) proteins used in the 
ELISA.  
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4.4.10. Both wild-type and mutant SETD6 are expressed in 
the tumor and compete for their substrates 
 
We next aimed to check if SETD6's mutant allele was expressed in the tumor, given 
that the variant was carried in heterozygosis. To this end, a digital PCR was carried out 
using two TaqMan probes that specifically recognized either the wild-type or the mutant 
cDNA (with the insertion of the adenine). As observed in Figure 4.9 A and B, the tumor 
from member II:2 showed a positive expression of both alleles. As expected, all non-
carrier controls only expressed the wild-type allele.  
 
The fact that both alleles were expressed raised the question of whether mutant 
and wild-type SETD6 would compete for their substrates. In order to address this issue, a 
cell-free in vitro methylation competition assay was performed in the presence of 
recombinant SETD6 wt and different amounts of recombinant SETD6-N, using RelA as the 
substrate. Figure 4.9 C shows how wild-type SETD6's activity was inhibited in the presence 
of SETD6-N in a concentration-dependent manner, with a significant reduction in the 
amount of methylated substrate even when the same amount of each form of the enzyme 
was present (lanes 2 and 3, respectively). Finally, a competition assay in HCT116 cells 
confirmed the cell-free in vitro results, showing that the methylation of RelA at K310 in 
cells was reduced upon SETD6-N overexpression in a dose-dependent manner (Figure 4.9 
D). Taken together, these results suggest that the expression of the mutant allele in the 
carriers is expected to compete with the enzymatic activity of SETD6 wt, supporting a 
dominant negative role of this mutation. 
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Figure 4.7. SETD6-N fails to methylate its substrates RelA and PAK4. A+B) Cell-free in vitro 
methylation assays in the presence of 
3
H-SAM, recombinant His-SETD6 (wt or N) and either 
MBP-RelA (A) or His-PAK4 (B). The methylated proteins were detected by autoradiogram (top 
images), and the input used in the reactions is shown by Coomassie staining (bottom). C+D) 
HEK293T cells were transfected with FLAG-RelA (C), FLAG-PAK4 (D) or empty plasmid. Cell 
extracts were immunoprecipitated with FLAG M2 beads, followed by a radioactive cell-free in 
vitro methylation assay in the presence of 
3
H-SAM and recombinant His-SETD6 (wt or N). The 
methylated proteins were detected by autoradiogram (top images), and the input used in the 
reactions was shown by Coomassie staining (bottom). E+F) HCT116 cells were transfected with 
either FLAG-SETD6 wt, FLAG-SETD6-N or empty plasmid. Cell extracts were 
immunoprecipitated with FLAG M2 beads, followed by a radioactive cell-free in vitro 
methylation assay in the presence of 
3
H-SAM and recombinant MBP-RelA (E) or His-PAK4 (F). 
The methylated proteins were detected by autoradiogram (top images), and the input used in 
the reactions was shown by Coomassie staining (bottom).  
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4.4.11. Downstream effects of SETD6-N 
 
Last but not least, the downstream effects of the SETD6 mutation were also 
addressed, studying the possible impact on the expression of target genes from pathways 
in which SETD6 is involved (Wnt, NF-κB and Nrf2), or on the viability of the cells. With that 
goal, a SETD6 knockout colon cancer cell line was developed using the state-of-the-art 
CRISPR/Cas9 technology to modify HCT116 cells. However, this process was time-
consuming and the knockout cell line was only ready by the very end of the stay in the 
host laboratory. For that reason, some preliminary assays studying the expression of 
target genes and the viability were performed meanwhile using normal HCT116 cells. 
  
Figure 4.8. SETD6-N binds its substrates RelA and PAK4, while failing to methylate them, in 
the colon cancer cell line HCT116. A+B) HCT116 cells were transfected with either HA-SETD6 
wt or HA-SETD6-N plasmids, in the absence or presence of FLAG-RelA (A) or FLAG-PAK4 (B). 
The chromatin fraction was then immunoprecipitated with FLAG M2 beads and analyzed by 
western blot with the indicated antibodies.  
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Figure 4.9. Both wild-type and mutant SETD6 are expressed in the tumor and compete for 
their substrates. (A) Allele-specific expression obtained by digital PCR presented as 
Target/Total, where "Target" is the mutant SETD6 allele (detected with the FAM dye). Data 
from the tumor of II:2 was collected from three independent experiments, and the error bars 
correspond to the confidence intervals. The Control represents tumor cDNA from four different 
sporadic CRC patients used as non-carrier controls. (B) Digital PCR visualization of the cDNA 
from the tumor of member II:2 (upper figure) and a non-carrier control (lower figure). The FAM 
dye detects the mutant allele (blue), while the VIC dye detects the wild-type allele (red). In 
green are those wells that showed both dyes (VIC and FAM) and in yellow those that did not 
amplify. (C) Radioactive cell-free in vitro methylation assay in the presence of recombinant 
wild-type SETD6 and different amounts (+ and ++) of recombinant SETD6-N. The methylated 
proteins were detected by autoradiogram (top image), and the input used in the reactions is 
shown by Coomassie staining. (D) HCT116 cells were transfected with HA-SETD6 wt, FLAG-RelA 
and with or without different concentrations (+ and ++) of HA-SETD6-N. The chromatin fraction 
was then immunoprecipitated with FLAG M2 beads and analyzed by western blot with the 
indicated antibodies. 
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From the target gene expression experiments, some differences were observed 
between the SETD6 wt and the SETD6-N transfected cells, although not always consistent. 
Among these, the levels of NF-κB target genes after TNF induction can be pointed out, 
with an overactivation of this pathway caused by the presence of mutant SETD6, as it had 
been hypothesized (Figure 4.10). While some differences were also observed for the Wnt 
and Nrf2 pathway between SETD6-N and wt SETD6, these observations were not 
consistent, and will have to be confirmed in the future (not shown). The viability of 
HCT116 cells, on the other hand, did not show any differences when SETD6-N was 
overexpressed as compared to SETD6 wt (not shown). However, these experiments 
should be ideally confirmed in the knockout cell line in the future. 
 
 
  
Figure 4.10. The expression of NF-ĸB downstream target genes is increased with the SETD6 
mutation. HCT116 cells were transfected with either SETD6 wt, SETD6-N or empty plasmids 
and induced with 20ng/mL of TNF for 1h. RNA was then extracted from the cell lysates and 
converted to cDNA, and a qPCR was performed to measure the expression of three NF-ĸB 
target genes: IL1A, IL8 and TNF. Data was collected from three technical replicates and the 
expression was calculated as 2
-ΔΔCt
. The error bars represent the standard deviation. An 
increase in the expression is observed in SETD6-N transfected wells compared to SETD6 wt 
transfected cells for both IL1A and IL8. However, it is most significant for the latter.  
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4.5 Characterization of a frameshift 
variant in PTPRT  
 
4.5.1. PTPRT c.4099dup (D1367Gfs*24) identified in 
family cc765 
 
The whole-exome sequencing study also revealed a PTPRT frameshift mutation 
carried by family cc765. This family fulfilled the Amsterdam II criteria, with 5 members 
diagnosed of different cancers in two successive generations (3 CRCs, 1 endometrial and 
1 breast cancer), the earliest age of onset being 28 years old (Figure 4.11 A). More 
information about the different members of this family is detailed in the Appendix (A2). 
The identified variant was PTPRT c.4099dup p.(Asp1367GlyfsTer24) (ENST00000373193), 
which is abbreviated as D1367Gfs*24. This variant was carried by the two affected 
members sequenced (II:6 and II:7), while not shared by the elderly healthy relative studied 
(II:5). 
 
Regarding the frequency in the general population, PTPRT D1367G*24 is a novel 
variant that is not present in any of the public databases. Given the type of mutation, 
which causes the loss of the N-terminal end of the protein, it was predicted to be 
deleterious a priori with no need of additional in silico analyses. In addition, this variant 
affects all of PTPRT’s long protein-coding transcripts.  
 
4.5.2. Other candidate variants 
 
Other candidate variants in this family included MAP3K6 c.2536C>T p.(Arg846Cys), 
ABTB1 c.1213G>C p.(Ala405Pro) and INVS c.3017-5T>G. However, the PTPRT variant was 
undoubtedly the most relevant among all of them, considering both the gene and the 
effect of the mutation.  
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Figure 4.11. PTPRT D1367Gfs*24 shows a compatible segregation in family cc765. A) Pedigree 
of Amsterdam II family cc765, where PTPRT c.4099dup, p.(Asp1367GlyfsTer24), was identified. 
Whole-exome sequencing was done in family members II:5, II:6 and II:7 (green box), and 
segregation was studied in members II:2, II:3, II:4 and III:5. Three of the affected participants 
were carriers (+), while the healthy elderly relatives were non-carriers (WT). The only exception 
was member II:3, who did not carry the mutation and had been diagnosed of colorectal cancer 
(CRC) at the age of 85. Member III:5 did carry the mutation and was healthy at the moment, 
but was still young to draw any conclusions. CRC-affected members are marked in red, HNPCC-
associated cancers such as endometrial cancer (EC) are marked in purple, and other non-
related cancers such as breast cancer (BC) are marked in green. The age at diagnosis or current 
age of healthy members is included beneath each individual (in years). B) Electropherogram of 
the wild-type and mutant sequence of the PTPRT gene. The arrows show the point where the 
guanine is inserted. 
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4.5.3. PTPRT D1367Gfs*24 affects the second catalytic 
domain of the protein 
 
The selected PTPRT mutation involves the insertion of a guanine between 
positions 4091 and 4092 of the cDNA (ENST00000373198) (Figure 4.11 B), causing a shift 
in the reading frame that is translated as the addition of 24 erroneous amino acids 
followed by a premature stop codon. Despite the frameshift nature of this mutation, 
PTPRT D1367Gfs*24 is located at the end of the gene, meaning the loss of just the last 95 
amino acids of the protein. However, this mutation affects the second phosphatase 
domain of PTPRT (also known as D2), which is responsible for the regulation of the 
enzyme's activity. Figure 4.12 A shows the different protein domains of PTPRT, together 
with the location of the variant and a schematic visualization of the resulting mutant 
protein. Figure 4.12 B represents the effect that the truncation is predicted to have on the 
3D structure of the cytoplasmatic region of PTPRT (including the D1 and D2 domains), 
showing a considerable gap caused by the mutation. 
 
4.5.4. PTPRT D1367Gfs*24 segregation and LOH 
 
Like all the other candidate genes of this family, PTPRT c.4099dup was carried by 
the two affected members whose whole-exome was sequenced (II:6 and II:7, with 
colorectal and endometrial cancer diagnosed at the age of 70 and 28, respectively), while 
absent in the 85-year-old healthy sibling sequenced. In addition, the segregation of this 
variant could be studied by Sanger sequencing in 3 other siblings: one with CRC diagnosed 
at 85, one with breast cancer diagnosed at 66, and one healthy at the age of 91. Although 
less informative, the 50-year-old healthy daughter of member II:6 was also analyzed (III:5). 
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The result from the segregation study is shown in Figure 4.11 A. Apart from the 
two affected probands originally studied, only members II:4 and III:5 carried the mutation, 
while II:2 and II:4 showed a wild-type PTPRT. The positive members include the breast 
cancer patient (II:4) and a healthy but still young relative (III:5), while the negative result 
was observed in the healthy elderly relative (II:2) and the CRC patient diagnosed at a very 
late age (II:3), which could be a phenocopy. As far as the tumor LOH is concerned, two 
FFPE tumor blocks could be studied: the CRC of member II:6 and the breast tumor of 
member II:4. No significant loss of any of the alleles was observed in the CRC, although a 
slight reduction of the mutant allele seemed to happen in the breast tumor (Figure 4.13). 
Figure 4.12. Effect of PTPRT D1367Gfs*24 on the protein structure. A) Schematic 
representation of PTPRT protein domains, with the location of the studied mutation (red 
arrow) and the resulting mutant protein (below). B) 3D representation of the cytoplasmatic 
region of wild-type (left) and mutant (right) PTPRT, showing the effect of the truncation. 3D 
models were obtained by SWISS-MODEL. 
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4.5.5. The expression of the wild-type PTPRT allele is 
decreased in the tumor from a carrier 
 
A digital PCR was performed in order to check the allele-specific expression of wild-
type and mutant PTPRT in the tumor. This assay confirmed that, although rather low, 
there was expression of both alleles (wild type and mutant) in tumor cDNA from a PTPRT 
mutation carrier (II:6). However, a significant reduction in the expression of the wild-type 
allele was observed in the CRC compared to healthy colon from the same individual 
(Figure 4.14). No decrease of the expression of the mutant allele could be appreciated. 
Unfortunately, no results could be obtained from the breast tumor of member II:4. 
 
Figure 4.13. LOH study for PTPRT D1367Gfs*24. A) Electropherogram obtained by Sanger 
sequencing of DNA from the CRC-diagnosed member (II:6): germline, healthy colon and CRC. 
B) Electropherogram obtained by Sanger sequencing of DNA from the breast cancer-diagnosed 
member (II:4): germline, healthy breast and breast tumor.  
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4.5.6. PTPRT promoter is hypermethylated in the tumors 
from two carriers 
 
The promoter region of PTPRT has been reported to be frequently 
hypermethylated in sporadic CRC177, and given that LOH of the wild-type allele was not 
detected, this could be a plausible second hit for the inactivation of the wild-type PTPRT 
Figure 4.14. The expression of the wild-type PTPRT allele is decreased in the tumor from a 
carrier. A) Digital PCR visualization of the allele-specific expression assay performed in the 
healthy colon tissue (top) and CRC (bottom) of cc765 family member II:6. The FAM dye detects 
the mutant allele (blue), while the VIC dye detects the wild-type allele (red). In green are those 
wells that showed both dyes (VIC and FAM) and in yellow those that did not amplify. B) 
Quantification of the allele-specific expression obtained by digital PCR presented as 
Target/Total, where "Target" is the mutant PTPRT allele. The relative expression of the mutant 
allele is increased in the tumor given that the expression of wt PTPRT is decreased. Data was 
collected from two independent experiments, and the error bars correspond to the confidence 
intervals. 
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allele in the tumors from the carriers. For this reason, the methylation status of PTPRT’s 
promoter was studied in the tumors available by methylation-specific PCR as previously 
reported177,178. To this aim, two different methylation sites were tested: one published by 
Laczmanska et al177 in CRC and another one described by Peyser et al178 in head and neck 
cancer. 
 
This assay showed that the CRC of one of the mutation carriers (II:6) was 
hypermethylated at the two PTPRT promoter sites tested, as compared to healthy colon 
tissue from the same carrier, as well as to a pool of 5 healthy colon samples used as a 
control (Figure 4.15 A, top). Although to a lesser extent, the same result was observed 
when the breast tumor and healthy breast from member II:4 were studied at the 
promoter site described by Peyser et al178 (Figure 4.15 A, bottom). However, no 
methylation was observed at all in any of the breast samples at the methylation site 
reported by Laczmanska et al177. These observation are quantified in Figure 4.15 B. 
 
In addition, a pyrosequencing assay targeting a region of PTPRT’s promoter 
confirmed the hypermethylaton observed by MSP in the CRC of member II:6 compared to 
its healthy colon tissue (Figure 4.15 C). Although once again more subtle, the breast cancer 
also showed an increased methylation compared to the healthy breast. 
 
4.5.7. Expression of PTPRT's downstream target genes 
 
The lack of a functional PTPRT would be predicted to have consequences on the 
phosphorylation status of its target proteins STAT3 and paxillin182,183,245. This would result, 
in turn, in an altered expression of STAT3’s target genes (such as BCL2-XL and SOCS3)182, 
as well as an abnormal phosphorylation of paxillin’s target proteins (such as Akt, p130Cas 
and Shp2)183,245. In order to check if these downstream effects were observed in the 
tumors from the PTPRT mutation carriers, a Taqman real-time qPCR was performed to 
evaluate the expression of BCL2-XL and SOCS3. 
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Figure 4.15. PTPRT’s promoter is hypermethylated in the colon and breast cancers of two 
mutation carriers. A) PTPRT’s promoter methylation status obtained by MSP of two different 
promoter sites previously described in CRC (primer set 1) or head and neck carcinoma (primer 
set 2), in the CRC vs healthy colon of member II:6 (top) or the breast cancer vs healthy breast 
of member II:4 (bottom). Both tumors show an increase in methylation when compared to 
their respective healthy tissue and controls. B) Graphical representation of the MSP results 
presented in A, portrayed as the ratio of methylated product versus total (methylated + 
unmethylated). Bands were quantified using the ImageJ software. C) PTPRT’s promoter 
methylation status (%) obtained by pyrosequencing for the same samples analyzed in A, 
together with a methylated and unmethylated commercial controls. The CRC of member II:6 
is hypermethylated compared to the corresponding healthy tissue, while a more subtle 
hypermethylation is observed for the breast cancer of member II:4. 
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As shown in Figure 4.16 A, BCL2-XL was significantly overexpressed in the colon 
tumor from member II:6 when compared to both the corresponding healthy colon tissue 
from the same patient and a healthy colon cDNA pool comprised of 4 different normal 
tissue samples. In the same way, the breast tumor from member II:4 showed a 
consistently higher BCL2-X expression than the commercial healthy breast sample that 
was used as a control (Figure 4.16 B). The healthy breast tissue from the same patient 
presented higher expression levels than the healthy colon pool, although lower than the 
Figure 4.16. Expression of STAT3’s target genes BCL-XL and SOCS3 in the tumor or healthy 
tissue of two PTPRT mutation carriers. qPCR data was collected from three technical replicates 
and represent 2 independent experiments. The expression was calculated as 2
-ΔΔCt
, and the 
error bars represent the standard deviation. A) The colorectal tumor of a PTPRT mutation 
carrier (II:6) shows a significant increase in the expression of STAT3’s target BCL-XL when 
compared to both its corresponding healthy colon and a pool of healthy colon tissue used as a 
control. B) The same increase in BCL-XL levels is shown in the breast tumor of another PTPRT 
mutation carrier (II:4). C) The CRC and healthy colon of member II:6 show a decreased SOCS3 
expression when compared to the healthy colon pool. C) Decreased SOCS3 is also observed in 
the breast cancer (but not healthy tissue) of member II:4. 
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corresponding tumor. It is worth noting, though, that this patient had an invasive 
(infiltrating) carcinoma of the breast, reason for which the whole breast had been 
removed. 
 
On the other hand, SOCS3 seemed to be considerably underexpressed in both 
tumors (CRC from II:6 and breast cancer from II:4). Interestingly, this lower expression was 
also observed in the healthy colon from II:6, while not in the healthy breast tissue from 
member II:4 (Figure 4.16 C and D). 
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4.6 Characterization of a missense 
variant in PYGO1 
 
4.6.1. PYGO1 c.1084T>C (S362P) identified in family cc28 
 
Among all the candidate variants obtained by the whole-exome sequencing study, 
a missense mutation in PYGO1 was selected in family cc28. This was an Amsterdam I 
family with 4 CRCs in two consecutive generations, the earliest diagnosed at the age of 41 
(Figure 4.17 A). In addition, there was one additional breast cancer in the family, 
diagnosed at the age of 49 in the daughter of one of the CRC-affected members. Two 
affected members of this family were sequenced (II:1 and III:1), both of which carried the 
mutation.  
 
This prioritized variant was PYGO1 c.1084T>C, p.(Ser362Pro) (ENST00000302000) 
– simplified as S362P – which is a novel variant that is therefore not described in any 
population in the public databases. In addition, this variant is predicted to have a 
deleterious effect on the protein by the 5 in silico tools used and affects all the protein-
coding transcripts of PYGO1 (ENST00000302000, ENST00000563719 and 
ENST00000645724).  
 
4.6.2. Location of S362P within the Pygo1 protein 
 
As mentioned before, the studied PYGO1 variant involved the change of a serine 
for a proline at position 362 of the encoded protein. Although just a missense variant, the 
five in silico tools used predicted a probable damage for the protein (Table 4.3), and it 
meant the substitution of a polar residue (serine) for a proline, which is a hydrophobic 
amino acid with very particular properties and structural limitations241. In addition, the 
affected serine was located in one of the Zn fingers of Pygo1’s PHD domain (Figure 4.18 
A). Pygo1’s 3D structure, visualized in Figure 4.18 B, shows how serine 362 (in red) in 
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situated in close proximity to one of the Zn atoms (in grey). In fact, according to the model 
published by Fiedler et al in 2008194, the affected serine would be situated right next to 
one of the residues (Cys363) that interacts directly with a Zn atom (Figure 4.18 C, red 
arrow). Although Ser362 is reportedly only semiconserved and is not part of any specific 
secondary structure (Figure 4.18 D), the different size and nature of the two amino acids 
(polar/hydrophobic) could be expected to affect the structure of the corresponding Zn 
finger and, consequently, Pygo’s function. 
 
  
Figure 4.17. PYGO1 S362P segregation in family cc28. A) Pedigree of Amsterdam I family cc28, 
where PYGO1 c.1084T>C, p.(Ser362Pro), was detected. Whole-exome sequencing was done in 
family members II:1 and III:1 (green box), and segregation was studied in germline DNA from 
members III:4, III:6, III:7 and in tumor DNA from member III:3. Only two of the affected 
participants were carriers (+), while the two out of the 3 healthy members studied were non-
carriers (WT). Unfortunately, the mutation was not observed in tumor DNA from member III:3, 
although there was no germline DNA to confirm this observation. CRC-affected members are 
marked in red, and the age at diagnosis or current age of healthy members is included beneath 
each individual (in years). B) Electropherogram of the wild-type and mutant sequence of the 
PYGO1 gene. The arrows show the point where the missense mutation occurs. 
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4.6.3. Other candidate variants 
 
Although there were no truncating variants selected for this family, there were 
other missense candidate variants, including CHID1 c.3G>A p.(Met1?), MMP11 c.232C>T 
p.(Pro78Ser), AHRR c.680G>C p.(Cys227Ser), and NKD2 c.431T>A p.(Met144Lys). The 
relevant location of the PYGO1 variant within the protein, together with Pygo1’s role in 
Figure 4.18. Consequences of PYGO1 S362P on the protein. A) Representation of Pygo1’s 
protein domains, with the location of the affected residue (red arrow). B) 3D visualization of 
the tertiary and secondary structure of Pygo1 with the substituted serine highlighted in red. 
The -helixes are marked in pink, while β-sheets are marked in yellow. The gray spheres 
represent the zinc atoms. C) Zn finger of Pygo1’s PHD domain obtained from Fiedler et al 2008. 
The red arrow points to the serine residue affected by the studied mutation. In purple are the 
two Zn atoms together with the 8 amino acids with which they interact directly (7 Cys and 1 
His). Serine 362 is situated right next to the 4
th
 Zn-bonded cysteine. D) Conservation of the Zn 
finger residues (Ser362 is marked in red with a yellow circle). 
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the Wnt pathway, was the reason why this variant was selected for further 
characterization.   
 
4.6.4. PYGO1 S362P segregation and LOH studies 
 
Apart from the two members who had been studied through NGS (II:1 and III:1, 
with CRC diagnosed at the age of 67 and 48, respectively), the segregation of this mutation 
could be initially studied in only 3 additional members of the family: III:4, III:6 and III:7, all 
of whom where currently healthy at ages of 59, 65 and 62 years old, respectively. The 
segregation study revealed that out of the 3 healthy relatives, only III:6 carried the PYGO1 
mutation (Figure 4.17 A). However, a later analysis of the tumor of member III:3 
(diagnosed of CRC at 41), showed that this member did not carry the mutation (Figure 
4.19). It is important to note that this discovery only happened after the variant had 
already been selected for further characterization, given that this tumor block was 
originally not available and that obtaining it meant a great effort. Unfortunately, this 
member had deceased so it was not possible to obtain germline DNA to confirm this 
result. 
 
  
 
 
Figure 4.19. LOH analysis of PYGO1 S362P. 
Electropherograms of the forward sequences of PYGO1's 
exon 3 (ENST00000302000) from tumor and germline DNA 
of member III:1 from family cc28, obtained by Sanger 
sequencing. There was no significant decrease of any of the 
alleles. A negative wild-type control has been added as a 
reference.   
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On the other hand, the loss of heterozygosity was studied in the tumor of member 
III:1, which was the only one available from the carriers. As can be seen in Figure 4.19, this 
analysis showed that there was no apparent loss of any of the alleles in the tumor 
compared to germline DNA. 
 
4.6.5. Mutant Pygo1 shows a decreased histone-binding 
affinity compared to the wild type 
 
The relevant location of this missense variant at one of the protein’s Zn fingers 
(PHD domain) prompted us to check if the serine to proline substitution affected Pygo1’s 
histone-binding affinity. In order to do this, the mutant PHD domain was expressed in 
association with the HD1 domain from either Bcl9 or B9L, and the affinity of the complexes 
to bind a histone H3K4me2 peptide was tested by Isothermal ITC196. The two 
corresponding wild-type PDH-HD1 complexes were also obtained and tested as a 
reference.  
 
It is worth noting that although all four protein complexes were expressed 
simultaneously, those that included mutant PDH gave lower yields of both overall and 
folded protein (~13.7mg for wt PHDPygo1-HD1BCL9; ~14.7mg for wt PHDPygo1-HD1B9L; ~4.6mg 
for S362P PHDPygo1-HD1Bcl9 and ~4.7mg for S362P PHDPygo1-HD1B9L). In addition, the 
proportion of protein that eluted off the gel filtration in the void (which is indicative of 
misfolded protein) was higher for the S362P mutation, although the overall amount of 
protein that eluted in the void was about the same for wt and mutant.  
 
The ITC measurements were carried out on freshly purified proteins for optimum 
results. This experiment showed that the S362P mutation led to a 5.5-fold decrease in 
affinity for the histone H3K4me2 peptide when Pygo1’s PHD formed a complex with Bcl9’s 
HD1 (Figure 4.20 A and B). A 4-fold reduction in affinity was observed when mutant 
PHDPygo1 was associated with B9L’s HD1 (Figure 4.20 D and E).  
149 
 
 
Figure 4.20. Pygo1 S362P shows a decreased histone-binding affinity compared to the wild 
type. The mutant PHD domain was expressed in association with the HD1 domain from either 
Bcl9 or B9L, and the affinity of the complexes to bind a histone H3K4me2 peptide was tested 
by Isothermal Titration Calorimetry (ITC). The two corresponding wild-type PDH-HD1 
complexes were also obtained and tested as a reference. The graphs represent the ITC profiles 
for the histone-binding of PDH-HD1 complexes. Dissociation constant (Kd) values are given in 
the individual panels (with fitting errors indicated). A+B) The S362P mutation led to a 5.5-fold 
decrease in affinity for the histone H3K4me2 peptide when Pygo1’s PHD formed a complex 
with Bcl9’s HD1. C) Input of each recombinant PDH-HD1 complex used for the ITC. D+E) A 4-
fold reduction in affinity was observed when mutant PHDPygo1 was associated with B9L’s HD1. 
F+G) Representation of the histone-binding dissociation constant values for the complex of 
PHD with HD1 from Bcl9 (F) or B9L (G). 
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5.1 Whole-exome sequencing strategy 
for the study of FCCTX 
 
5.1.1. FCCTX study cohort 
 
The present work focused on the study of FCCTX, which is a term used to describe 
a group of HNPCC families with a still unknown genetic basis246. Although families 
classified as FCCTX fulfill the same clinical criteria than LS (Amsterdam I/II), they lack 
germline mutations in the MMR genes and their tumors are MMR proficient with stable 
microsatellites. In addition, differences in gene expression patterns, epigenetic profiles, 
genomic alterations and deregulated canonical pathways have been reported between 
these two entities101,105,113, further suggesting that different molecular mechanisms 
mediate the progression of these two pathologies. Other differences between these two 
groups have been described at the clinical level, including a higher average age of disease 
onset and lower risk (or even lack of risk) for extracolonic tumors reported in FCCTX 
patients101,105,106. Although the mean age at diagnosis of our cohort was 54.3 years old, it 
is worth noting that this cohort was selected from a larger group of FCCTX families whose 
mean age of onset was 55.1 years old, as previously published116. Both of these averages 
are higher than LS’s reported average age at diagnosis (38-54 years old)106,108–111,102,112–117 
and agree with the mean age of onset described for FCCTX in some studies (53-55 
years)109,110,112,114, although they are lower than the average reported by some other (58-
63 years)106,108,111,102,113.  
 
On the other hand, the absence of other types of tumors in FCCTX reported by 
some groups101,106 is not supported by our cohort, given that 53.8% of the families here 
studied fulfilled the Amsterdam II criteria and hence presented at least one HNPCC-
associated extracolonic cancer. Even though there were just 2 sequenced individuals with 
only extracolonic tumors and no CRC, over half of the patients had at least one relative 
with an HNPCC-associated extracolonic tumor, as shown by the fulfillment of the AMS-II 
criteria. In addition, it had already been reported that the larger cohort of FCCTX families 
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studied at our laboratory did not show a lower risk for extracolonic tumors than LS116. 
While this contrasts with some studies101,106, it is in agreement with some others101. It is 
worth noting that the difference in the clinical criteria used to select FCCTX families in the 
different studies (only Ams-I versus Ams-I/II) entails a bias in the estimation of the 
extracolonic cancer cumulative risk in these families. Finally, a preferential distal location 
was observed in 83.3% of the CRC-affected probands, consistent with other studies and 
even higher than the 65-75% reported in the literature101,105,117 and the average reported 
for the larger FCCTX cohort from our hospital (76%)116. 
 
5.1.2. Suitability of the WES strategy 
 
The different strategies that can be used for the identification of cancer-risk alleles 
that would explain the cancer susceptibility in FCCTX families include linkage analyses, 
GWAS and NGS. However, among these, the former presents considerable limitations in 
the presence of heterogeneity99. This questions it’s suitability for the study of this 
condition, given that FCCTX is thought to be a heterogeneous group of families 
presumably comprising different yet-to-be-discovered genetic syndromes involving high- 
or moderate-penetrance mutations in novel cancer-predisposing genes99. Moreover, 
FCCTX could also result from a combination of low-penetrance mutations in different 
genes107, or even from aggregation of sporadic cases due to shared lifestyle 
factors11,106,247,106, which makes even harder the identification of such cancer-
predisposing genes. Given the challenge that the study of FCCTX families poses, the two 
strategies currently used for the study of this group of families are NGS, which focuses on 
the search for high or medium-penetrance risk genes248,249, and GWAS, which addresses 
the low-penetrance multi-gene approach78. However, GWAS require much larger sample 
sizes  to achieve an adequate statistical power135, reason for which NGS was the chosen 
strategy in our study.  
 
On the other hand, NGS's WES application was selected based on its lower cost-
efficiency and more manageable data analysis compared to WGS. Multigene targeted 
sequencing was not chosen for its reduced number of genes included compared to WES, 
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which limits the identification of new predisposition genes, and given that most FCCTX 
families are thought to be inherited by still unknown mechanisms. It is worth noting that, 
although not included in this thesis, a much larger cohort of 98 patients from high-risk 
CRC families was assessed by a 94-gene panel at our laboratory. These families fulfilled 
either the Amsterdam I/II or the Bethesda criteria and presented either MSI or MSS 
tumors, but without previously detected germline mutations. Among these, 35 were 
strictly considered FCCTX (AC-I/II and MSS) but could not be included in the present WES 
study because only one member per family was available, which is the case in most 
families. Out of these FCCTX cases, pathogenic or likely-pathogenic variants were 
identified in 4 genes: CHEK2, SMAD4, HNF1A and TP53250 (see publication attached in the 
Appendix, A6). These explained a small portion of the families, but, as expected, most of 
them remained unexplained with either no mutation detected or one or more variants of 
unknown significance250. This shows that the multigene panel approach is a good strategy 
when no more family members are available and for clinical purposes, but a high number 
of families is necessary in order to ensure the achievements of results. 
 
WES-based studies for the search of germline disease-causing variants require the 
sequencing of at least 2 (and ideally more) affected members of each family in order to 
select shared variants. Therefore, the present thesis shows the results obtained by an NGS 
whole-exome analysis of between 2 and 3 members from 13 FCCTX families. Even though 
we did not expect to explain all the families, we hoped to find potential causal mutations 
in at least a fraction of the studied families. The heterogeneity of FCCTX families implied 
that it was unlikely that the different families here studied would share a common genetic 
predisposition, reason for which each family was studied individually. Indeed, many 
research groups with much larger sample sizes have failed to find a common genetic 
predisposition in this group of families, losing hope of discovering a few shared genes 
responsible for the increased cancer risk in most FCCTX families136,146,150,248,249. 
Alternatively, claiming that this group of families is excessively diverse, some researchers 
are now opting for dividing FCCTX into more homogeneous subgroups, hoping to be able 
to solve the problem this way. 
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5.1.3. NGS data analysis, filtering and prioritization 
 
One of the most critical points in NGS is the data analysis, reason for which 
bioinformaticians have become indispensable99. Nothing could be done without the 
correct interpretation of the vast amount of data that NGS generates249. However, it is 
worth noting that there is always a bias attached to the data analysis, the in silico studies 
and the filtering strategy, which highlights the importance of choosing the best filtering 
approach in order not to miss any potential cancer-risk variant. The strategy used for 
variant analysis and filtering in this study intended to be as objective as possible, always 
stablishing cutoffs based on other published studies249,251.  
 
After the data analysis and thorough filtering of the variants detected, a total of 
460 filtered variants were left for the 13 families, ranging from 11 to 73 in each of the 
families. The discrepancy in the number of filtered variants could be explained based on 
the family members that were sequenced. Consistent with other studies248, those families 
in which 3 members were sequenced had a lower number of filtered variants, and 
therefore candidate variants, than those in which only 2 members were studied. In the 
same way, the availability of distant family members resulted in a more stringent filtering 
and a consequent lower number of shared variants, while the study of first-degree 
relatives, such as siblings, meant a larger number of shared variants and a more time-
consuming prioritization step. Certainly, the only families with less than 20 filtered 
variants were those in which extended family members had been sequenced (cc406, 
cc525, cc565, and cc763). On the other hand, sequencing a healthy member from the 
family was another way of reducing the number of variants left. However, it is worth 
noting that there is always the risk of missing a variant that does not have a complete 
penetrance, which could be expected in FCCTX families. For that reason, even when using 
a healthy relative for the filtering, special attention was paid to all the variants prior to 
that filtering step, in order not to miss any important mutation. 
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A further prioritization of these filtered variants, validation and segregation study, 
led to a final list of candidate genes. The prioritization step based on the search of online 
databases and literature is unarguably the most biased as well as the most time-
consuming step, but was indispensable given the high number of filtered variants. The 
prioritization step was also in the lines with other similar studies249,251, and based on the 
obtained results, we believe that the designed strategy has been successful.  
 
5.1.4. Validation, segregation and LOH 
 
The segregation study was used to discard those variants that clearly did not 
segregate with the disease when using germline DNA. Unfortunately, it was not very 
informative in quite some of the cases, mainly for being done in young healthy relatives 
that may or may not develop CRC and other cancers in the future. Regarding the LOH, it 
was only used as additional information because it does not predict the pathogenicity of 
a mutation, since it has been reported to have a dual role in HNPCC families, with no 
preferential loss of the wild-type or the mutant allele. As a matter of fact, different carriers 
of well-known pathogenic MMR mutations have been reported to show the three 
different LOH statuses (no LOH, LOH of the mutant and LOH of the wild-type), even within 
the same family252. In addition, there are other forms of inactivation of the wild-type 
allele, such as the presence of somatic mutations in the other allele, or hypermethylation 
of the promoters. It is also worth noting that Sanger sequencing is not a quantitative 
method for the detection of LOH, so observations of the reduction of one of the alleles 
would need to be confirmed by other methods, such as the analysis of polymorphic 
microsatellites close to the region of interest. Interestingly, LOH of the mutant allele was 
more frequently observed than LOH of the wild-type allele. 
 
5.1.5. CRC susceptibility genes 
 
Even though genes reported to be involved in CRC predisposition were carefully 
screened with a more lenient filtering strategy, no deleterious mutations in any of the 
high-risk CRC susceptibility genes reported in previous studies110 were found in our 
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cohort. We did detect 5 missense variants in well-characterized cancer genes shared by 
the affected members sequenced in 6 of the families, including 3 families with POLE 
variants, another 2 with BRCA2 variants and 1 with a PALB2 variant. Out of these, POLE is 
the only “typical” CRC gene, and germline mutations in the exonuclease domain of the 
POLE are associated with an increased risk for CRC253. However, none of the variants 
affected the exonuclease domain, which is the one reported to have pathogenic variants. 
On the other hand, BRCA2 and PALB2 are breast cancer genes, but have been previously 
described in a CRC context75. As a matter of fact, a BRCA2 mutation had been previously 
identified in our laboratory in another FCCTX family142. However, based on the nature of 
the variants and ClinVar reports, we believe there is enough evidence to claim that these 
variants are not involved in the increased cancer susceptibility of the families here 
studied. On the other hand, two missense mutations in two genes that had been 
considered potentially involved in CRC predisposition (WIF1 and LAMB4) were also found, 
but based on the effect of the variants and that the causality of neither of them was 
supported in their corresponding studies, they were not selected as candidate variants 
either. 
 
In addition, a number of variants were identified in genes previously reported to 
be associated to CRC risk through GWAS studies. Nonetheless, only one of these variants 
provided strong enough evidence for its further consideration. This variants was ABCC2 
c.1209+2T>G, a splice donor variant detected in family cc406. ABCC2  is an ABC 
transporter that has been associated with chemoresistance254 involved in the ARE–Nrf2 
cellular detoxification pathway255 under oxidative stress256. The remaining variants were 
all missense and did not suggest to play a relevant role as high or moderate-risk alleles, 
although they may still act as low-risk variants. It is worth noting that this selection only 
included low frequency variants (MAF≤0.05), given that the purpose of this study was the 
identification of moderate or high-risk CRC genes. Other common variants in GWAS loci 
could also be playing a role in the cancer predisposition of these families, most of which 
are actually located in non-coding regions of the genome not detected by WES. 
 
 
159 
5.1.6. Other approaches: tumor WES and CNV analysis 
 
Another application of NGS for the search of causal mutations in unexplained 
families is the study of germline-tumor pairs. To this aim, the tumor of 2 individuals was 
sequenced and compared to their germline WES data. This was done in order to look for 
second hits in the tumor that suggest a causality of the corresponding germline variants. 
However, no second hits were detected in any of the tumors for the filtered variants, 
which was not a surprise given the low number of samples studied. In order to achieve 
more results a larger number of samples would need to be analyzed, but that was not 
possible in our case based on the quality and/or quantity of the FFPE tumors required for 
optimal results. It is worth noting that this analysis has to take into account the tumor cell 
content of the FFPE blocks, and can be challenging when a low tumor percentage is 
observed by the pathologists, which could lead to the loss of some alterations. 
 
NGS data can be also used to look for germline CNVs in the studied samples, and 
some studies have indeed found alterations this way138 and reported germline CNVs in 
FCCTX257. For this reason, in addition to the main search for candidate variants in which 
our study has focused, we also analyzed the WES data searching for CNVs. Unfortunately, 
our efforts were not fruitful and we did not detect any potential variation. It is worth 
noting that WES is less reliable than WGS when it comes to this type of study, due to its 
lower coverage uniformity153. Therefore, we cannot rule out the possibility of the 
presence of CNVs not detected by the exome sequencing in those patients that were not 
confirmed by CGH. 
 
5.1.7. Candidate variants and genes 
 
A total of 45 candidate variants were selected for the 13 FCCTX families, ranging 
from 1 to 5 for each of the families. Deleterious mutations were more often prioritized 
than missense ones based on the relevance of the consequences, which explains the high 
proportion of this kind of mutations, even though missense changes are more common.  
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Regarding the pathways in which the genes affected by candidate variants are 
involved, 12 variants (27.3%) were located in genes involved in DNA repair. Out of these, 
a truncating variant in POLQ was detected, involving the loss of most of the protein. POLQ, 
also known as polymerase theta, is involved in the response to DNA double-strand 
breaks258,259, interstrand-cross-link repair, base excision repair and DNA end-joining260–262. 
And even though POLQ has never been linked to CRC before, some other polymerases 
have (namely POLE and POLD1)83. Interestingly, a case-control study showed an 
association between a POLQ variant (c.-1060A>G) and hereditary breast cancer263. On the 
other hand, higher expression levels of POLQ in breast and colorectal cancer are 
correlated with poor outcomes264,265. Another gene that harbored a frameshift variant 
was MUS81, which plays a critical role in the resolution of recombination intermediates 
during DNA repair after inter-strand cross-links, replication fork collapse and DNA double-
strand breaks219. In addition, MUS81 is involved in the Fanconi anemia pathway266, which 
has been previously reported to be associated to some FCCTX families150. These two 
candidate variants have a high potential of playing a role in the cancer predisposition of 
the families in which they were found, although the one in MUS81 is located at the end 
of the protein and does not affect any protein domains.  
 
HELQ is also involved in the fanconi anemia pathway and interacts directly with 
the RAD51 paralogue complex BCDX2. It this way, it functions in parallel to the Fanconi 
anemia pathway to promote efficient homologous recombination at damaged replication 
forks, suggesting a critical role for HELQ in replication-coupled DNA repair, germ cell 
maintenance and tumor suppression in mammals267. However, the variant identified in 
HELQ is an inframe variant that only means the elimination of lysine residue. Although not 
located in any protein domain, this change affected an alpha-helix, but its relevance is still 
questionable. 
 
On the other hand, other of the reported DNA repair genes affected by deleterious 
candidate variants do not have such a clear role and may be arguable. That is the  case of 
NME7, a gene encoding a nucleoside diphosphate kinase whose 3'-5' exonuclease activity 
suggests roles in DNA proofreading and repair268. Another controversial gene is PHACTR2, 
reported to contribute to the DNA repair capacity in lung cancer269, but with little 
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supporting evidence other than that. As for the variants affecting the NRF2 pathway, a 
frameshift mutation in TXNRD3 and a splice donor variant in ABCC2 can be pointed out. 
TXNRD3 is a thioredoxin reductase that plays a key role in redox homoeostasis270, while 
ABCC2 is an ATP-binding cassette transporter that acts as a oxidative stress adaptation 
factor271. Apart from these, another frameshift variant was found in SETD6, but since this 
gene was studied more extensively it will be further discussed in section 5.2. 
 
A considerable number of candidate variants (22.7%) also affected putative tumor 
suppressor genes. Out of these, there were only 2 deleterious variants, in PTPRT and in 
IQGAP2. The former is a well reported tumor suppressor that was studied more in depth 
and will be discussed in section 5.3, while the latter has been more recently identified as 
a tumor suppressor in hepatocellular carcinoma and prostate cancer272–274. In addition, its 
reduced expression has been related to poor prognosis275 and it has also been associated 
to ovarian cancer progression via activating Wnt/β-catenin signaling276. It has also been 
reported to play a role in the NF-κB pathway277. There were other relevant pathways 
affected by candidate genes, including the Wnt pathway, which has very important 
implications in CRC243. Among the variants located in Wnt genes there are two missense 
variants in PYGO1 and NKD2, which will be further discussed in section 5.4, and a splice 
region variant in INVS, which acts as a molecular switch between the different Wnt 
signaling pathways, inhibiting the canonical Wnt pathway278. 
 
5.1.8.  Variants selected for further characterization 
 
Based on the nature of the alteration and the relevance of the genes involved, 3 
candidate variants were selected for further characterization. These variants were the 
most promising candidates in their respective families at the time of selection, and were 
the following affected the genes SETD6, PTPRT and PYGO1. However, this does not mean 
that other candidate genes from other families have any less causal potential. The results 
obtained in the more extensive characterization of these 3 variants are further discussed 
in sections 5.2, 5.3 and 5.4. Although there is obviously not enough evidence to support 
the investment in time and costs that further studies to characterize all of the candidate 
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variants would involve, there are some candidates that would undoubtedly deserve a 
deeper characterization in the future. 
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5.2 Characterization of SETD6 
M264Ifs*3 
 
5.2.1. SETD6 frameshift variant in family cc598 
 
The first candidate variant selected for further characterization was SETD6 
c.791_792insA, p.(Met264Ilefs*3), identified in FCCTX family cc598. This was a rare 
frameshift mutation found to cosegregate with the disease within the family, since it was 
carried by three CRC-affected members (II:1, II:2 and II:4) while absent in three healthy 
relatives (II:3, III:1 and III:2). Even though two of the healthy individuals were too young 
to be informative, the segregation of the variant with CRC in this family was as perfect as 
it could have been. 
 
On the other hand, no LOH was observed in the tumor of member II:2, and while 
the tumor of deceased member II:4 seemed to show a reduction of the mutant allele, it 
was not possible to compare the electropherogram with its corresponding germline DNA 
to confirm this observation. Nevertheless, it is worth noting that member II:4 had a more 
advanced form of the disease than II:2 and hence such loss may have been a later event 
during tumorigenesis. Not to mention that in HNPCC tumors, both wild-type and mutant 
LOH (as wells as no LOH) have been reported in the past, even for well-known pathogenic 
MMR mutations252. 
 
5.2.2. Selection of SETD6 M264Ifs*3 as a candidate variant 
 
SETD6 is a lysine methyltransferase involved in many relevant pathways. In the 
first place, it has been known for a long time to monomethylate the RelA subunit of 
transcription factor NF-ĸB, negatively regulating such pathway163. Additionally, SETD6 has 
been proven to participate in the canonical Wnt signaling cascade by forming a complex 
with PAK4 and the transcription factor β-catenin, activating the transcription of its target 
genes167. Recent studies have also linked SETD6 to the regulation of the nuclear hormone 
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receptor signaling pathway170, embryonic stem cell differentiation169, oxidative stress 
response168,279, mitosis and proliferation171. The relevance of many of these pathways in 
the context of cancer and the predicted impact of the truncation justify the selection of 
this variant for additional characterization. 
 
5.2.3. Consequences of SETD6 M264Ifs*3 
 
Regarding the consequences of the studied SETD6 mutation, this variant results in 
the introduction of two amino acids at positions 264 and 265 of the protein, followed by 
a premature stop codon. The truncated protein (SETD6-N) lacks its C-terminal half but 
retains an intact SET domain, which is responsible for its catalytic activity. Functional 
assays have shown that mutant SETD6 exhibits dominant negative properties in cell-free 
in vitro systems and in a colon cancer in vitro cell line model. It has been proved that, 
although mutant SETD6 displays similar localization, expression and substrate-binding 
ability as the wild-type, the mutant protein loses its enzymatic activity. Indeed, unlike 
wild-type SETD6, SETD6-N lacks both its automethylation activity and the ability to 
methylate two previously identified substrates, PAK4 and RelA163,167. In addition, the two 
alleles (wild type and mutant) were found to be expressed in the tumor of one of the 
carriers, and the two forms of SETD6 were shown to compete for their substrates both in 
cell-free systems and in colon cancer cells, pointing to a dominant negative role.  
 
5.2.4. Downstream effects 
 
As a result of the aforementioned consequences, this mutation may have several 
downstream effects on the different pathways in which SETD6 is involved163,167–171. For 
example, SETD6-dependent methylation of the NF-ĸB subunit RelA has been shown to be 
critical for basal inhibition of NF-ĸB signaling in the absence of stimulation, so a deficient 
SETD6 could be predicted to result in the hyperactivation of the NF-ĸB pathway163. As 
expected, two NF-ĸB target genes (IL1A and IL8) were shown to be overexpressed in a CRC 
cell line as a result of the mutation, pointing to the upregulation of the NF-ĸB signaling 
pathway. The NF-ĸB family of transcription factors has an essential role in inflammation 
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and innate immunity, but it has also been increasingly recognized as a crucial player in 
many steps of cancer initiation and progression242. In fact, activation of the NF-ĸB pathway 
has been positively associated with multiple types of cancer, including CRC280.  
 
In addition, it had been previously demonstrated that methylation of PAK4 by 
SETD6 promotes the activation of the Wnt/β-catenin pathway167, whose deregulation has 
been shown to contribute to CRC development, including in HNPCC129,281–283. Although 
some differences were observed in Wnt target gene expression for the 2 forms of the 
enzyme, these preliminary results were not consistent and need to be addressed in the 
future. The loss of SETD6's function and predicted aberrant regulation of NF-ĸB and/or 
Wnt signaling could be contributing to the initiation or progression of CRC in the studied 
FCCTX family. However, SETD6 has several other substrates and is involved in numerous 
other signaling pathways166,168,170,279, so future studies are also needed in order to define 
other downstream consequences of this SETD6 truncating mutation, ideally using the 
SETD6 knock-out HCT116 cell line generated. 
 
5.2.5. Involvement of SETD6 in cancer predisposition 
 
Given all the results presented earlier, we propose that the presence of SETD6's 
mutant allele would presumably increase the cumulative risk of developing CRC 
throughout the life of the carriers, as compared with the general population. More 
research should be done in order to determine the penetrance of this mutation, whether 
it is a high or moderate-risk allele, and if there is also an association with other HNPCC-
associated cancers. Interestingly, the same SETD6 frameshift mutation had already been 
proposed to be associated with ovarian cancer in an extensive study by Kanchi and 
colleagues284. Nonetheless, the search for new genes by exome sequencing in FCCTX 
families has demonstrated that more than one gene can be involved in the increased 
cancer, and even when there is a high-risk gene involved, there might be also low-
penetrance alleles cooperating in the process as risk modifiers. Moreover, there are other 
elements that might be modulating the cancer risk, including lifestyle and other 
environmental factors8,285. Although our results are not enough to claim that SETD6 alone 
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is responsible for the increased CRC-risk in this FCCTX family, they certainly point to a role 
of this variant in cancer development. 
 
5.2.6. Other candidate variants in this family 
 
Noteworthy, the WES analysis followed by rigorous filtering identified additional 
candidate genes beside SETD6 (Table 4.3). CCDC60 showed a stop gain variant that results 
in the loss of 30 amino acids, 20 of which belong to a domain of unknown function, while 
the remaining 10 belong to a low complexity region. This is a gene of unknown function, 
but that has been associated with renal cancer286. ST18 showed a missense variant and is 
tumor suppressor gene that has been associated with breast cancer287. Even though just 
missense, the candidate variant affects a protein domain and involved a change to proline, 
which is an amino acid with very special conformational properties241.  It is worth noting 
that other candidate variants initially considered were later disregarded based on the lack 
robust evidence supporting their prioritization. Even though SETD6 M264Ifs*3 was 
undoubtedly the most promising candidate among them all, we cannot exclude the 
possibility that the additional candidate variants – and even other filtered variants – may 
contribute independently or together to the pathology of FCCTX. As previously 
mentioned, the selection of the SETD6 variant over the others was based on the effect of 
the mutation and the function of the protein. 
 
5.2.7. SETD6 as a candidate CRC predisposing gene 
 
Together, our findings suggest that this truncating dominant negative mutation in 
SETD6 could potentially explain the cancer predisposition of this FCCTX family. We 
therefore propose SETD6 as a novel gene involved in CRC predisposition. The results here 
presented certainly point to a pathogenic role of SETD6 c.791_792insA, p.(M264Ifs*3), 
though not enough to prove that SETD6 alone is responsible for their increased cancer 
risk. Although no other SETD6 variants were found in the remaining 12 families studied, 
nor in 109 familial CRC cases provided by the Clinic Hospital (IDIBAPS, Barcelona), the 
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screening of this gene in a larger group of patients could provide more insights into its 
role in other FCCTX families. 
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5.3 Characterization of PTPRT 
D1367Gfs*24 
 
5.3.1. PTPRT frameshift variant in family cc765 
 
The most promising candidate variant for family cc765 was a novel frameshift 
mutation in the PTPRT gene: c.4099dup, p.(Asp1367GlyfsTer24). Although the segregation 
within the family was not perfect, this variant showed a compatible segregation with the 
disease. That is because it was not carried by a member who had developed CRC at the 
age of 85 (II:3). However, if we take into account the elevated age of this patient and the 
prevalence of the disease in the general population, this could be perfectly explained as a 
phenocopy. In addition, this variant was carried by 3 other members affected with 
different cancers at younger ages, two of which belonged to the HNPCC spectrum: II:6 had 
CRC at 70, II:7 had endometrial cancer at 28, and II:4 had a breast cancer at 66. Moreover, 
the variant was not present in the two elderly healthy relatives studied (II:2 and II:5, of 
ages 91 and 85, respectively). 
 
On the other hand, there was no LOH of the wild-type allele in any of the tumors 
tested (from members II:4 and II:6), although the breast tumor showed a possible partial 
loss of the mutant allele. This would need to be confirmed, given that Sanger sequencing 
is not a quantitative method for the detection of LOH. Nonetheless, PTPRT has been 
recently reported to have frequent promoter hypermethylation in CRC among other 
tumors177,178, and the promoter region of PTPRT was certainly found to be 
hypermethylated in the two tumors of the carriers that were tested (breast and colon), 
which could be a different mechanism of inactivation of the wild-type allele in the tumor. 
Indeed, an allele-specific expression assay showed that the expression of the wild-type 
PTPRT allele was significantly reduced in the colorectal tumor of member II:6 when 
compared to healthy colon from the same individual, while no decrease was observed in 
the expression of the mutant allele. This suggests that the aforementioned 
hypermethylation only affects the wild-type allele and could be considered a second hit 
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involved in the inactivation of this tumor suppressor, leading to tumor development in 
the carriers. 
 
5.3.2. Selection of PTPRT D1367Gfs*24 as a candidate 
variant 
 
PTPRT is a tyrosine phosphatase that has been proven to behave as a tumor 
suppressor through the inactivation of at least two well-known oncogenes, STAT3 and 
paxillin. Its involvement in relevant pathways (including the paxillin-p130-PI3K-Akt 
signaling axis and the IL6-JAK-STAT3 pathway) can be pointed out, through which it 
regulates the expression of genes involved in cell survival, apoptosis, proliferation, growth 
and cell migration182,245. In addition, frequent somatic inactivating alterations in many 
tumors have been reported to act as driver mutations that promote tumor development 
and progression269. Last but not least, even though it is located quite at the end of the 
protein, the identified variant is a truncating mutation that affects one of the two catalytic 
domains of PTPRT. For all of the above, this variant was further prioritized among the 
other candidate variants for a more in-depth characterization. 
 
5.3.3. Consequences of PTPRT D1367Gfs*24 
 
PTPRT D1367Gfs*24 results in the loss of the last 95 amino acids of the protein, 
including an important portion of the second phosphatase domain, also known as D2. 
Figure 5.1 A has been adapted from Lui et al186 to show a representation of the tertiary 
structure of the D2 domain, showing the region that surrounds the phosphorylated 
tyrosine. The yellow striped area shows all the residues that are lost with the identified 
frameshift mutation. The 95 amino acids lost represent 35.7% of the D2 domain, as seen 
in Figure 5.1 B, which shows the amino acid sequence of such domain with and without 
the mutation. The different colors mark the proximity to the phosphorylated tyrosine, 
pointing out that a considerable amount of essential D2 residues are lost with the 
mutation. Actually, the majority (69.2%) of residues surrounding the phosphotyrosine and 
in direct contact with the target protein are lost with this mutation (amino acids in red)186. 
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Although the first phosphatase domain (D1) is the one known to be responsible 
for the phosphatase activity of the protein, D2 is responsible for the regulation of this 
activity and has been proven to be essential for PTPRT’s activity245. As a matter of fact, 
Wang et al reported that just a missense mutation affecting D2’s residue 1368, which is 
lost in our mutant, was enough to decrease the enzyme’s activity by half (Figure 5.1 C, 
Figure 5.1. Additional consequences of PTPRT D1367Gfs*24. A) Visualization of the D2 domain 
residues surrounding the substrate’s phosphotyrosine (pTyr, in green). The colors indicate the 
proximity to the pTyr, with the closest residues marked in red, followed by the purple and blue 
ones. The yellow stripped area shows all the residues in contact with the pTyr that are lost with 
the mutation. The figure has been modified from Lui et al. 2013. B) Amino acid sequence of 
PTPRT’s D2 domain with the effect produced by the mutation. Colors indicate the proximity to 
the pTyr as in A. Underlined are all the residues that differ between the two forms of PTPRT. 
C) Previous studies proving that the D2 domain is essential for PTPRT’s phosphatase activity, 
modified from Wang et al. 2004 (top) and Zhang et al. 2007 (bottom). Circled in red are the 
minimum expected consequences of the studied mutation. The top figure shows how PTPRT’s 
catalytic activity is reduced by half in a missense mutant that affects one on the residues that 
are lost with our mutation. The bottom figure shows how deletion of the D2 domain has a 
significant effect on the levels of phosphorylated STAT3 and expression of two of it’s target 
genes (BCL-XL and SOCS3), all of which are increased upon D2 deletion. 
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top)176. The relevance of this second catalytic domain was also pointed out by Zhang et al, 
who showed how the deletion of just the D2 domain had significant effects on the levels 
of phosphorylated STAT3 (a well-known PTPRT target), as well as on the expression levels 
of two of its downstream target genes, BCL-XL and SOCS3 (Figure 5.1 C, bottom)182. All 
things considered, it can be predicted that this mutation will result in significant 
consequences for the activity of this phosphatase. 
 
5.3.4. Downstream effects 
 
The PTPRT phosphatase is known to dephosphorylate two main target proteins, 
STAT3 and paxillin182,183,245, both of which are well-known oncogenes288. These two 
proteins are activated upon phosphorylation by different protein tyrosine kinases, so the 
PTPRT-mediated removal of the phosphate group results in their inactivation. This results, 
in turn, in the inhibition of their downstream pathways, through a decreased 
phosphorylation of paxillin’s target proteins183,245 and a decreased expression of STAT3’s 
target genes182. BCL-XL and SOCS3 are two of those STAT3’s target genes, which have been 
proven to show increased expression upon PTPRT depletion182. Consistent with our 
hypothesis that this germline PTPRT variant may be involved in the cancers of this FCCTX 
family, the tumors from the two carriers tested presented a significantly increased 
expression of BCL-XL, which is an oncogenic driver in CRC289. This was observed in both 
the colon and breast tumors when compared to healthy tissue controls, as well as to the 
corresponding healthy colon or breast tissue from the same patient.  
 
In contrast, SOCS3 expression was decreased in both tumors. Nonetheless, SOCS 
proteins are negative feedback regulators of the JAK-STAT signaling pathway290,291, and it 
has been proven that SOCS3 is usually downregulated in CRC, even when IL-6 and STAT3 
are upregulated292. This is thought to occur through different mechanisms, such as the 
hypermethylation of SOCS3 gene promoters, allowing inflammatory cytokines IL-6 to 
activate STAT3’s signaling pathway while inhibiting the expression of SOCS3292, with the 
purpose of inactivating its negative feedback. This negative regulation of SOCS3 
expression, mediated by the activation of IL-6/STAT3, leads to imbalance and sustained 
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activation of STAT3 signaling pathway292. The same study by Chu et al also showed that 
SOCS3 plays an important role inhibiting tumor development and that reduced SOCS3’s 
expression affects tumorigenesis and CRC progression, promoting growth and 
metastasis292. For all the things mentioned, both results are compatible with a pathogenic 
role of this PTPRT variant. 
 
5.3.5. Involvement of PTPRT in cancer predisposition 
 
PTPRT has been long known to be frequently mutated at the somatic level in many 
cancers, including CRC176. These mutations have been proposed to be driver mutations 
involved in the development of the tumors in which they are found176. In addition, 
frequent hypermethylation of PTPRT’s promoter has been recently described as a 
mechanism of genetic inactivation in CRC and head and neck cancer177,178. It has been 
proven that PTPRT normally functions as a tumor suppressor gene based on a number of 
reasons. In the first place, overexpression of wild-type PTPRT suppresses colony formation 
of CRC cells, whereas tumor-derived mutations impair this ability. Furthermore, PTPRT 
knock-out mice are susceptible to carcinogen-induced colon tumor formation183 and 
PTPRT knock-out increases the size of colon tumors in the Apcmin/+ genetic background245. 
Such tumor suppressor role may be mediated by the inhibition of two well-known 
oncogenes (STAT3 and paxillin), both of which have been proven to be targets of PTPRT's 
phosphatase activity182,183.  
 
However, this is the first time that PTPRT is linked to hereditary cancer, which 
highlights the importance of the results here presented. Even though the role of this 
protein in tumor development is undeniable, more studies are needed to confirm its 
involvement as a cancer susceptibility gene. Studying this gene in a larger FCCTX cohort 
would help with this task. As a matter of fact, the screening of PTPRT in a FCCTX cohort 
from the Catalan Institute of Oncology (IDIBELL, Barcelona) identified one additional rare 
missense germline mutation in the D2 domain of PTPRT in one of the CRC-affected 
patients. However, the effect of this variant cannot be currently established. Even if PTPRT 
is validated as a cancer-risk gene, we cannot discard the possibility that other factors – 
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either environmental or genetic – may be contributing to the increased cancer 
susceptibility or modifying its effect.  
 
5.3.6. Other candidate variants in the family 
 
Even though PTPRT had the highest potential for the explanation of the increased 
cancer risk, another 4 candidate variants were prioritized for this family: 2 missense 
variants in MAP3K6 and ABTB1, and a splice region variant in INVS. MAP3K6 is reported 
to act as a tumor suppressor, while ABTB1 is a mediator of PTEN and INVS acts as a 
molecular switch between the different Wnt signaling pathways, inhibiting the canonical 
Wnt pathway.  
 
5.3.7. PTPRT as a candidate cancer predisposition gene 
 
Taken together, all the results here presented point to a probable causal role of 
PTPRT c.4099dup, (p.D1367Gfs*24), in the cancer susceptibility of FCCTX family cc765. For 
that reason, we propose PTPRT as a novel cancer predisposition gene. However, more 
research is necessary to confirm the causality, penetrance, conferred risk, preferred 
cancer location and the like. 
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5.4 Characterization of PYGO1 S362P 
 
5.4.1. PYGO1 missense variant in family cc28 
 
Even though no truncating candidate variants were prioritized for family cc28, a 
novel PYGO1 missense mutation was selected for further characterization. This variant 
was c.1084T>C, p.(Ser362Pro), and was predicted to be deleterious by all the in silico tools 
used and to affect an important functional domain of the protein. The two CRC-affected 
studied members of this family (II:1 and III:1) carried this variant, and the initial 
segregation study done for this mutation showed that it was not present in 2 out of the 3 
healthy relatives tested (III:4 and III:7).  Unfortunately, a later analysis of the tumor of a 
third CRC-affected member that was initially not available revealed that this mutation was 
not shared by this patient. It is worth noting that this result was obtained from tumor 
DNA, so there is always the possibility that one of the alleles had been previously lost 
(which is sometimes observed despite the fact that a remainder of the lost allele is 
expected to be seen). For this reason, a negative segregation result from tumor tissue is 
always controversial and was not used to discard any variant. As far as the LOH study is 
concerned, there was no loss of any of the alleles in the tumor of member (III:3), which, 
as already discussed, is not informative in the context of HNPCC. 
 
5.4.2. Selection of PYGO1 S362P as a candidate variant 
 
 Pygo1 is a nuclear protein that forms a complex with β-catenin, BCL9 and other 
proteins at the chromatin, promoting the transcription of Wnt target genes191. In addition, 
the canonical Wnt pathway has an important role in cancer, especially in CRC, where it is 
frequently upregulated243. Considering that no truncating mutations were prioritized for 
this family, the relevance of the Wnt pathway in CRC and that this missense variant 
affected the most important functional domain of the protein, this candidate variant was 
selected for further characterization. It is worth noting that at the moment of selection 
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the segregation study in the tumor of member III:3 had not been performed since the 
tumor block was still not available. 
 
5.4.3. Consequences of PYGO1 S362P 
 
PYGO1 S362P consists on the substitution of a serine for a proline and affects the 
PHD domain of the protein, which is a zinc finger domain essential for Pygo1’s function. 
Moreover, the affected residue is situated in a turn between two β-sheets, and is in very 
close proximity to one of the Zn atoms bound to the protein. As a matter of fact, Ser362 
is situated right next to one of the cysteines that directly interacts with such Zn194, and 
considering that proline is a very special amino acid it was reasonable to expect an effect 
on the Zn binding ability and function of the protein241. However, based on Pygo1’s 
positive role in the Wnt pathway191, the original hypothesis was that this change could be 
increasing the affinity of the protein for its substrates, which, although less likely than the 
opposite effect, would make more sense in the context of CRC. Nonetheless, mutant 
Pygo1 showed a significant decrease in the histone-binding affinity when forming a 
complex with both Bcl9 and B9L, when compared to the wild type protein. This result is 
contrary to our initial hypothesis and means that mutant Pygo1 could entail a decreased 
Wnt pathway. The effects that this could have in the tumor development are not known. 
Interestingly, the proportion of protein that eluted off the gel filtration in the void (which 
is indicative of misfolded protein) was higher for the S362P mutation, although the overall 
amount of protein that eluted in the void was about the same for wt and mutant. Although 
not a strong piece of data, this may indicate a slight reduction in stability of the mutant 
protein. 
 
5.4.4. Other candidate variants in the family 
 
Other candidate variants in the family included 4 missense variants in CHID1, 
MMP11, AHRR and NKD2. Given that PYGO1 has not been proven to be responsible for 
the increased CRC susceptibility of this family, one or more of the other candidate variants 
selected for family cc28 may be able to explain the increased CRC-susceptibility in this 
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family. CHID1 encodes a saccharide- and LPS-binding protein with possible roles in 
pathogen sensing and endotoxin neutralization that is involved in chronic inflammatory 
diseases and shows a decreased secretion in CRC166. MMP11 is a matrix metalloprotease 
or zinc-dependent endopeptidase that is overexpressed in many cancers293 and plays an 
important role in the progression of epithelial malignancies, including CRC294. Even though 
it has been shown that MMP11 knock-down inhibits proliferation and invasion295, the 
mutation detected is located in the cysteine switch of the protein, which binds a zinc atom 
in the inhibited form296. Actually, one of the cysteines responsible for the interaction with 
the Zn atom (Cys80) is only two amino acids away from the affected residue (Pro78), so 
this substitution may impair the Zn union, which would activate the protein leading to 
invasion and proliferation. AHRR is a tumor suppressor in multiple cancers168, and has 
been reported to be involved in CD40/CD40L signaling that inhibits CRC proliferation, 
induces apoptosis, stalls cells at G0/G1 and influences cell adhesion and metastasis169. 
Last but not least, NKD2 is an antagonist of the Wnt signaling pathway190, and although 
no domains have been described so far in this protein, the change affects the only known 
helix in the area, which makes it a good candidate for future characterization. 
 
5.4.5. PYGO1 is not confirmed as a candidate CRC 
predisposition gene 
 
All the results presented above do not point to a causal role of PYGO1 c.1084T>C 
p.(Ser362Pro) in this family. This is based mainly in the lack of segregation and on the fact 
that the mutation would be expected to decrease the Wnt pathway, which is the opposite 
of what is usually seen in CRC. Although we cannot be sure of the consequences that this 
mutation may have on tumor initiation and progression, the results here presented do 
not justify additional characterization. Instead, some of the remaining candidate variants 
may be involved in the increased cancer predisposition and could be further studied in 
the future. 
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5.5  Limitations of this study 
 
5.5.1. Cohort and patient selection 
 
One of the limitations of this study is the reduced size of our cohort due to the 
difficulty of finding families that meet the specific criteria and have enough available 
members. Although this may not be so relevant given that each family was studied 
individually, the study of the selected candidate variants in a bigger cohort of FCCTX or 
even early-onset CRC patients will provide further insights into the potential role of these 
genes in cancer susceptibility. 
 
The relevance of selecting the best suitable family members for this kind of study 
should be also pointed out, ideally including three affected relatives as distant as possible. 
Although some of the families in which the search for candidate genes has been more 
successful included 2 affected and 1 healthy relative sequenced, the inclusion of a healthy 
member can be also considered a limitation, given that the penetrance may not be 
complete and a healthy member could be the carrier of a pathogenic mutation. In 
addition, in most of the cases extended family members could not be recruited and two 
or three first-degree relatives were sequenced, which hinders the filtering and 
prioritization steps given the higher number of shared variants. Lastly, the inclusion of 4 
members with adenomas but without a diagnosed cancer is an important limitation. For 
that reason, apart from the regular filtering strategy, cancer-risk genes were checked in 
these families without taking into account these patients. 
 
5.5.2. Family history 
 
There are also limitations attached to the family history provided, which may be 
incomplete and sometimes inaccurate. The achievement of results strongly depends on 
the veracity of the information supplied. For this reason, it is always essential to confirm 
all the diagnoses with medical reports. However, there is still some family information 
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that completely relies on the good communication between the patients and the genetic 
counselors. The information provided by the family is also used to classify families 
according to the clinical criteria (Amsterdam, Bethesda and the like), so inaccurate data 
could result in the erroneous classification of a family. The reduced size of some modern 
families also hamper the fulfillment of the clinical criteria, and hence could result in the 
misclassification of high-risk families. 
 
5.5.3. Methodology 
 
Some of the limitations of NGS, and more specifically WES, have already been 
discussed in the Introduction section. However, it is worth emphasizing that the main 
limitation of this chosen method is that some areas of the exome are poorly covered or 
even uncovered, and that WES only sequences the coding regions of the genome, missing 
any intergenic or intronic regulatory elements153. Therefore, any alterations in those 
regions would not be detected, so we should assume that we are dismissing a fraction of 
potential causal variants. However, given that the majority of currently known cancer-
causing mutations are located within coding regions and that a minimum coverage of x20 
was achieved in >95% of the targeted region, we consider that the lost fraction that could 
be currently interpreted is relatively small. In addition, WES is not the most reliable 
method for the detection of CNVs, so we cannot rule out the presence of these alterations 
in the families not studied by CGH.  
 
5.5.4. Filtering and prioritization strategy 
 
Section 5.1 also addressed another of the main limitations of this study: the 
filtering and prioritization steps. This limitation is mainly due to the bias introduced by in 
silico analyses and the prioritization approach, the cutoffs used in the filtering strategy 
and the availability of information in public databases. For instance, variants detected 
with a very low allele frequency due to technical issues (such as the preferential 
amplification of one of the alleles) would be lost in the first filtering step. In the same way, 
this allele frequency cutoff can fail to detected mosaicisms, which have been described in 
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other hereditary syndromes such as polyposis79,297. However, lowering this cutoff would 
significantly increase the amount of false positives in certain regions, complicating the 
analysis of the vast amount of data obtained.  
 
In addition, low frequency variants (0.01<MAF<0.05) with moderate or modest 
effects would be also discarded during the filtering stage, as well pathogenic variants with 
incomplete penetrance carried by healthy members, as previously discussed. For this 
reason, healthy relatives were only taken into account at the end of the filtering strategy 
in order to examine the shared variants prior to this step, and genes previously associated 
with cancer predisposition were allowed to have a MAF≤0.05. Finally, the prioritization of 
the genes based on previous information can lead to the underestimation of genes that 
are still not fully understood and have little information in public databases. This is 
particularly relevant given that there is always a delay in the publication of scientific 
discoveries. Moreover, the prioritization step based on the search of online databases and 
literature is unarguably the most biased step. 
 
All this means that although any finding obtained by this type of study is certain, 
there might always be some information lost. For this reason, the raw data should be 
always kept available for possible future new data analyses with different approaches.  
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5.6 Future perspectives 
 
5.6.1. Candidate variant screening in a larger cohort 
 
One of the first things planned for the future is the screening of the most appealing 
candidate genes in a larger set of FCCTX families, or even in other high-risk CRC cases, 
such as early onset CRC or families with a weaker but still noticeable CRC family history. 
This could confirm the implication of these genes in cancer susceptibility and clarify their 
role. However, none of the genes here presented are thought to be major contributors of 
CRC susceptibility in FCCTX families, suggesting that a high number of families should be 
screened in order to increase the odds of finding other carriers. In addition, population-
based studies confirming the absence of the identified variants in healthy individuals from 
a certain population would strengthen any associations observed with CRC.  
 
These screenings should be done specially for SETD6 and PTPRT, but also some of 
the still uncharacterized candidate genes with the strongest causal potential, such as 
those involved in DNA repair or those affected by truncating variants. The follow-up of 
the families will also make the segregation studies more informative, given that many of 
the available family members were still too young to be taken into account. 
 
5.6.2. Further characterization of SETD6 mutation 
 
Although a quite thorough characterization was performed for the germline 
mutation identified in SETD6, little is still known about its downstream consequences. 
Future plans include the study of the effects of this mutation on the different pathways in 
which SETD6 is involved, such as the NF-κB, Wnt and Nrf2 pathways, but also on cell cycle 
and proliferation. Although some preliminary assays were already performed, the 
expression of the different target genes should be analyzed by qPCR using the CRIPR-Cas9 
SETD6 knock-out CRC cell line that was generated during the stay at Ben Gurion University 
(Israel). In addition, other approaches could be designed for the study of the cell cycle, 
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proliferation and response to oxidative stress. These could include wound healing, 
viability and cellular antioxidant activity assays. 
 
5.6.3. Further characterization of PTPRT mutation 
 
Even though previous literature firmly supports the detrimental effect of the 
germline mutation identified in PTPRT on the function of the protein, future plans for this 
gene include the functional characterization of this alteration. As a matter of fact, the 
mutant version of PTPRT has already been cloned during a stay at Case Western Reserve 
University, and assays to determine the effects of this mutation on PTPRT’s phosphatase 
activity, as well as on a newly identified activity of the D2 domain, are currently being 
addressed. However, this approach has not been included in this thesis given that 
experiments are still ongoing and it is too early to draw any conclusions. Other future 
plans could include the study of the expression of a larger number of target genes in the 
tumor and healthy tissues from the carriers, as well as in cells transfected with the mutant 
PTPRT clone. 
 
5.6.4. Characterization of other candidate variants 
 
Finally, future plans include the characterization of other candidate variants, 
which will provide insights into their role in cancer predisposition. However, in order to 
proceed with additional assays, it is crucial to select the best candidates with strong 
evidence supporting their likely causal role, given the costs and dedication required for 
these analyses. Some of the candidate genes that are more likely to benefit from these 
studies include those involved in DNA repair (especially in the fanconi anemia pathway), 
as well as those affecting well-described tumor suppressors. On the other hand, 
truncating variants a priori entail better candidates for further characterization. 
 
It is worth noting that some preliminary expression studies have already been 
started for a few other candidate variants, including two truncating variants in SHF and 
POLQ. 
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6.1 Conclusions 
 
1. The strategy used in this study allowed the successful achievement of a list of 
candidate variants for each of the 13 FCCTX families.  
 
2. A total of 44 candidate variants were selected, out of which: 
 27.3% affect genes involved in DNA repair, including a 6.8% involved in the 
fanconi anemia pathway. 
 22.7% affect reported tumor suppressor genes. 
 The remaining affect, for the most part, genes involved in pathways that 
modulate proliferation, differentiation and apoptosis. 
 
3. None of the studied families is explained by high or moderate-risk mutations in 
previously known cancer predisposition genes. 
 
4. The mutation c.791_792insA, p.(Met264IlefsTer3), identified in the SETD6 gene in 
FCCTX family cc598:  
 Impairs the protein’s methyltransferase activity without affecting its 
binding ability.  
 Is expressed in the tumor, competing with the wild-type protein in a 
dominant negative manner. 
 Increases the expression of NF-ĸB target genes and has the potential of 
affecting other SETD6-associated cellular events (such as the Wnt 
pathway, cell cycle and oxidative stress response). 
 Shows a perfect cosegregation with all the cancers in the family. 
 Is consistent with a causal role in the cancer predisposition of this family, 
reason for which SETD6 is proposed as a new cancer risk gene. 
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5. The mutation c.4099dup, p.(Asp1367GlyfsTer24), identified in tumor suppressor 
gene PTPRT in FCCTX family cc765:  
 Affects key residues of the D2 catalytic domain, which is essential for the 
protein’s phosphatase activity.  
 Presents hypermethylation of PTPRT’s promoter in the tumor, together 
with decreased expression of the wild-type allele.  
 Entails the altered expression of PTPRT’s downstream target genes in the 
tumor. 
 Shows a compatible segregation with the different cancers in the family. 
 Is consistent with a causal role in the cancer predisposition of this family, 
reason for which PTPRT is proposed as a new cancer risk gene. 
 
6. The mutation c.1084T>C, p.(Ser362Pro), identified in PYGO1 in FCCTX family cc28: 
 Involves a drastic amino acid change that affects one of the zinc fingers 
of the PHD domain. 
 Decreases its histone-binding affinity, which could decrease the 
expression of Wnt target genes, opposite to what is expected in a 
colorectal cancer context.  
 Does not segregate with all the cancers in the family. 
 Is not confirmed as the cause underlying the cancer predisposition of this 
family. 
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6.2 Conclusiones 
 
1. La estrategia utilizada en este estudio ha permitido la obtención de una lista de 
genes candidatos para cada una de las 13 familias FCCTX. 
 
2. Un total de 44 variantes candidatas fueron seleccionadas, de las cuales:  
 El 27.3% afecta a genes involucrados en la reparación del ADN, incluyendo 
un 6.8% implicado en la vía de la anemia de fanconi. 
 El 22.7% afecta a genes descritos como supresores tumorales. 
 El resto afectan, en su mayoría, a genes implicados en vías que regulan los 
mecanismos de proliferación, diferenciación y apoptosis. 
 
3. Ninguna de las familias estudiadas se explica por mutaciones causales de alto o 
moderado riesgo en genes conocidos de predisposición al cáncer. 
 
4. La mutación c.791_792insA, p.(Met264IlefsTer3), encontrada en el gen SETD6 en la 
familia FCCTX cc598: 
 Conlleva la pérdida de la actividad metiltransferasa de la proteína sin 
afectar a su habilidad de unión a sustrato. 
 Se expresa en el tumor, compitiendo con la proteína nativa con un efecto 
dominante negativo. 
 Aumenta la expresión de genes diana de la vía NF-ĸB, teniendo el potencial 
de afectar otros mecanismos asociados a SETD6 (como la vía Wnt, el ciclo 
celular y la respuesta a daño oxidativo). 
 Muestra una perfecta cosegregación con el cáncer en la familia. 
 Concuerda con un papel causal en la predisposición al cáncer en esta 
familia, por lo que proponemos a SETD6 como un nuevo gen de riesgo al 
cáncer. 
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5. La mutación c.4099dup, p.(Asp1367GlyfsTer24), encontrada en el gen supresor 
tumoral PTPRT en la familia FCCTX cc765: 
 Afecta a residuos clave del dominio catalítico D2, que es esencial para su 
actividad fosfatasa. 
 Presenta hipermetilación del promotor de PTPRT en el tumor, junto con 
disminuida expresión del alelo nativo. 
 Conlleva la alteración de la expresión de genes diana de vías asociadas a 
PTPRT en el tumor. 
 Muestra una segregación compatible con los distintos tipos de cáncer de 
la familia.  
 Concuerda con un papel causal en la predisposición al cáncer de esta 
familia, por lo que proponemos a PTPRT como un nuevo gen de riesgo al 
cáncer. 
 
6. La mutación c.1084T>C, p.(Ser362Pro), encontrada en el gen PYGO1 en la familia 
FCCTX cc28: 
 Conlleva un cambio de aminoácido drástico, que afecta a uno de los dedos 
de zinc del dominio PHD. 
 Reduce la afinidad de unión a histonas de la proteína, lo que disminuiría 
la expresión de genes diana de la vía Wnt, al contrario de lo esperado en 
un contexto de cáncer de colon.  
 No segrega con todos los cánceres de la familia. 
 No se puede confirmar su implicación en la susceptibilidad al cáncer de 
esta familia. 
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A1. Pedigrees of the 13 families 
 
 
 
 
 
 
 
 
  
Family cc7 
Family cc28 
Family cc81 
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Family cc89 
Family cc108 
Family cc122 
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Family cc406 
Family cc440 
Family cc525 
214 
 
 
 
 
 
Family cc565 
Family cc598 
Family cc763 
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Family cc765 
Pedigrees of the 13 families studied in this thesis. Males and females are represented by 
squares and circles, respectively.  Identification numbers are displayed below each family 
member, with roman numerals indicating the different generations. Reported cancers and 
ages at diagnosis are detailed underneath and marked in 3 different colors: red for CRC, 
purple for HNPCC-associated cancers (including all defined by the International Collaborative 
Group on HNPCC, not just those included in the Amsterdam II criteria), and green for other 
cancers. Red circles in the center show those patients with adenomas, while black circles 
designate other polyps. Green boxes indicate those members whose whole-exome was 
sequenced, and arrows indicate those members whose germline DNA available. CRC: 
colorectal cancer, ADE: adenoma, EC: endometrial cancer, RC: renal cancer, BladC: bladder 
cancer, GIC: gastrointestinal cancer, OC: ovary cancer, CNSC: central nervous system cancer, 
BC: breast cancer, LC: lung cancer, PrC: prostate cancer, HNC: head and neck cancer, ThyrC: 
thyroid cancer, VulvC: vulvar cancer, Mel: melanoma, Linf: linfoma, Sar: sarcoma, Myel: 
myeloma. 
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A3. Primers and PCR conditions 
 
PCR conditions: 
 
 
 
 
 
 
Primers for cDNA validation: 
 
 
 
  
Stock 
concentration
Working 
concentration
Buffer (no MgCl2) 10x 1x
MgCl2 25mM 2mM
dNTPs 2.5mM 0.2mM
Forward primer 10µM 0.2µM
Reverse primer 10µM 0.2µM
Fast-Taq 5U/uL 1U
H2O - -
DNA template 25ng/uL 25ng
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Primers for validation, segregation and LOH: 
 
 
  
Family Gene Exon Primer Sequence PCR cond Product Sanger
FOR TACAACAGCCAAGCCTGTGA
REV ACACTCGCCCTTTTGGTTC
FOR TCCATACCAGTTGAACATAGGG
REV CACCACCGATGATGATGAGA
FOR CCAGAGGCCAAGATGATGTC
REV AGTCACTTCCTTCGAAAGACAAAC
FOR CCATCAGCAGAGGGGTTG
REV TGGCATCTGACTTTGACAGG
FOR CTCTTCACCCAAACCGTCAT
REV TGCAGTTAAGAGGCCATAAGC
FOR CCAGACCCTCATGTCATCCT
REV GGCACTCAGCCCATCAGA
FOR AGTACTCGGCCTTCCTGACC
REV CCTCTGTTTCCTTCCACACC
FOR CTGGGGTCTGCTCTGTCAGT
REV GAGGACCCTCCTTCCTCTTG
FOR CAAAGGAGATGATGTGGCCC
REV GGCGCGTATGGAGAAAGATC
FOR TCTGTGGCCTCCTTTCCTC
REV TTCTCCCCACACACTCACCT
FOR TAGGGCCGCAAAAGGAGATT
REV GCCTATAGTCCAGACAAACGC
FOR GAGCGACTAAGATAGATCATTTGGA
REV TTGTGAATCAGTAACAGAAACTTCAA
FOR ACTGTGCTGGACCTTGGAAT
REV GATGGTTGCTTCTGGAGAGC
FOR AGAAGGTTGTGAGTGGGAGC
REV TTCTCCTTTCCTGCCTTGGA
FOR GCTCTCTAAGGCCTCCGC
REV ATACCTGATGCTGTTGTCGC
FOR CTGAAGTCCTGACCAACCTCT
REV TGTCCCAACCTGTGACTTCT
FOR TCCACAGTTATGCAAACACACT
REV ACCTTCTTCTCCCACTATGCT
FOR TCCTTCTACCTGCCCCTAGA
REV CCTACCTTGTCCGTCCTTGT
FOR GGCTTACCTTGTCTCTGGGA
REV GGCCATTTCATAGACACAGCA
RASSF5 ex4 AT=55ºC, 
35 cycles
159bp REV
NEK4 ex4 AT=58ºC 203bp FOR
FOR
IQGAP2 ex12 AT=55ºC 179bp REV
NUP153 ex13 AT=53ºC, 
35 cycles
190bp FOR
cc108
NME7 ex12 AT=58ºC 157bp
REV
ADIPOQ ex3 AT=55ºC 197bp FOR
cc89
POLQ ex16 AT=58ºC 176bp FOR
C19orf40 ex4 AT=55ºC, 
35 cycles
150bp
FOR
ATR ex13 AT=58ºC 206bp FOR
cc81
ECH1 ex4 AT=58ºC 127bp FOR
MAPK15 ex2 AT=60ºC 350bp
AHRR ex7 AT=58ºC, 
GC rich
150bp REV
NKD2 ex7 AT=60ºC 177bp REV
FOR
MMP11 ex2 AT=56ºC, 
GC rich
194bp FORcc28
CHID1 ex1 AT=58ºC 194bp FOR
PYGO1 ex3 AT=58ºC 176bp
FOR
GAL3ST2 ex1 AT=60ºC 146bp REV
cc7
MUC6 ex17 AT=60ºC 132bp FOR
TXNRD3 ex4 AT=58ºC 165bp
222 
 
Family Gene Exon Primer Sequence PCR cond Product Sanger
FOR GAGACACTGCTGAGCACCAT
REV GCTGCAGTAGAGCTGGGATAA
FOR AGTTTCACACTCCAGAGGAAGT
REV GCTGGTATGTCTCCCCTGTT
FOR GACAAATTTCGTGACCCACA
REV TCAATTCAAAGCTATTGGGAGT
FOR AAGCAAATCTTCCATGAAACTGT
REV ACACCAGCATCATGAGAGGA
FOR GGACCCAGGAGATTTTGGTA
REV TGACCTTATCCAATGCCACTT
FOR CCCCCAAGGGTAGTCTGAGT
REV GCCAGTTGCTTTTCTTCTTCTG
FOR TCATTCAGTCTTTCTGCCTTCA
REV TGAGGGGATTTTCTTTGGTG
FOR TGCAGTTAGCCAAACCCTGT
REV GTTGTGGAAGGGGATGATGA
FOR AATCACCTGTGCCTCCGAAA
REV AGAGCCAAGCACCCTAGAAG
FOR CATCCTCTTAAGCCATGGAGA
REV TGCAATCTTTCCCATTTTCA
FOR TGGTAGCATTGGTGACAGAAG
REV GCATAATTAGTGTTTGCCCAAT
FOR CCATCCCGAAGATTTGAAGA
REV TGAGTGGGAGTACCACAAAGG
FOR CATCCCCAAGAGAAGACACAA
REV CCGTGGCTGATAATTTTTCG
FOR GCCGTCAACCAAATACAAGG
REV CCCCAGGTTTTTAGCCTCTT
FOR AGTTCACCAAATACGGCTGC
REV CATAGAACCAGACTCCCCGT
FOR GGTGGTAAGATTCCAAAAGAGAAAC
REV ATACCTTACACACCTTGAAAAGCAA
FOR TGCATCTTTCCTTCACCAGA
REV CACTTTCGTCTTGAGCGATG
FOR CCACTCAGCCCATTCCTAAA
REV TGATACACTCACCCTGTAATGCT
FOR GCCACCAGTCTCAGTCACAA
REV GCAGCCAGCTGATGTAATCC
FOR TCTCTCTTCAACAGCAAAGCA
REV TGGCTTGTTGGAGAGGATGT
FOR TTCTCTTTTGGGCAGCCATA
REV ACCACAACCACTTTGCCAGT
FOR CAGCCCTAACAGCCTCTCTG
REV GCAGTGGACCACAGTACGTC
FOR TGTCATTGAGATGGCCACAG
REV GGGTGAACAAGGGTGACATT
FOR GCAGCCTATGATGTGCTGAG
REV ACTGGCCCACCTTCTCAAT
FOR GGACTTTACCCTGGGCCTAC
REV TTCCCTTCGTGAGAACAACC
INVS ex16 AT=60ºC 176bp FOR
156bp REV
ABTB1 ex11 AT=60ºC 199bp FOR
FOR
cc765
PTPRT ex29 AT=60ºC 189bp FOR / 
REV
MAP3K6 ex20 AT=56ºC
ST18 ex15 AT=55ºC, 
35 cycles
208bp FOR
cc763 WWOX ex4 AT=58ºC 171bp
REV
CCDC60 ex14 AT=60ºC 162bp FOR
RHOBTB1 ex11 AT=58ºC 155bp REV
cc598
SETD6 ex6 AT=58ºC 174bp
FOR
ARMC3 ex18 AT=60ºC 157bp REV
C9orf116 ex2 AT=58ºC 230bp FOR
cc565
ADAMTS14 ex18 AT=53ºC, 
35c, GC rich
167bp
FOR
EIF4G3 ex12 AT=58ºC 198bp FOR
HELQ ex8 AT=58ºC 198bp REV
cc525
ECT2L ex17 AT=58ºC 201bp
201bp REV
CASP7 ex6 AT=58ºC 183bp FOR
FOR
cc440
GALNT10 ex4 AT=58ºC 150bp FOR
PHACTR2 ex5 AT=55ºC, 
35 cycles
cc406
SHF ex2 AT=60ºC 150bp FOR
ABCC2 ex9 AT=58ºC 137bp
ABCB1 ex5 AT=55ºC 160bp FOR
CTNNAL1 ex6 AT=58ºC 206bp FOR
FOR
RNMT ex7 AT=58ºC 169bp FORcc122
MUS81 ex15 AT=60ºC 181bp REV
VEPH1 ex9 AT=55ºC 199bp
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Primers for SETD6 cloning: 
 
 
 
Primers for PTPRT methylation: 
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A4. Plasmids 
 
 
 
pcDNA3.1 plasmid with SETD6-N insert: 
 
 
225 
 
 
Other vectors: 
226 
 
Inserts: 
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A5. Buffers and antibodies  
 
DNA gels: 
 
 
Protein gels and westerns: 
 
        
 
       
 
    
 
TAE buffer x50
2M Tris
50mM EDTA
Acetic acid
8% 10% 12%
Acrylamide 2.7mL 3.3mL 4mL
1.5M Tris, pH 8.8 2.5mL 2.5mL 2.5mL
SDS (20%) 50µL 50µL 50µL
APS (10%) 100µL 100µL 100µL
TEMED 10µL 10µL 10µL
H2O 4.7mL 4.1mL 3.4mL
Separating gel
Acrylamide
1M Tris, pH 6.8
SDS (20%)
APS (10%)
TEMED
H2O
40µL
4µL
2.7mL
Stacking gel
0.8mL
0.5mL
20µL
Protein sample buffer (PSB)
250mM Tris-HCl, pH=6.8
10% SDS
30% Glycerol
5% β-mercaptoethanol
Bromophenol blue (very little)
Running buffer x10
250mM Tris
1.92M Glycine
1% SDS
pH 8.1-8.5
Transfer buffer
25mM Tris
192mM Glycine
20% methanol
pH 8.3
PBST 0.1%
3.2mM Na2HPO4
0.5mM KH2PO4
1.3mM KCl
135mM NaCl
0.1% Tween
TBST 0.1%
50mmM Tris pH=7.5
150mM NaCl
0.1% Tween
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Protein purification: 
 
       
 
       
 
Cells: 
 
 
 
 
  
Antibody Dilution Secondary Reference Notes
α-FLAG 1:5000 α-Mouse Sigma-Aldrich, F1804 10% skim milk in PBST
α-HA 1:3000 α-Mouse Millipore, 05-904 10% skim milk in PBST
α-H3 1:2000 α-Mouse Abcam, ab10799 10% skim milk in PBST
α-tubulin 1:3000 α-Mouse Abcam, ab44928 10% skim milk in PBST
α-GAPDH 1:2000 α-Mouse Abcam, ab8245 10% skim milk in PBST
α-SETD6 1:2000 α-Mouse Genetex, GTX629891 10% skim milk in PBST
α-RelAK310me1 α-Rabbit Levy et al. 2011
α-Pan Me 1:500 N/A ImmuneChem, ICP0502 5% BSA in TBST
Wash buffer
PBS x1
20-25mM Imidazole
Elution buffer
PBS x1
500mM Imidazole
Dialysis buffer
PBS x1
10% Glycerol
Lysis buffer
PBS x1
10mM Imidazole
PMSF (1:100)
Protease inhibitors tablet
Lysis buffer (GST proteins)
50mM Tris pH=7.5
150mM NaCl
0.05% NP-40
PKMT buffer x5
50mM Tris pH 8
10% Glycerol
20mM KCl
5mM MgCl2
Ripa buffer
15mM NaCl
50mM Tris-HCl, pH=8
1% NP-40
0.5% DOC
0.1% SDS
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Abstract
Familiar colorectal cancer type X (FCCTX) comprises families that fulfill the Amsterdam criteria for hereditary non-polyposis
colorectal cancer, but that lack the mismatch repair deficiency that defines the Lynch syndrome. Thus, the genetic cause
that increases the predisposition to colorectal and other related cancers in families with FCCTX remains to be elucidated.
Using whole-exome sequencing, we have identified a truncating mutation in the SETD6 gene (c.791_792insA,
p.Met264IlefsTer3) in all the affected members of a FCCTX family. SETD6 is a mono-methyltransferase previously shown to
modulate the NF-jB and Wnt signaling pathways, among other. In the present study, we characterized the truncated ver-
sion of SETD6, providing evidence that this SETD6 mutation may play a role in the cancer inheritance in this family. Here
we demonstrate that the truncated SETD6 lacks its enzymatic activity as a methyltransferase, while maintaining other
properties such as its expression, localization and substrate-binding ability. In addition, we show that the mutant allele is
expressed and that the resulting protein competes with the wild type for their substrates, pointing to a dominant negative
nature. These findings suggest that the identified mutation impairs the normal function of SETD6, which may result in the
deregulation of the different pathways in which it is involved, contributing to the increased susceptibility to cancer in this
FCCTX family.
Introduction
Colorectal cancer (CRC) is the third most common cancer and
the second leading cancer-related cause of death in the world
(1,2). It is estimated that familial risk is involved in up to 30% of
all CRC cases (3,4), although not more than 5–6% are caused by
known germline mutations in cancer-predisposing genes (5).
Hereditary non-polyposis colorectal cancer (HNPCC) is the most
common form of inherited CRC. HNPCC is a familial syndrome
characterized by an increased incidence of CRC and other
extracolonic tumors (6) that has been defined by the
Amsterdam I and II clinical criteria (7,8). Approximately half of
HNPCC families are referred to as Lynch syndrome, since they
are explained by germline inactivating mutations in the mis-
match repair (MMR) genes—including MLH1, MSH2, MSH6 and
PMS2—or by a large deletion in EPCAM (located upstream of
MSH2) (9,10). As a consequence, Lynch syndrome tumors lack
the corresponding MMR proteins and fail to repair DNA through
the mismatch repair pathway. This, in turn, causes microsatel-
lite instability (MSI) and leads to the accumulation of somatic
mutations. It is worth noting that although HNPCC and Lynch
Syndrome used to be employed as synonyms, nowadays HNPCC
is defined by the clinical criteria (Amsterdam I or II), while
Lynch Syndrome refers to the families with MMR defects.
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The other half of HNPCC families are MMR-proficient and
present microsatellite-stable (MSS) tumors. These cases have
been grouped under the term familial colorectal cancer type X
(FCCTX), and the genetic basis underlying their cancer predispo-
sition remains unknown (11). Several studies have reported that
the tumors from FCCTX patients have different molecular and
clinical features than both Lynch syndrome and sporadic CRC
(12,13), suggesting the presence of other forms of genomic insta-
bility. FCCTX’s tumors also show distinct gene expression pro-
files and deregulation of different canonical pathways, although
some similarities have been described between FCCTX and MSS
sporadic tumors (12,14,15). These alterations could result in the
deregulation of genes involved in chromosomal segregation, ge-
nomic instability, apoptosis, proliferation, growth inhibition
and migration (14,16). Nonetheless, FCCTX is a heterogeneous
group of families, and we are still far from fully understanding
the different events that may be involved in their tumor pro-
gression. In the same way, our knowledge regarding the genetic
alterations that contribute to FCCTX’s heredity is fairly limited.
Although previous studies had identified a few genes involved
in the cancer susceptibility of these FCCTX families (17–19), it
was not until the arrival of Next-Generation Sequencing (NGS)
that a larger amount of new cancer-predisposing genes are be-
ing discovered (20). In view of the published results, it seems
that FCCTX does not form a single entity, since multiple differ-
ent genes are thought to be involved in their cancer heritability
(21). However, together they still explain the inheritance in only
a small portion of these FCCTX families. Thus, the identification
of new high-risk genes that contribute to the increased cancer
susceptibility of FCCTX families remains to be a challenge and a
priority.
Covalent post-translational modification (PTM) of proteins is
key for the regulation of many biological processes (22). Among
these modifications, lysine methylation plays a vital role in the
regulation of many cellular signaling pathways (23,24). A lysine
residue in a given protein can accept up to three methyl groups,
forming mono-, di- and tri-methylated derivatives. The most
studied is the methylation of histones, which can either sup-
press or activate gene transcription depending on which lysine
is methylated (25). Similar to histones, non-histone proteins
can be also targeted for methylation with diverse biological out-
comes, such as changes in gene expression, protein stability
and subcellular localization (26–34). Lysine methylation is cata-
lyzed by protein lysine methyltransferases (PKMTs) that trans-
fer a methyl group from a donor S-adenosyl-L-methionine
(SAM) (35–39). Even though there are more than 70 PKMTs pre-
sent in the human proteome, little is known about their enzy-
matic activity beyond histones.
SETD6 (SET domain-containing protein 6) is a member of the
lysine methyltransferase family known to monomethylate
RelA—a subunit of the transcription factor NF-jB—on lysine 310
(RelAK310me1). This methyl mark is recognized by GLP (a his-
tone methyltransferase), which in turn methylates histone H3
on lysine 9, promoting a repressed chromatin state and thereby
silencing the transcription of NF-jB target genes (40). In con-
trast, it was recently reported that SETD6 promotes RelA’s tran-
scriptional activity in bladder cancer (41). Additionally, SETD6
has been proven to participate in the canonical Wnt signaling
cascade by forming a complex with PAK4 (p21-activated kinase
4) and the transcription factor b-catenin at the chromatin, lead-
ing to the activation of b-catenin target gene transcription (42).
In recent studies, SETD6 has also been linked to the regulation
of the nuclear hormone receptor signaling (43), embryonic stem
cell differentiation (44) and oxidative stress response (45,46).
In the present study, we sequenced the whole exome from a
FCCTX family with the aim of identifying new causative cancer-
predisposing genetic variants. Among the different mutations
that were detected, a rare frameshift mutation in the SETD6
gene (resulting in a premature termination of the enzyme) was
identified and further characterized, both in cell-free systems
and in colon cancer cell line models. This mutation causes the
loss of the C-terminal portion of SETD6, leaving an intact cata-
lytic SET domain. Here we demonstrate that, while the trun-
cated protein shows the same subcellular localization and
substrate-binding properties as the wild type, it completely
loses its catalytic activity. We also show that mutant SETD6 is
expressed in the tumor and competes against the wild type in
the ability to methylate its substrate, suggesting a dominant
negative effect. Taken together, our findings support a model by
which a dominant negative mutation in SETD6 may contribute
to FCCTX’s pathology.
Results
Whole-exome sequencing results from FCCTX family
cc598
The whole exome was sequenced from two affected members
and one healthy relative of a FCCTX family (II: 1, II: 2 and II: 3,
Fig. 1A). The corresponding family—known as family cc598—
fulfilled the Amsterdam I criteria (7,8), with four colorectal can-
cers affecting two successive generations and the earliest age at
diagnosis being 34 years old. Supplementary Material, Table S1
shows in detail the clinical data from the different members of
this family.
After rigorous filtering of the variants detected aiming to select
shared rare heterozygote damaging variants, a number of candi-
date genes were prioritized. The candidate variants selected were:
SETD6 c.791_792insA (p.Met264IlefsTer3), CCDC60 c.1558 C>T
(p.Arg20*), L3MBTL1 c.1125 A>G (p.Lys375¼), CCDC62 c.79 C>T
(p.Arg27Trp) and WDR33 c.3266 G>C (p.Arg1089Pro). All the candi-
date variants (detailed in Supplementary Material, Table S2) were
present in the two affected members (II: 1 and II: 2) and absent in
the healthy sibling (II: 3). However, among these, the most relevant
changes in the protein were observed in SETD6.
Rare SETD6 variant cosegregates with CRC within family
cc598
The SETD6 variant was a frameshift mutation known as
c.791_792insA, p.Met264IlefsTer3, or just M264Ifs*3 (rs768456822,
ENST00000310682), and it affected the three main protein-coding
transcripts of this gene (ENST00000310682.6, ENST00000219315.8
and ENST00000394266.8). This mutation consisted of an insertion
of an adenine between positions 791 and 792 of the cDNA and,
like the other candidate variants, was carried by the two affected
members sequenced (II: 1 and II: 2, with CRC diagnosed at ages 64
and 56, respectively), while not present in the healthy sibling (II:
3, 76 years old) (Fig. 1). In addition, the segregation study con-
firmed that the mutation was also present in II: 4 (CRC diagnosed
at 34), while absent in two other healthy relatives (III: 1 and III: 2,
51 and 49 years old, respectively) (Fig. 1 and Supplementary
Material, Fig. S2). The segregation for the other candidate variants
is shown in Supplementary Material, Table S3. Loss of heterozy-
gosity (LOH) analysis of SETD6 c.791_792insA revealed that LOH
did not occur in the tumor of II: 2 (Supplementary Material,
Fig. S2B).
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Figure 1. SETD6 mutation c.791_792insA (p.M264Ifs*3) cosegregates with colorectal cancer in a FCCTX family. (A) Pedigree of family cc598 carrying the SETD6 deleterious
mutation c.791_792insA (p.Met264IlefsTer3). Whole-exome sequencing was done in family members II: 1, II: 2 and II: 3, and segregation was studied in members II: 4,
III: 1 and III: 2. All affected participants were carriers (Mutþ), while the healthy were non-carriers (Mut -). Colorectal cancer (CRC)-affected members are marked in
black. The age at diagnosis (dx) or current age of healthy members is included beneath each individual (in years). (B) Electropherogram of the reverse wild-type and
mutant sequence of the SETD6 gene. The arrows show the point where the adenine is inserted.
A B
C D
Figure 2. SETD6 mutation causes the loss of the C-terminal half of the protein, but the mutant protein is still successfully overexpressed. (A) Amino acid sequence of
SETD6 wt and SETD6-N with the changes marked in bold. (B) Representation of the different domains within the SETD6 protein showing the loss produced by the trun-
cation (top), and the effect that the mutation is predicted to have on the 3D structure by SWISS-MODEL (53) (bottom). (C, D) Overexpression of FLAG-SETD6 (wt, N or C)
in HEK293T (C) or HCT116 (D) cells. SETD6-N is the truncated version of the protein that mimics the mutation found in our family; SETD6-C is a truncated SETD6 that
lacks the N-terminal part of the protein and the SET domain. The different versions of SETD6 were detected by western blot using an anti-FLAG antibody. GAPDH was
used as a loading control.
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On the other hand, although SETD6 c.791_792insA
(p.M264Ifs*3) is not a novel variant, it is quite rare in the general
population, with a minor allele frequency (MAF) of 0.001285 ac-
cording to ExAc and 0.00123 when the TCGA cohort is removed
(47). Moreover, it is not found in the 1000 Genomes Project nor ob-
served in homozygous state in neither of these databases.
Finally, this variant produces a shift in the reading frame of the
codons, and is therefore predicted to be Disease Causing by the
MutationTaster software (48) (score¼ 1), further supporting its
pathogenicity.
SETD6 c.791_792insA (p.M264Ifs*3) results in the loss of
the C-terminal half of the protein
As mentioned above, the identified SETD6 mutation (Fig. 1B)
results in a frameshift with the consequent introduction
of two new amino acids at positions 264 and 265
(ENST00000310682)—Ile264 and Gly265, instead of the original
Met and Ala—followed by a premature stop codon (Fig. 2A).
The resulting truncated SETD6 has an intact SET domain but
lacks the C-terminal half of the protein, which includes a
linker sequence and the whole Rubisco domain, presumably
responsible of mediating protein-protein interactions (49) (Fig.
2B). With the aim of checking whether mutant SETD6 is stable
and normally expressed, a truncated version of the protein
mimicking the frameshift mutation—hereon referred to as
SETD6-N—was cloned and overexpressed. SETD6-N was found
to be expressed to the same extent as wild-type SETD6 both in
HEK293T and HCT116 cells (Fig. 2C and D, respectively). It is
worth noting that an attempt to overexpress the C-terminal
half of SETD6 (containing everything which SETD6-N is miss-
ing) was unsuccessful. Our working hypothesis was that the
premature termination of the protein would impair SETD6’s
cellular function.
SETD6-N shows the same localization pattern as
wild-type SETD6
In order to test if the SETD6 mutation affects its subcellular lo-
calization, HEK293T and HCT116 cells were transfected with
GFP-tagged SETD6 (either SETD6 wt or SETD6-N). Fluorescence
microscopy of the transfected cells revealed that SETD6-N pre-
sented the same distribution within the cell as the wild type,
both of which were mainly concentrated to the nucleus (Fig. 3A
and B). We could detect, however, the presence of speckles in-
side the nucleus of the cells expressing mutant SETD6, which
suggested that the association with the chromatin might be al-
tered. To better understand the localization pattern, both pro-
teins were transfected into cells followed by a biochemical
fractionation of the cytosolic and chromatin fractions (50). This
experiment confirmed a similar subcellular localization be-
tween the mutant and the wild-type, with no significant differ-
ences in the cytosolic fraction (Fig. 3C and D). Some differences
between the wild-type and SETD6-N were only observed at the
chromatin level. To further establish the presence of mutant
SETD6 at chromatin, we used an additional method to extract
the chromatin (see the Materials and Methods section for more
details). This experiment confirmed comparable amounts of
SETD6 wt and SETD6-N at this fraction (Fig. 3E and F). This data
suggests that SETD6-N shows the same chromatin localization
pattern as the wild-type enzyme.
Recombinant SETD6-N binds its substrates to the same
extent as wild-type SETD6
We next performed an ELISA experiment to test whether the
studied mutation would affect the binding ability of SETD6 in a
cell-free in vitro system. To this end, we compared the direct
binding of the wild type and SETD6-N to two well-known
A B C
D E F
Figure 3. SETD6-N shows similar subcellular localization as wild-type SETD6. (A, B) HEK293T (A) and HCT116 (B) cells were transfected with GFP-tagged empty,
SETD6 wt or SETD6-N plasmids. The distribution of GFP within the cells was observed by fluorescence microscopy. (C, D) HEK293T (C) or HCT116 (D) cells were trans-
fected with FLAG-SETD6 (wt or N) and biochemically separated into cytoplasmic (Cyt) and chromatin (Chr) fractions. SETD6 was detected by western blot with an anti-
FLAG antibody. Histone H3 and a-tubulin were used as chromatin and cytoplasmic controls, respectively. (E, F) The chromatin fraction of HEK293T (E) or HCT116 (D)
cells transfected with FLAG-SETD6 (wt or N) was isolated and SETD6 was detected by western blot using the indicated antibodies. Histone H3 was used as a chromatin
control.
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substrates, RelA and PAK4 (40,42). Recombinant RelA and PAK4
were used to coat an ELISA plate, together with BSA, which was
used as a negative control. Recombinant SETD6 wt, SETD6-N
and SUMO were used as tested proteins, with the latter as an-
other negative control. As shown in Figure 4A–C, SETD6-N
bound at equal levels to both substrates as did wild-type SETD6,
which suggests that the mutation does not impair the interac-
tion between SETD6 and its substrates in vitro.
Recombinant SETD6-N fails to methylate its substrates
To compare the enzymatic activity of wild-type SETD6 and
SETD6-N, both proteins were subjected to a cell-free in vitro
methylation assay with RelA and PAK4 as substrates (Fig. 5A
and B, respectively). As expected, both substrates were specifi-
cally methylated by wild-type SETD6. However, no methylation
was observed when SETD6-N was present in the reaction in-
stead. It is of note that SETD6’s automethylation activity was
also lost in the truncated mutant. Consistent with these results,
we found that while the recombinant wild-type SETD6 methyl-
ated immunoprecipitated RelA and PAK4 from HEK293T cells,
SETD6-N failed to do so (Fig. 5C and D, respectively). In a recip-
rocal experiment, we observed that recombinant RelA and PAK4
were specifically methylated by wild-type SETD6 isolated from
human cells and not by SETD6-N (Fig. 5E and F, respectively).
These complementary assays further demonstrate that the
SETD6 truncating mutation identified in the FCCTX family abro-
gates the enzymatic activity of SETD6.
SETD6-N binds its substrates but loses its activity in
colon cancer cells
Since the SETD6 mutation was identified in hereditary colon
cancer patients, we next aimed to confirm our findings in the
colon cancer cell line HCT116. For this purpose, either wild-type
SETD6 or SETD6-N were overexpressed in the presence or ab-
sence of FLAG-RelA (Fig. 6A). As expected, SETD6 wt and SETD6-
N physically interacted with RelA at the chromatin to the same
extent. Consistent with our cell-free in vitro experiments, we
also observed that while SETD6 wt methylated RelA, SETD6-N
did not. The methylation of RelA at the chromatin was identi-
fied using a RelAK310me1 antibody that could specifically
recognize monomethylation of RelA at position K310 (40). The
same results were obtained when PAK4 was used as the sub-
strate (Fig. 6B). These findings support the dominant negative
nature of SETD6 c.791_792insA (p.M264Ifs*3) in a colon cancer
cellular model.
Both wild-type and mutant SETD6 are expressed in the
tumor and compete for their substrates
Last but not least, we aimed to check if SETD6’s mutant allele
was expressed, given that the variant was carried in heterozy-
gosis. To this end, a digital PCR was carried out using two
TaqMan probes that specifically recognized either the wild-type
or the mutant cDNA (with the insertion of the adenine). As ob-
served in Figure 7A and B, the tumor from member II: 2 showed
positive expression of both alleles. As expected, all non-carrier
controls only expressed the wild-type allele.
The fact that both alleles were expressed raised the question
of whether mutant and wild-type SETD6 would compete for
their substrates. In order to address this issue, a cell-free in vitro
methylation competition assay was performed in the presence
of recombinant SETD6 wt and different amounts of recombinant
SETD6-N, using RelA as the substrate. Figure 7C shows how
wild-type SETD6’s activity was inhibited in the presence of
SETD6-N in a concentration-dependent manner, with a signifi-
cant reduction in the amount of methylated substrate even
when the same amount of each form of the enzyme was pre-
sent (lanes 2 and 3, respectively). Finally, a competition assay in
HCT116 cells confirmed the cell-free in vitro results, showing
that the methylation of RelA at K310 in cells is reduced upon
SETD6-N overexpression in a dose-dependent manner (Fig. 7D).
Taken together, these results suggest that the expression of the
mutant allele in the carriers is expected to compete with the en-
zymatic activity of SETD6 wt, supporting a dominant negative
role of this mutation.
Discussion
Familial colorectal cancer type X (FCCTX) is a term used to de-
scribe a heterogeneous group of CRC families for whom the ge-
netic basis underlying their cancer predisposition remains
unknown. Genome-wide analyses of gene expression patterns
A B C
Figure 4. Recombinant SETD6-N shows similar binding to its substrates RelA and PAK4 as wild-type SETD6. (A) Interaction between recombinant SETD6 (wt or N) and
PAK4/RelA determined by an ELISA. The plate was coated with 2 lg of His-PAK4, MBP-RelA or BSA (negative control), and then covered with 0.5 lg of His-SETD6 wt, His-
SETD6-N or His-SUMO (negative control). Bound proteins were detected using a rabbit anti-SETD6 antibody. Data and error bars are from two technical replicates and
represent two independent biological experiments. (B, C) Coomassie staining for the coating (B) and tested (C) proteins used in the ELISA.
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Figure 5. SETD6-N fails to methylate its substrates RelA and PAK4. (A, B) Cell-free in vitro methylation assays in the presence of 3 H-SAM, recombinant His-SETD6 (wt or
N) and either MBP-RelA (A) or His-PAK4 (B). The methylated proteins were detected by autoradiogram (top images), and the input used in the reactions is shown by
Coomassie staining (bottom). (C, D) HEK293T cells were transfected with FLAG-RelA (C), FLAG-PAK4 (D) or empty plasmid. Cell extracts were immunoprecipitated with
anti-FLAG M2 beads, followed by a radioactive cell-free in vitro methylation assay in the presence of 3 H-SAM and recombinant His-SETD6 (wt or N). The methylated
proteins were detected by autoradiogram (top images), and the input used in the reactions was shown by Coomassie staining (bottom). (E, F) HCT116 cells were trans-
fected with either FLAG-SETD6 wt, FLAG-SETD6-N or empty plasmid. Cell extracts were immunoprecipitated with anti-FLAG M2 beads, followed by a radioactive cell-
free in vitro methylation assay in the presence of 3 H-SAM and recombinant MBP-RelA (E) or His-PAK4 (F). The methylated proteins were detected by autoradiogram (top
images), and the input used in the reactions was shown by Coomassie staining (bottom).
A B
Figure 6. SETD6-N binds its substrates RelA and PAK4, while failing to methylate them, in the colon cancer cell line HCT116. (A, B) HCT116 cells were transfected with
either HA-SETD6 wt or HA-SETD6-N plasmids, in the absence or presence of FLAG-RelA (A) or FLAG-PAK4 (B). The chromatin fraction was then immunoprecipitated
with anti-FLAG M2 beads and analysed by western blot with the indicated antibodies.
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in FCCTX in comparison to Lynch syndrome tumors (15) have
shown differences in three major cancer-related pathways: cell
cycle progression, oxidative phosphorylation and G protein-
coupled receptor signaling, all of which have been previously
linked to CRC (51–53). The fact that different genes are ex-
pressed in the tumors of FCCTX and Lynch syndrome patients
may suggest that different molecular mechanisms mediate the
progression of these two pathologies. FCCTX presumably com-
prises different yet-to-be-discovered genetic syndromes involv-
ing high-penetrance mutations in novel cancer-predisposing
genes. However, it is thought that some FCCTX cases would re-
sult from a combination of low-penetrance mutations in differ-
ent genes, or even from aggregation of sporadic cases due to
shared lifestyle factors (5), what makes their study more diffi-
cult. The arrival of Next-Generation Sequencing (NGS) has been
an important milestone in the search for new predisposition
genes that explain the cancer heritability in these families.
Nevertheless, this task is still a challenge and it is believed that
the best strategy is to address each family individually, due to
their wide diversity.
Using whole-exome sequencing, a rare frameshift mutation
in the SETD6 gene was identified in a FCCTX family. This
mutation was found to cosegregate with the disease within the
family, since it was carried by three CRC-affected members (II:
1, II: 2 and II: 4) while absent in three healthy relatives (II: 3, III: 1
and III: 2). No LOH was observed in the tumor of member II: 2,
suggesting that in this family the SETD6 mutation does not fol-
low Knudson‘s two-hit mechanism for tumor suppressor genes,
consistent with a dominant negative nature. Nonetheless, the
LOH does not predict the pathogenicity of a mutation, since it
has been reported to have a dual role in HNPCC families, with
no preferential loss of the wild-type or the mutant allele. As a
matter of fact, different carriers of well-known pathogenic MMR
mutations have been reported to show the three different LOH
statuses (no LOH, LOH of the mutant and LOH of the wild-type),
even within the same family (54).
Regarding the consequences of the studied SETD6 mutation,
this variant results in the introduction of two amino acids at po-
sitions 264 and 265 followed by a premature stop codon. The
truncated protein (SETD6-N) lacks its C-terminal half but retains
an intact SET domain, which is responsible for its catalytic ac-
tivity. Here, we show that mutant SETD6 exhibits dominant
negative properties in cell-free in vitro systems and in a colon
cancer in vitro cell line model. Although mutant SETD6 displays
A
C D
B
Figure 7. Both wild-type and mutant SETD6 are expressed in the tumor and compete for their substrates. (A) Allele-specific expression obtained by digital PCR pre-
sented as Target/Total, where “Target” is the mutant SETD6 allele (detected with the FAM dye). Data from the tumor of II:2 was collected from three independent
experiments, and the error bars correspond to the confidence intervals. The Control represents tumor cDNA from four different sporadic CRC patients used as non-car-
rier controls. (B) Digital PCR visualization of the cDNA from the tumor of member II:2 (top) and a non-carrier control (bottom). The FAM dye detects the mutant allele,
while the VIC dye detects the wild-type allele. (C) Radioactive cell-free in vitro methylation assay in the presence of recombinant wild-type SETD6 and different
amounts (+ and ++) of recombinant SETD6-N. The methylated proteins were detected by autoradiogram (top), and the input used in the reactions is shown by
Coomassie staining (bottom). (D) HCT116 cells were transfected with HA-SETD6 wt, FLAG-RelA and with or without different concentrations (þ and þþ) of HA-SETD6-
N. The chromatin fraction was then immunoprecipitated with anti-FLAG M2 beads and analyzed by western blot with the indicated antibodies.
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similar localization, expression and binding to its known part-
ners as the wild-type, the mutant protein loses its enzymatic
activity. Indeed, unlike wild-type SETD6, SETD6-N lacks both its
automethylation activity and the ability to methylate two previ-
ously identified substrates, PAK4 and RelA (40,42). In addition,
the two alleles (wild type and mutant) were found to be ex-
pressed in the tumor of one of the carriers, and the two forms of
SETD6 were shown to compete for their substrates both in cell-
free systems and in a colon cancer cellular model, pointing to a
dominant negative role. As a result, this mutation may have
several downstream effects on the different pathways in which
SETD6 is involved. For example, SETD6-dependent methylation
of the NF-jB subunit RelA has been shown to be critical for basal
inhibition of NF-jB signaling in the absence of stimulation (40).
The NF-jB family of transcription factors has an essential role
in inflammation and innate immunity, but it has also been in-
creasingly recognized as a crucial player in many steps of can-
cer initiation and progression (55). In fact, activation of the NF-
jB pathway has been positively associated with multiple types
of cancer, including CRC (56). In addition, we had previously
demonstrated that methylation of PAK4 by SETD6 promotes the
activation of the Wnt/b-catenin pathway (42). On the other
hand, deregulation of the Wnt signaling pathway has been
shown to contribute to CRC development, including in HNPCC
(57–60). Thus, the loss of SETD6’s function, together with the ab-
errant regulation of NF-jB and/or Wnt signaling, could contrib-
ute to the initiation or progression of CRC in the studied FCCTX
family. However, since SETD6 has several other substrates and
is involved in numerous other signaling pathways (41,43,45,46),
future studies are needed in order to define the downstream
consequences of this SETD6 truncating mutation that we have
identified.
Given all the results presented above, we propose that the
presence of SETD6’s mutant allele would presumably increase
the cumulative risk of developing colorectal cancer throughout
the life of the carriers, as compared with the general population.
More research should be done in order to determine the pene-
trance of this mutation (that is to say the percentage of individ-
uals who present this variant that will develop the disease,
which is not complete even in well-known pathogenic MMR
variants), whether it is a high, moderate or low-risk allele, and if
there is also an association with other CRC-related cancers.
Interestingly, the same SETD6 frameshift mutation had already
been proposed to be associated with ovarian cancer in an exten-
sive study by Kanchi and colleagues (61). Nonetheless, the
search for new genes by exome sequencing in FCCTX families
has demonstrated that more than one gene can be implicated
in their increased risk of developing cancer. Actually, even
when there is a high-risk gene involved, there might be also
low-penetrance alleles that cooperate in the process as risk
modifiers. Apart from these polygenic approaches, there are
many other factors that might take part in modulating the can-
cer risk, including lifestyle and other environmental factors. For
all these reasons, our results are not enough to claim that
SETD6 alone is responsible for the increased CRC-risk in this
FCCTX family. Hence, it is still difficult to know the effect that
this mutation might have in the other carriers found in the pub-
lic databases, as much as it is hard to predict if they are going to
develop cancer at some point in their life or even if they have al-
ready developed it.
Noteworthy, the whole-exome sequencing followed by rigor-
ous filtering identified additional candidate genes beside SETD6
(Supplementary Material, Table S2). For instance, CCDC60
showed a stop gain variant that results in the loss of 30 amino
acids, 20 of which belong to a domain of unknown function,
while the remaining 10 belong to a low complexity region.
Another candidate was L3MBTL1, located on the long arm of
chromosome 20 within a region that has been previously shown
to be deleted in several malignancies (62). This gene presented a
splicing variant that does not imply the gain or loss of a splicing
acceptor/donor, but that is predicted to create a new exonic
splicing silencer site instead. Finally, missense mutations were
found in CCDC62, previously linked to prostate cancer (63), and
in the polyadenylation regulating factor WDR33 (64). Both vari-
ants affect low complexity regions of the corresponding pro-
teins, and although they are predicted to be damaging in silico,
they do not alter any known protein domains. While the current
paper focuses on SETD6, we cannot exclude the possibility that
the additional candidate variants identified may contribute in-
dependently or together to the pathology of FCCTX.
Together, our findings suggest that a truncating dominant
negative mutation in SETD6 could potentially explain the can-
cer predisposition of this FCCTX family. These results certainly
point to a pathogenic role of SETD6 c.791_792insA (p.M264Ifs*3),
though not enough to prove that SETD6 alone is responsible for
their increased cancer risk. Although no other SETD6 variants
were found in the remaining 12 families that were studied, nor
in 109 familial CRC cases provided by Dr. Castellvi-Bel (Hospital
Clinic, IDIBAPS, Barcelona, Spain), the screening of this gene in
a larger group of patients could provide more insights into its
role in other FCCTX families.
Materials and Methods
Study population
The studied family (cc598) was selected among a group of
FCCTX families collected in the Genetic Counseling Unit at the
Hospital Clı´nico San Carlos of Madrid. All FCCTX families ful-
filled the Amsterdam I or II criteria for HNPCC (7) (at least three
relatives with CRC or other related cancers, one being a first
degree relative of the other two, with at least two successive
generations involved, the earliest age of onset being 50 years
old or lower and familial adenomatous polyposis excluded). In
addition, all the CRC tumors from these families were MSS and
presented normal expression of the MMR proteins. The study
was approved by the Institutional Review Boards of the
Hospital Clı´nico San Carlos, and an informed consent was ob-
tained from each participant. Personal and family histories
were obtained from the proband and participating relatives,
and cancer diagnoses were confirmed by medical and pathol-
ogy records.
Family cc598
Family cc598 (Fig. 1A), selected for the whole-exome study, is an
Amsterdam I family in which the father (I: 1) was diagnosed
with CRC at the age of 80. He had two daughters and two sons,
three of whom were diagnosed with CRC at ages 64 (II: 1), 56 (II:
2) and 34 (II: 4). Only one daughter was healthy (II: 3). The stage
and location of the CRCs developed by II: 1, II: 2 and II: 4 were
pT3N0M1 (splenic flexure, left colon), pT2N0M0 (right colon) and
pT3N1M0 (rectum), respectively. The tumors from members II: 1
and II: 4 were MSS and showed normal expression of the MMR
proteins (MLH1, MSH2, MSH6 and PMS2) (Supplementary
Material, Table S1). The whole-exome sequencing was per-
formed in germline DNA from members II: 1, II: 2 and II: 3.
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DNA and RNA extraction
Germline DNA and RNA were extracted from peripheral blood
using the MagNA Pure Compact extractor system (Roche
Diagnostics), according to the manufacturer’s protocol. The
PAXgene Blood RNA Kit (PreAnalytiX) was used to extract germ-
line RNA conforming to its manual when the patient could not
come to our hospital. Tumor DNA and RNA were extracted from
7 mm-thick haematoxylin/eosin-stained sections of the paraffin-
embedded tumor tissues with a tumor content of more than
80% as determined by two experienced pathologists. Tumor
DNA was extracted using the QIAamp DNA FFPE Tissue Kit from
Qiagen, while tumor RNA was isolated employing the RNeasy
FFPE Kit (Qiagen), according to their corresponding protocols. A
NanoDropVR (ND1000) spectrophotometer was used to assess the
DNA quantity and quality.
Whole-exome sequencing
The whole-exome sequencing was outsourced to Sistemas
Geno´micosVR . Library preparation for the capture of selected
DNA regions was performed according to Agilent‘s SureSelect
protocol for Illumina paired-end sequencing (SureSelectXT
Human All Exon V3, 51 Mb, Agilent Technologies). The final li-
brary size and concentration were determined on an Agilent
2100 Bioanalyzer and a Qubit Fluorometer (Thermo Fisher
Scientific), respectively. Finally, the library was sequenced on
an Illumina HiSeq 2000 platform with paired-end reads of
101 bp, following the manufacturer‘s protocol. Images produced
by the HiSeq 2000 were processed using the manufacturer‘s
software to generate FASTQ sequence files. Reads were aligned
against the human reference genome version GRCh37/hg19 us-
ing the BWA software, creating the BAM files. Low quality reads,
PCR duplicates and other sequences that could introduce major
biases were removed using Picard-tools (http://picard.source
forge.net/) and SAMtools (65). Variant calling was performed us-
ing a combination of two different algorithms [VarScan (66) and
GATK (67)] and the identified variants were annotated using the
HGMD (68) and Ensembl (69) databases.
Filtering and prioritization of the variants
The variants identified by whole-exome sequencing where sub-
sequently filtered as follows: 1. Variants shared by the two af-
fected members but not by the healthy relative were selected. 2.
Homozygous variants were discarded, as well as variants pre-
sent in allosomes. 3. Only coding non-synonymous (missense,
stop gain, stop loss, in-frame, frameshift) and splicing variants
were selected. 4. Variants with a minor allele frequency (MAF)
in the general population greater than 0.01 were eliminated. 5.
Missense and in-frame variants not predicted to be damaging
by in silico programs [SIFT (70), Polyphen (71), MutationTaster
(48)] were discarded, as well as splicing variants not directly af-
fecting the donor/acceptor sites nor predicted to alter the splic-
ing by the Human Splicing Finder (HSF) (72). Finally, the filtered
variants were prioritized according to the genes and pathways
involved.
Variant validation, segregation and loss of
heterozygosity (LOH) studies
All the candidate variants were validated by PCR followed by
Sanger sequencing of the corresponding region of each gene,
using specific primers that were designed with Primer3 (73). The
segregation and LOH studies for the SETD6 variant were also as-
sessed by PCR and subsequent Sanger sequencing of the se-
lected area of the SETD6 gene (exon 7, ENST00000310682). The
segregation study was carried out in germline DNA from the
available members of the family (III: 1 and III: 2). However, al-
though no germline DNA was available from the deceased
member II: 4, we were able to study the segregation in this
member extracting DNA from the paraffin-embedded tumor.
For the LOH analysis, tumor DNA was extracted from the
paraffin-embedded tumor available, and the electropherograms
of the germline and tumor sequences were compared, allowing
the discrimination of the wild-type and the mutant alleles. LOH
was considered when the intensity of any allele was reduced by
50% relative to the other allele. The SETD6 primers used for
the PCRs were CCACTCAGCCCATTCCTAAA (forward) and
TGATACACTCACCCTGTAATGCT (reverse).
Plasmids and cloning
The wild-type SETD6 gene, as well as mutant SETD6 (with the
same variant identified in family cc598), was amplified by high-
fidelity PCR and cloned into pcDNA3.1 and pET-Duet plasmids
for overexpression and protein purification, respectively. The
pcDNA3.1 plasmids in which the two forms of the gene were
subcloned include pcDNA3.1-FLAG, pcDNA3.1-HA and
pcDNA3.1-GFP, for the different experiments. In the same way,
RelA and PAK4 were also cloned into pcDNA3.1-FLAG for the
overexpression experiments (42) and pMAL-c2x or pET-Duet
plasmids (respectively) for the expression and purification of
the recombinant proteins.
Cell lines and transfection
Two different cell lines were used in this study: human embry-
onic kidney cells (HEK293T) and human colon carcinoma cells
(HCT116). Both were maintained in Dulbecco‘s modified Eagle‘s
medium (Sigma-Aldrich, D5671) with 10% fetal bovine serum
(Gibco), 2 mg/ml L-glutamine (Sigma-Aldrich, G7513), 1%
penicillin-streptomycin (Sigma, P0781) and non-essential amino
acids (Sigma-Aldrich, M7145), and they were cultured at 37 C in
a humidified incubator with 5% CO2. For transient transfection,
Mirus transfection reagents (TransITVR -LT1 for HEK293T cells
and TransITVR -X2 for HCT116 cells) were used according to the
manufacturer‘s instructions, together with Opti-MEM serum-
free medium (Gibco).
Western blot analysis
For western blot analyses, cells were homogenized and lysed in
RIPA buffer [50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% Nonidet
P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM DTT, and 1:
100 protease inhibitor mixture (Sigma-Aldrich)], except for the
biochemical fractionation and chromatin immunoprecipitation
experiments, in which the cells were lysed as described below.
Samples were heated at 95 C for 5 min in Laemmli sample buf-
fer, run on a 8-12% SDS-PAGE electrophoresis gel, and then
transferred to a polyvinylidene difluoride (PVDF) membrane.
Membranes were blocked with either 10% skim milk in PBST or
5% BSA in TBST for 1 h on a shaking platform, and subsequently
incubated with primary antibody for another hour with agita-
tion. After three washes with the corresponding buffer (PBST or
TBST), a 30-min incubation with HRP-conjugated secondary an-
tibody and three additional washes, a 2-min reaction with a
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chemiluminiscent substrate (EZ-ECL, Biological industries, 20-
500-120) allowed the visualization of the proteins.
The mouse monoclonal antibodies used were: anti-FLAG M2
(Sigma-Aldrich, F1804), anti-HA (Millipore, 05–904), anti-GAPDH
(Abcam, ab8245), anti-SETD6 (Genetex, GTX629891), and anti-
histone H3 (Abcam, ab10799). The rabbit polyclonal antibodies
used were: an HRP-conjugated pan methyl lysine antibody
(ImmuneChem, ICP0502) and a specific antibody against mono-
methylated RelA-Lys310 developed by Levy et al. (40). HRP-
conjugated secondary antibodies (goat anti-rabbit and goat
anti-mouse) were purchased from Jackson ImmunoResearch
(111-035-144 and 115-035-062, respectively). Antibodies were di-
luted and prepared in PBST with 10% skim milk or in TBST with
5% BSA, according to the manufacturer‘s recommendations.
Biochemical fractionation
Biochemical fractionation was performed as previously de-
scribed by Mendez et al. (50), with the addition of a final resus-
pension of the chromatin pellet for 30 min on ice in RIPA buffer
with 1 mM MgCl2 and benzonase nuclease enzyme (Sigma-
Aldrich). The chromatin fraction was obtained by the collection
of the supernatant after low-speed centrifugation (5 min, 1700 g,
4 C).
Recombinant protein expression and purification
The Escherichia coli BL21-derivative Rosetta host strain was
transformed with pET-Duet plasmids containing the gene of
interest (SETD6 wt, SETD6-N, PAK4 or RelA) and grown over-
night in 3 ml LB mediumþ100 lg/ml ampicillin (37 C, 220 rpm).
The culture was then expanded to 100 ml LB medium and in-
cubated at 37 C until the absorbance (OD) reached values of
0.6–0.8, when it was induced with 1: 10000 IPTG and left over-
night at 18 C and 220 rpm. After IPTG induction, the bacteria
were harvested by centrifugation (10 min, 12000 rpm, 4 C), re-
suspended in cold lysis buffer (10 mM imidazole, 1% PMSF,
protease inhibitor cocktail, 0.1% triton and PBS) and then lysed
by sonication on ice (25% amplitude, 1 min 30 s, 10 s on/5 s off).
Finally, the lysate was centrifuged (20 min, 4 C, 18000 rpm)
and filtered, and the His-tagged proteins were purified using
an A¨KTATM column.
ELISA
A high-binding 96-well polystyrene microplate (Greiner Bio-One
MICROLONVR ) was coated with 2 mg of the recombinant proteins
of interest (His-PAK4, MBP-RelA or BSA) diluted in PBS. The plate
was blocked with 3% BSA in PBST and subsequently covered
with 0.5 mg of the recombinant tested proteins (His-SETD6 wt,
His-SETD6-N or His-SUMO as a control) diluted in 1% BSA in
PBST. The rabbit polyclonal anti-SETD6 primary antibody (40)
was then added, followed by incubation with an HRP-
conjugated secondary antibody (goat anti-rabbit, 1: 2000;
Jackson ImmunoResearch, 111-035-144). All the incubation
steps were performed at room temperature with vigorous agita-
tion for 1 h, and followed by three washes with PBST. After the
final washes, 100 ll of TMB reagent were added to each well,
succeeded after a few minutes by the same amount of 1 N
H2SO4, in order to stop the reaction. The absorbance at 450 nm
was then detected using an InfiniteVR M200 plate reader (Tecan).
All samples were analysed in duplicates.
Cell-free in vitromethylation assay
Cell-free in vitro methylation reactions with recombinant pro-
teins took place in a final volume of 25 ll, containing 4 lg of sub-
strate (His-PAK4 or MBP-RelA), 4 lg (or increasing amounts for
the competition assay) of His-SETD6 (either wt or N), 2 mCi of
3 H-labeled S-adenosyl-methionine (SAM) (AdoMet, Perkin-
Elmer) and PKMT buffer (20 mM Tris-HCl, pH 8, 10% glycerol,
20 mM KCl, 5 mM MgCl2). The reaction tubes were incubated
overnight at 30 C and then resolved by SDS-PAGE electrophore-
sis and subsequent autoradiogram. For the immunoprecipita-
tion followed by cell-free in vitro methylation, human cells were
transfected with empty, FLAG-SETD6 wt, FLAG-SETD6-N, FLAG-
RelA or FLAG-PAK4 pcDNA3.1 plasmids, and 24 h post-
transfection they were lysed with RIPA buffer and pulled down
overnight with anti-FLAG M2 Affinity gel beads (Sigma-Aldrich,
A2220) on a rotor at 4 C. After two washes in RIPA buffer and
another two in PKMT buffer, samples were subjected to an on-
beads cell-free in vitro methylation assay as described above.
Protein–protein chromatin immunoprecipitation
Protein-protein chromatin immunoprecipitation was modified
from a published protocol (74). After cross-linking, cells were
harvested and washed twice with PBS and then lysed in 1 ml of
lysis buffer (20 mM Tris-HCl, pH 8, 85 mM KCl, 0.5% Nonidet
P-40, and 1: 100 protease inhibitor mixture) for 10 min on ice.
Nuclear pellets were resuspended in 200 ll of nuclei lysis buffer
(50 mM Tris-HCl pH 8, 10 mM EDTA, 1% SDS, 1: 100 protease in-
hibitor mixture) for 10 min on ice, and sonicated (Bioruptor,
Diagenode) with high power settings for three cycles of 6 min
each (30 s on/off). Samples were then centrifuged (20 min,
13000 rpm, 4 C), and the soluble chromatin fraction was col-
lected. The FLAG-labeled substrates present in the soluble chro-
matin were then immunoprecipitated overnight on a rotor at
4 C, using 20 ll per tube of anti-FLAG M2 Affinity gel beads
(Sigma-Aldrich, A2220). The beads were then washed according
to the published protocol, heated for 30 min in Laemmli sample
buffer at 95 C, and resolved on 10-12% SDS-PAGE gels followed
by western blot analyses.
Reverse transcription polymerase chain reaction and
digital PCR
Reverse transcription polymerase chain reaction (RT-PCR) was
performed to convert RNA into complementary DNA (cDNA) us-
ing the PrimeScript RT Reagent Kit (Perfect Real Time) (Takara,
Clontech), following the kit’s instructions. For the expression
assays, a TaqMan digital PCR (dPCR) was carried out taking ad-
vantage of the QuantStudioTM 3 D Digital PCR System (Thermo
Fisher Scientific), according to the manufacturer’s recommen-
dations. The primers and TaqMan probes used in the dPCR were
designed with the Custom TaqManVR Assay Design Tool
(Thermo Fisher Scientific) and produced by the same company.
The FAM probe specifically identified the mutant transcript,
while the VIC probe only recognized the wild type. The dPCR
was used to analyse the cDNA from the paraffin-embedded tu-
mor of member II: 2. Tumor cDNA from four sporadic CRC pa-
tients were used as non-carrier controls.
Supplementary Material
Supplementary Material is available at HMG online.
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Abstract
Half of the high-risk colorectal cancer families that fulfill the clinical criteria for Lynch syn-
drome lack germline mutations in the mismatch repair (MMR) genes and remain unex-
plained. Genetic testing for hereditary cancers is rapidly evolving due to the introduction of
multigene panels, which may identify more mutations than the old screening methods. The
aim of this study is the use of a Next Generation Sequencing panel in order to find the genes
involved in the cancer predisposition of these families. For this study, 98 patients from these
unexplained families were tested with a multigene panel targeting 94 genes involved in
cancer predisposition. The mutations found were validated by Sanger sequencing and the
segregation was studied when possible. We identified 19 likely pathogenic variants in 18
patients. Out of these, 8 were found in MMR genes (5 in MLH1, 1 in MSH6 and 2 in PMS2).
In addition, 11 mutations were detected in other genes, including high penetrance genes
(APC, SMAD4 and TP53) and moderate penetrance genes (BRIP1, CHEK2, MUTYH,
HNF1A and XPC). Mutations c.1194G>A in SMAD4, c.714_720dup in PMS2, c.2050T>G in
MLH1 and c.1635_1636del in MSH6 were novel. In conclusion, the detection of new patho-
genic mutations in high and moderate penetrance genes could contribute to the explanation
of the heritability of colorectal cancer, changing the individual clinical management. Multi-
gene panel testing is a more effective method to identify germline variants in cancer patients
compared to single-gene approaches and should be therefore included in clinical
laboratories.
Introduction
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is a familial syndrome with an
increased incidence of colorectal (CRC) and other related cancers [1,2], defined by the
Amsterdam I or II clinical criteria. It is well established that approximately half of HNPCC
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cases are explained by germline mutations in the DNA mismatch repair (MMR) genes, mainly
MLH1, MSH2, MSH6 and PMS2. As a consequence, these cases present MMR pathway defects
and microsatellite instability (MSI) in the tumors, and are referred to as Lynch Syndrome (LS)
[3,4].
The universal screening for LS currently comprises two different stages. Firstly, the immu-
nohistochemistry (IHC) of the MMR proteins and/or the MSI status is studied in the tumor of
every CRC patient, as well as in some endometrial cancers [5,6]. When this result is positive
(MSI/absence of MMR) or if the tumor is not available, patients with a family history of CRC
are then screened for germline mutations in the MMR genes, which was previously performed
by methods such as Denaturation Gradient Gel Electrophoresis (DGGE) or High Resolution
Melting (HRM), followed by Sanger sequencing of samples with altered patterns. Initially, can-
didates for this LS genetic testing were identified based on the Amsterdam criteria [7,8] How-
ever, these algorithms may miss some individuals with LS [9], reason for which the more
lenient Bethesda guidelines were created to identify high-risk families that should undergo
genetic testing. Although all of these are effective screening tools, they may still miss a propor-
tion of patients with LS. It is worth noting that the IHC and MSI tests have lower sensitivity
for detecting MSH6 and PMS2 mutation carriers in particular [9], and that the screening of
PMS2 is a challenge due to the high number of pseudogenes.
After this screening, only those families in which a germline pathogenic mutation is found
in one of the MMR genes are diagnosed with Lynch Syndrome. Those cases that show MSI/
MMR defects in the tumor but lack the corresponding germline MMR mutations are classified
as unexplained MMR deficiency, whereas the other half of HNPCC families with no evidence
of MMR deficiency has been designated Familial Colorectal Cancer Type X (FCCTX) [10–13].
FCCTX patients lack germline MMR mutations and their tumors are microsatellite stable
(MSS). The lack of information about the hereditability of cancer risk in all these unexplained
families makes it difficult to carry out an individualized genetic counseling.
Next-generation sequencing (NGS) has revolutionized cancer genomics research, and can
be used to search for Mendelian disease genes in an unbiased manner by sequencing the entire
protein-coding sequence of known predisposition genes [14]. The practice of genetic testing is
rapidly evolving owing to the recent introduction of multigene panels for the diagnosis of
hereditary cancer [15]. Multigene panels can be a cost and time-effective alternative to sequen-
tially testing multiple genes. Virtually all multigene panels include high-penetrance genes that
establish the risk of a particular type of cancer (such as breast or colon), but also many moder-
ate and low-risk genes. This challenges the personalized management of guidelines when a
pathogenic mutation is found, since the phenotypic spectrum and penetrance are less defined
or unknown for the latter [16]. The TruSight Cancer Sequencing Panel has been developed by
Illumina in collaboration with experts in cancer genomics, and targets a set of 94 well-known
cancer-predisposing genes.
The purpose of the present study is the use of multigene panel testing for the diagnosis of
hereditary cancer in individuals from high-risk colorectal cancer families.
Methods
Patient selection
A total of 1204 high-risk CRC families have been referred for genetic counseling and/or gene
testing for Lynch Syndrome at the Cancer Genetic Clinic of Hospital Clinico San Carlos
between the years 2000 and 2016. Among them, 393 families fulfilled the Amsterdam I/II or
Bethesda clinical criteria and were molecularly characterized by the study of MSI and/or
MMR protein expression in the tumor, and the screening of germline MMR gene mutations
NGS gene panel for diagnosis of hereditary CRC
PLOS ONE | https://doi.org/10.1371/journal.pone.0203885 September 26, 2018 2 / 14
(MLH1, MSH2, MSH6, PMS2 and EPCAM, located upstream of MSH2) by HRM followed by
Sanger sequencing [17,18]. Only 141 families in which a pathogenic germline MMR mutation
was found were diagnosed with Lynch Syndrome, while the rest of the families could not be
explained by these single-gene analyses. Other genes such as POLE, POLD1 and NTHL1were
also studied with no positive outcome.
For the present study, we selected 98 patients from those unexplained high-risk CRC fami-
lies for the test of a multigene cancer panel by NGS (Fig 1). The prioritization of the families
was based on the absence of MMR proteins, presence of MSI, lower age at diagnosis or higher
number of cancer patients in the pedigree. An MLH1 mutation carrier was added as a positive
control. Participants were asked to donate 10ml of blood at the time of their initial visit. Per-
sonal and family histories were obtained from the proband and participating relatives, and
cancer diagnoses were confirmed by medical and pathology records. A written informed con-
sent was signed by each participant, and the study was approved wirh an internal code n˚ 16/
204-E_BS by the Clinical Investigation Ethics Committee (CEIC) from the Hospital Clinico
San Carlos.
Genomic DNA extraction
Peripheral-blood genomic DNA was extracted with the MagnaPure Compact extractor
(Roche, Switzerland) according to the manufacturer’s recommended protocol. DNA concen-
tration was measured by Nanodrop (Life Technologies, USA) and Qubit (Life Technologies,
USA). The DNA integrity was evaluated by agarose gel electrophoresis.
Next generation sequencing of multiplex PCR amplicons
The patients were tested with the TruSight Cancer Sequencing Panel, targeting 94 genes
known to play a role in cancer predisposition (S1 Table). The kit includes more than 5,000
highly-optimized probes (80 mer) that cover the genes and that have been constructed against
the human NCBI37/hg19 reference genome. The integrated sample preparation and sequenc-
ing was done following the protocol from Illumina, using the Nextera enrichment method and
as little as 50ng of DNA for the library. The NGS workflow is summarized in Fig 1.
Fig 1. Next generation sequencing workflow using the TruSight cancer sequencing panel.
https://doi.org/10.1371/journal.pone.0203885.g001
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Data analysis
Sequencing data was analyzed by the MySeq Reporter Software. After the demultiplexing and
FASQ file generation, the reads were aligned against the Homo sapiens reference genome hg19
to create the BAM files. The genome analysis software Toolkit was used to perform the variant
calling and generate the VCF files. After this, Variant Studio 3.0 was used for the variant filter-
ing and annotation. Only variants with 95% of exon covered, labeled as “PASS”, with a mini-
mum coverage of 20X and a minor allele frequency (MAF) <0.03 were selected. The variants
present in more than 10 different patients were discarded. Regarding the consequence, we
only considered missense, nonsense, splicing, in frame and frameshift variants.
Copy number variation analysis
In order to look for DNA copy number variations (CNVs), the BAM files obtained by NGS
were analyzed using the Enrichment v3.0.0 app from Illumina’s BaseSpace. Those CNVs
observed with a quality value greater than 4 and a length greater than 10kb were labeled as
“PASS” and selected for further evaluation. Variants present in 4 or more different patients
were discarded. The areas affected by potential variations were then examined by the Database
of Genomic Variants (DGV) [19] and the Integrative Genomics Viewer (IGV) [20]. CNVs
with a frequency above 1% and described by at least two studies were also eliminated. Multi-
plex ligation-dependent probe amplification (MLPA) was finally carried out in samples 786
and 2954 to confirm BRCA2,MSH2 and EPCAM structural variations using SALSA MLPA
probe mixes P045, P003 and P072-B2 (MRC-Holland, Netherlands), according to the manu-
facturer’s protocol.
Confirmation of the variants
All clinically actionable variants identified by NGS were validated by Sanger sequencing on a
3130 Genetic Analyzer, with the BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo
Fisher Scientific, USA). Sequencing data was aligned against the appropriate reference
sequences and analyzed using the Sequencing Analysis Software v5.3.1 (Gene Codes Corp.,
USA). Unconfirmed variants were eliminated from the results.
Annotation and variant classification
Variants were annotated according to nomenclature recommendations from the Human
Genome Variation Society (www.hgvs.org/mutnomen) and further categorized according to
the American College of Medical Genetics and Genomics [21] as: benign (class 1), likely
benign (class 2), uncertain significance (class 3), likely pathogenic (class 4) and pathogenic
(class 5). The following public databases were used for the interpretation of the variants: Clin-
Var (https://www.ncbi.nlm.nih.gov/clinvar/), UMD (http://www.umd.be/), InSight (https://
www.insight-group.org/variants/databases/), COSMIC (https://cancer.sanger.ac.uk/cosmic)
and Ensembl (http://www.ensembl.org/). Last access: April 2018. Four different in silico pro-
grams were used for the damage prediction of missense variants (Sift, Provean, PolyPhen-2
and MutationTaster).
Data accesibility
Sequencing data have been deposited at the NCBI SRA archive with BioProject record
PRJNA474807 and SRA accession SUB4117212.
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Results
Patient samples
Germline DNA was analyzed from 98 patients belonging to high-risk CRC families using the
Illumina TruSight Cancer Sequencing Panel, which targets a set of 94 genes known to play a
role in cancer predisposition. All patients had been previously tested for Lynch Syndrome by
IHC/MSI analyses in the tumor and/or germline MMR single-gene mutation screening, with a
negative result for the latter. Characteristics of the studied cohort are detailed in Table 1. The
studied families were predominantly affected by CRC; however, other malignancies were
observed in some family members, including endometrial, gastric, ovarian, breast, renal and
pancreatic cancers. The mean age at diagnosis was 49.1 years old. Most of the carcinomas had
an MSS phenotype and presence of the MMR proteins in the tumor. Only 11 patients showed
an MSI phenotype, 7 of which had absence of at least one MMR protein (but with no germline
MMR mutations detected). The majority of CRCs were Dukes B or C, and nearly all were left-
sided.
Results from the NGS targeted sequencing
Among the 98 patients, we found 19 pathogenic or likely pathogenic variants in 18 patients
(18.4%), all of which were validated by Sanger sequencing. Table 2 shows the clinical and
molecular features of the patients with these mutations. Out of the 18 patients, 8 had MLH1/
Table 1. Clinical and molecular characteristics of the 98 probands.
Amsterdam I
(N = 31)
Amsterdam II
(N = 22)
Bethesda (N = 45) Total n˚
(N = 98)
Gender
M 14 12 20 46
F 17 10 25 52
Diagnosis age
<50 19 6 31 56
>50 12 16 14 42
Tumor type
CRC 31 18 42 91
Breast 0 0 1 1
Gastric 0 1 1 2
Other tumors 0 3 1 4
MSI result
MSI 6 1 4 11
MSS 19 17 27 63
Unknown 6 4 14 24
IHC result
MMR-presence 21 16 18 55
MMR-absence 4 1 4 9
Unknown 6 5 23 34
MMR gene test
MMR wt 28 21 33 82
Unknown 3 1 12 16
N: number of patients; M: male; F: female; CRC: colorectal cancer; MSI: microsatellite instability; MSS: microsatellite
stable; IHC: immunohistochemistry; MMR: mismatch repair; wt: wild type.
https://doi.org/10.1371/journal.pone.0203885.t001
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MSH6/PMS2mutations and 10 carried non-MMR mutations. Four out of the 8 patients with
MMR mutations had MSI tumors and absence of the corresponding MMR proteins, while
another 3 patients had a discordant tumor screening: one (ID 820) with a frameshift mutation
in PMS2, c.714_720dup (MSI/presence of PMS2), another (ID 7400) with a splicing mutation
in MLH1, c.1731+4A>G (MSS/absence of MLH1/PMS2), and the last (ID 7934) with a mis-
sense mutation in MLH1, c.677G>T (MSI/presence of MLH1/PMS2). Patient ID 555 carried
two MMR variants, one in MLH1 (c.2050T>G, p.Y684D) and another in PMS2 (c.825A>T, p.
Q275H). This patient was diagnosed of CRC at 35 years old, belonged to an Amsterdam I fam-
ily and had an MSI tumor with absence of MLH1/PMS2. In silico studies of both mutations
showed that the PMS2 mutation was neutral while the MLH1 mutation was predicted to be
highly damaging. On the other hand, all of the 10 families with pathogenic variants in non-
MMR genes showed MSS tumors, and in one of the families (patient ID 1041) we found two
pathogenic variants in MUTYH (Table 2). From the remaining patients, 55 (56.1%) were
revealed to only carry variants of unknown significance (VUS) in 38 different genes (S2
Table), while 25 (25.5%) just carried polymorphisms.
It is worth noting that, in total, only three splicing variants were not validated by Sanger
sequencing (EZH2 c.1947+1G>T, MSH2 c.942+2T>G and MLH1 c.1059-1G>A) and were
eliminated from the data. The CNVs were also analyzed as described in Materials and Methods
(S3 Table). However, potential structural variations were discarded by the study of SNPs in the
corresponding chromosome localization using IGV. It was not possible to analyze some CNVs
Table 2. MMR status in tumors from patients with selected variants identified by the TruSight cancer sequencing panel.
Patient ID Family
Criteria
Cancer
Type
Dx Age MMR status
(MLH1 / MSH2 / MSH6 / PMS2)
Mutations detected by TruSight Cancer Panel
MSI IHC HRM Gene Variant
499 BETH CRC 63 MSS Presence Wild Type BRIP1 c.903del (p.L301FfsTer2)
555 AMS I CRC 35 MSI-H Absence MLH1/PMS2 Wild Type MLH1 c.2050T>G (p.Y684D)
763 AMS I CRC 47 MSS Presence Wild Type CHEK2 c.349A>G (p.R117G)
820 AMS I CRC 44 MSI-H Presence Wild Type PMS2 c.714_720dup (p.F242HfsTer9)
987 AMS I CRC 62 MSS Presence Wild Type SMAD4 c.1194G>A (p.W398Ter)
1041 BETH CRC 60 MSS Presence Wild Type MUTYH c.1187G>A (p.G396D)
c.1227_1228dupGG (p.E410GfsTer43)
1144 AMS I CRC 45 MSI-H Absence MLH1/PMS2 Wild Type MLH1 c.2141G>A (p.W714Ter)
1564 AMS II CRC 58 MSS Presence Wild Type HNF1A c.92G>A (p.G31D)
1652 BETH CRC 62 MSS Presence Wild Type XPC c.1001C>A (p.P334H)
1756 BETH CRC 31 MSI-H Absence MLH1/PMS2 Wild Type MLH1 c.1896+2T>C
1803 AMS II CRC 79 MSS Presence Wild Type MUTYH c.536A>G (p.Y179C)
1936 AMS I CRC 47 MSI-H Absence MSH2/MSH6 Wild Type MSH6 c.1635_1636delAG (p.E546GfsTer16)
2291 AMS I CRC 51 ND ND Wild Type PMS2 c.903G>T (p.K301N)
2456 AMS II Ovary 35 MSS Presence Wild Type TP53 c.783-1G>A
2910 BETH CRC 39 MSS Presence Wild Type APC c.3199C>T (p.Q1067Ter)
3775 AMS I CRC 47 MSS Presence Wild Type MUTYH c.1187G>A (p.G396D)
7400 AMS II CRC 39 MSS Absence
MLH1/PMS2
Wild Type MLH1 c.1731+4A>G
7934 BETH CRC 35 MSI-H Presence ND MLH1 c.677G>T (p.R226L)
BETH: Bethesda; AMS I/II: Amsterdam I and II; CRC: colorectal cancer; Dx Age: age at diagnosis; MMR: mismatch repair; MSS: microsatellite stable; MSI-H:
microsatellite instablility-high; IHC: immunohistochemistry; HRM: high resolution melting (for germline screening); ND: not determined.
https://doi.org/10.1371/journal.pone.0203885.t002
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due to the low coverage or absence of SNPs in the region. Three CNVs affecting BRCA2,
MSH2 and EPCAMwere not confirmed in 2 of the samples (786 and 2954) by MLPA.
Type, prediction and frequency of likely pathogenic mutations by gene
Out of the 19 germline pathogenic or likely pathogenic mutations detected, 8 (42.1%) were
found in MMR genes (5 in MLH1, 1 in MSH6 and 2 in PMS2). The remaining 11 mutations
were detected in other cancer predisposing genes, including BRIP1 (n = 1), CHEK2 (n = 1),
SMAD4 (n = 1), MUTYH (n = 4), HNF1A (n = 1), XPC (n = 1), TP53 (n = 1), and APC (n = 1).
The type, prediction and frequency of all the mutations can be observed in Table 3. Among
them, there were 9 missense, 4 frameshift, 3 stop-gained and 3 splice site variants. All these
variants were rare, and 11 had frequency data not available (NA) in ExAc nor in GnomAD
(Table 3). 15 of these mutations were classified as pathogenic or likely pathogenic by the Clin-
Var and/or InSight databases, following the 5-tier classification system proposed by Plon and
colleagues [22]. In addition, 4 of them did not appear in any of the variant databases men-
tioned earlier, but were considered likely pathogenic due to the type of mutation, in silico pre-
dictions and/or the molecular features of the tumor. These novel variants were: SMAD4
c.1194G>A, PMS2 c.714_720dup, MSH6 c.1635_1636del and MLH1 c.2050T>G.
Segregation studies
Unfortunately, segregation studies could not be performed in most of the families, given the
unavailability of other family members. Among the few families in which the segregation was
Table 3. Pathogenic and likely pathogenic variants by gene identified by the TruSight cancer sequencing panel.
Patient
ID
Family
Criteria
Gene Variant (c.) Variant (p.) Type of Mutation Prediction Database Frequency (ExAC)
499 BETH BRIP1 c.903delG p.Leu301PhefsTer2 Frameshift Pathogenic ClinVar NA
555 AMS I MLH1 c.2050T>G p.Tyr684Asp Missense Likely Pathogenic# Novel NA
763 AMS I CHEK2 c.349A>G p.Arg117Gly Missense Likely Pathogenic ClinVar 0.00013
820 AMS I PMS2 c.714_720dup p.Phe242HisfsTer9 Frameshift Pathogenic Novel NA
987 AMS I SMAD4 c.1194G>A p.Trp398Ter Stop gained Pathogenic Novel† NA
1041 BETH MUTYH c.1187G>A
c.1227_1228dup
p.Gly396Asp
p.Glu410GlyfsTer43
Miss, SP region
Frameshift
Pathogenic
Pathogenic
ClinVar, InSiGHT
ClinVar, InSiGHT
0.00280
0.00015¶
1144 AMS I MLH1 c.2141G>A p.Trp714Ter Stop gained Pathogenic ClinVar, InSiGHT NA
1564 AMS II HNF1A c.92G>A p.Gly31Asp Missense Likely pathogenic ClinVar 0.00071
1652 BETH XPC c.1001C>A p.Pro334His Missense Likely pathogenic ClinVar 0.00286
1756 BETH MLH1 c.1896+2T>C - Splice donor Likely pathogenic ClinVar, InSiGHT NA
1803 AMS II MUTYH c.536A>G p.Tyr179Cys Missense Pathogenic ClinVar, InSiGHT 0.00162
1936 AMS I MSH6 c.1635_1636del p.Glu546GlyfsTer16 Frameshift Pathogenic Novel NA
2291 AMS I PMS2 c.903G>T p.Lys301Asn Miss, SP region Likely Pathogenic ClinVar, InSiGHT 0.000008
2456 AMS II TP53 c.783-1G>A - Splice acceptor Pathogenic ClinVar, IARC TP53 NA
2910 BETH APC c.3199C>T p.Gln1067Ter Stop gained Pathogenic ClinVar, InSiGHT NA
3775 AMS I MUTYH c.1187G>A p.Gly396Asp Miss, SP region Pathogenic ClinVar, InSiGHT 0.00280
7400 AMS II MLH1 c.1731+4A>G - Splice donor Likely Pathogenic ClinVar, InSiGHT NA
7934 BETH MLH1 c.677G>T p. Arg226Leu Miss, SP region Likely Pathogenic ClinVar, InSiGHT NA
BETH: Bethesda; AMS I/II: Amsterdam I and II; Miss: missense; SP: splicing; NA: not available
#predicted to be probably damaging by in silico tools
only causal in homozygosis or in co-occurrence with other mutations
†described in COSMIC
¶frequency data from gnomAD exomes.
https://doi.org/10.1371/journal.pone.0203885.t003
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studied is the one with the MLH1 c.2050T>G mutation (ID 555). However, this was not very
informative, since all the affected members were deceased and only healthy relatives could be
tested. Out of the 4 members analyzed, only one carried the variant but was too young to have
developed the disease. On the other hand, in the family of ID 1144 (MLH1 c.2141G>A) 9 rela-
tives were studied, one of whom had developed CRC at the age of 56. As expected, this affected
member was shown to carry the mutation, together with another 5 healthy members who were
all under 60 (3 of them especially young) and will follow the surveillance recommendations of
the Genetic Counseling Unit. For the CHEK2 variant (c.349A>G), only one distant relative
with polyps could be tested and was wild type for the mutation. However, this member also
had a CRC history coming from the other side of the family, so no conclusions can be drawn
from this result. Finally, the son of participant ID 3775 (monoallelic MUTYH c.1187G>A
mutation) was also evaluated with a negative result. Although this member had also been
reported to have some polyps, not much information was available.
Frequency of VUS in cancer susceptibility genes
All the variants found by NGS were analyzed by ClinVar, and those variants classified as class
3 were selected as VUS. Only those VUS with a very low frequency (<0.005) in ExAc are
included in S2 Table. The VUS in cancer genes can be grouped by their functional effect; Fig
2A shows that most of the VUS selected were located in genes involved in DNA repair mecha-
nisms, tumor suppressor genes and proto-oncogenes. Fig 2B shows that the relationship
between the number of patients and the number of variants per patient is inversely propor-
tional: 33 patients had 1 VUS, while only one patient (ID 1008) had 5 VUS, and was curiously
a patient with a strong family history. Eleven patients (IDs 499, 763, 820, 987, 1041, 1144,
1564, 1652, 1936, 3775 and 7934) with VUS also had a concomitant deleterious mutation (data
Fig 2. Class 3 variants found in genes implicated in hereditary cancer and clinical experience. A) Number of rare
VUS (MAF<0.005) per gene or group of genes, in those cancer susceptibility genes with at least 2 filtered VUS. The
different FANC, ERCC and SDH genes were grouped together for simplification. B) Number of unclassified variants
per patient of the study cohort. C) Clinical practice experience with multigene panel study. VUS: variants of unknown
significance.
https://doi.org/10.1371/journal.pone.0203885.g002
NGS gene panel for diagnosis of hereditary CRC
PLOS ONE | https://doi.org/10.1371/journal.pone.0203885 September 26, 2018 8 / 14
shown in Tables 3 and S2 Table). Among the 55 patients that carried only VUS (56.1%), 31 ful-
filled the Amsterdam I/II clinical criteria.
Discussion
Approximately half of HNPCC families carry a germline, pathogenic mutation in one of the
MMR genes and are thus considered Lynch Syndrome families. The other half does not pres-
ent any evidence of MMR deficiency and the genetic basis underlying their cancer predisposi-
tion remains unknown, reason for which they are called FCCTX [13,23,24]. However,
unexplained families also comprise cases which present MMR defects and/or MSI in the
tumors but lack the corresponding germline MMR mutations. All together, these families rep-
resent a significant number of cases at the Genetic Counseling Units and they are considered a
problem in the clinic. Despite this, the genetic understanding of hereditary CRC syndromes
has grown over the years, leading to an increasing request for genetic testing [25]. The limita-
tion of the old screening methods due to their lower sensitivity and the reduced number of
genes studied has led to the rise of multigene panel testing in oncology [16,26], and given the
advantages of analyzing multiple genes, the benefits of its application in the clinical practice
are obvious [15,27].
In this study, 98 unexplained families were reanalyzed using Illumina’s NGS TruSight Can-
cer Sequencing Panel, which targets 94 genes known to play a role in cancer predisposition.
The panel testing identified 8 MMR mutations in our cohort (5 in MLH1, 1 in MSH6 and 2 in
PMS2), 7 of which were found in patients whose tumors showed an altered MMR status (MSI
and/or absence of MMR). These cases were missed by our prior screening, and are thus a result
from improved testing for these genes. Although these patients represent most of the Lynch-
suspected families included in our study, there were another 6 families that were not resolved.
The panel also allowed the identification of mutations in other well-known CRC high-pene-
trance genes, such as MUTYH (biallelic), APC, SMAD4 and TP53, as well as in moderate-pene-
trance genes like MUTYH (monoallelic), CHEK2,HNF1A, BRIP1 and XPC. In total, pathogenic
or likely pathogenic mutations were found in 18.4% of our cohort, while high-penetrance muta-
tions represented 12.2% of the studied patients.
Four of the identified variants were novel and had not been previously described in
any of the variant databases checked (ClinVar, InSiGHT and UMD), although SMAD4
c.1194G>A had been reported at somatic level in COSMIC. There is enough evidence to
claim that the 3 deleterious novel variants (SMAD4 c.1194G>A, PMS2 c.714_720dup and
MSH6 c.1635_1636del) are pathogenic, so they will be added to the public databases for
future reference. Regarding the missense variant (MLH1 c.2050T>G), it was present in a
patient whose tumor was MSI with absence of MLH1/PMS2. In addition, in silico studies
showed the change as likely pathogenic. However, the segregation studies performed were
not very informative given the lack of affected living relatives, so more studies are needed in
order to confirm the pathogenicity of this variant.
Among all the non-MMR genes, APC, MUTYH and SMAD4 are well known to be impli-
cated in CRC, specifically in polyposis. It is worth noting that the patient in which the APC
mutation was found had over 30 polyps. However, APC as well as other polyposis-associated
genes had already been screened with no positive results (data not shown). For that reason, the
family was added to our study on the grounds that it fulfilled the Bethesda criteria. Like the
MMR mutations identified, this variant represents a false-negative of previous screenings.
Regarding the biallelic MUTYH carrier, there was no information of the presence of polyps at
the time of patient selection, but a deeper look into the family history revealed that the patient
did present multiple polyps. On the contrary, neither the SMAD4 nor the 2 monoallelic
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MUTYHmutation carriers showed any sign of polyposis to our knowledge. Nevertheless, the
risk that monoallelic MUTYHmutations confer is uncertain, so it is unlikely that they are the
only cause of cancer in the corresponding families [27].
The family that carried the TP53mutation was not a classic Li-Fraumeni family, but did ful-
fill the revised Chompret criteria. It had been classified as an Amsterdam II family because
there was one member affected with ovary cancer and another 3 with CRC at early ages, but
there were also 2 lung cancers within the family and a cousin of the proband had developed a
sarcoma very young.
The remaining genes with pathogenic or likely pathogenic mutations had moderate or less
defined cancer risks. In the first place, the BRIP1 gene encodes a member of the RecQ DEAH
helicase family that interacts with the BRCT repeats of BRCA1. The bound complex is impor-
tant in the normal double-strand DNA break repair and appears to be involved in breast and
ovarian cancer, where it acts as a tumor suppressor [28]. Rafnar et al. showed that women with
BRIP1mutations have an increased risk for ovarian cancer that may be as much as 5 times
higher than the risk in non-carriers [29]. Noteworthy, one of the BRIP1 mutations reported by
Rafnar et al. (c.1702_1703delAA, p.N568WfsTer9) was also found in a Spanish CRC patient
[30], and the tumor showed a loss of the wild type allele in both studies. Here we have identi-
fied a different frameshift BRIP1mutation (c.903delG, p.L301FfsTer2) in a patient diagnosed
with CRC at 63 years old. The family fulfilled the Bethesda criteria but was not very informa-
tive due to its reduced size and limited information. Therefore, we still cannot determine the
risk for CRC that BRIP1mutations confer.
Another gene was CHEK2, a tumor suppressor that is activated when DNA is damaged or
when DNA strands break. The c.1100delC mutation of CHEK2 has been confirmed to confer
an increased risk of breast cancer in women unselected by family history [31,32,33]. The life-
time risk of developing breast cancer among women with a CHEK2mutation has been
reported to be approximately 25% [34]. In our cohort, we have found CHEK2 c.349A>G (p.
Arg117Gly), which was considered likely pathogenic by Shoda et al. and proved to produce a
nonfunctional protein both by biochemical and bioinformatics analyses [35]. In addition, their
results suggest that both of these mutations cannot act in a dominant-negative manner and
that tumorigenesis associated with this mutation may be due to haploinsufficiency [35].
We also identified a mutation in XPC, a key component of the XPC complex that plays an
important role in the early steps of global genome nucleotide excision repair and is involved in
damage sensing and DNA binding. The XPC mutation found in our study (c.1001C>A, p.
Pro334His) had been described as pathogenic in ClinVar by Johns Hopkins University. How-
ever, we have identified this mutation for the first time in a CRC patient, who was diagnosed at
the age of 50 and did not have any cancer family history. The patient died soon after the diag-
nosis, not being able to get any additional information. Last but not least, HNF1A is a tran-
scription factor that regulates tissue specific expression of many genes. This gene is implicated
in diabetes and had been described in renal cancer, but its role in CRC is unknown. We are
also describing the mutation HNF1A c.92G>A (p.Gly31Asp) in CRC for the first time.
An increasing number of studies have been published over the past few years addressing the
benefits of NGS panel testing for the diagnosis of hereditary cancers as compared with the tradi-
tional targeted single-gene screenings. While all of them agree on the huge advantages of panel
testing, especially due to its time and cost-efficiency and its higher sensitivity, the only question
that remains open to debate is the selection of genes that should be included [36–40]. Here we
have used a 94-gene panel, which is to our knowledge the highest number of genes reported in
this kind of studies by far. However, this choice was made based on a number of reasons. On
the one hand, we have learned from the Genetic Counseling Unit that there is a relatively fre-
quent overlapping of phenotypes among the different hereditary cancer syndromes [36,37],
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since the tumor spectrum is sometimes wider than expected [27,41] and the information pro-
vided by the family is sometimes incomplete. Therefore, we believe that the best strategy is to
group all the syndromes into one single cancer-predisposing multigene panel, as proposed by
some other groups [27,36], instead of dividing patients based on their phenotypes.
On the other hand, we strongly support the incorporation of lesser-known genes to NGS
panels on a research basis, since the additional cost of adding these genes is minimal [42], and
with the intensity of current research the uncertainty of many emerging genes is likely to be
resolved soon [38]. This means that some variants that are not informative at the moment may
be actionable in the future [38]. In addition, by adding these genes to our panel we are contrib-
uting to the accumulation of international research data, which is the only way to continue
improving our understanding of CRC genetics [39]. For this reason, we also believe it is highly
valuable to include a detailed list of VUS (S2 Table), something that most published studies fail
to do [38]. The number of VUS identified cannot be compared with other studies, though, since
it is associated with the number of genes on the panel [40]. Despite the high number of genes
included in the panel used for the present study, there were some genes that were left out, such
as POLE, POLD1, NTHL1 or MSH3. Although some of them (POLE, POLD1 and NTHL1) had
already been screened in our cohort, this is a limitation of our study. It goes without saying that
we would definitely recommend that future panels used in clinical studies for colorectal cancer
families should include those genes as well, for the same reasons that were discussed above.
The clinical practice experience obtained with this multigene panel is shown in Fig 2C.
Among all the families that were screened only 18.4% were informative, although this group is
underrepresented considering that only unexplained families from previous screenings were
included in the study. Out of these, 66.7% carried likely pathogenic mutations in high-pene-
trance genes and could benefit from a true genetic counseling, taking measures such as reduc-
ing the surveillance in non-carriers, who would avoid the stress attached to the lack of
awareness. Regarding moderate-penetrance genes, a study with a larger number of patients is
needed in order to establish the exact risk they confer. The introduction of NGS panels in the
clinical routine of the hospital will help us with this task. Those patients who were just
informed of VUS (56.1%) would also take advantage of this measure, since the only thing we
can do for now is to keep track of public databases, study the segregation and do functional
studies when recommended in order to improve their genetic counseling in the future. The
remaining patients (25.5%) were informed that no gene had been found to be involved in their
cancer predisposition. Although data regarding lesser-known genes and VUS is highly valu-
able from a research point of view, participants should be always informed about the limited
clinical actionability of testing for genes that are not associated with their phenotype or have
moderate penetrance.
In conclusion, the detection of new pathogenic mutations in high-penetrance genes can
contribute to the explanation of the cancer heritability in our families, changing the individual
clinical management. The NGS panel approach has the advantage of analyzing multiple genes
in multiple samples simultaneously, reducing costs and time and increasing the sensitivity in
comparison to targeted single-gene screenings. Therefore, multigene panels should be
included in clinical laboratories for the screening of all high-risk cancer families regardless of
other analyses in the tumor. The number of genes to be included in these panels is debatable,
though, and should fit the purposes of each study.
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